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Foreword
Animals and Medicine: The Contribution of Animal Experiments to the Control 
of Disease presents a detailed, scholarly historical review of the critical role 
experiments using animals have played in advancing medical knowledge. 
Laboratory animals have been essential, and the knowledge gained has saved 
countless human lives – and not only human lives. Animals, themselves, 
have benefitted. Unfortunately, those opposed to using animals in research, 
some even physicians, have presented doctored evidence that using animals 
has impeded medical progress. Therefore, the articles Jack Botting wrote for 
the Research Defence Society News from 1991 to 1996 have provided scientists 
– those willing to speak out – with the information needed to rebut such 
foolish claims.
Of course, animals are only used when necessary and other methods 
will not answer the question posed. It must be admitted that in days gone 
by attention to their welfare was not uppermost in the minds of some 
scientists. In the modern era, though, laboratory animal medicine has made 
major advances, and scientists are enjoined legally and morally to follow the 
principles of the 3Rs expounded by Russell and Burch: reduction (in numbers 
used); refinement (of experimental techniques to eliminate or reduce pain); 
and replacement (with alternative approaches when available).1 An extensive 
philosophical defence of the use of animals can be found elsewhere.2
It is tragic that Jack’s book had to be published posthumously. But 
thankfully, his efforts to put his many articles into book form were not initiated 
in vain because his wife, Regina, has carried his work on to publication. 
1  Russell W M S and Burch (1959), The Principles of Humane Experimental Technique. London: 
Metheun.
2  Morrison A R (2009), An Odyssey with Animals: Reflections of a Veterinarian on the Animal 
Rights & Welfare Debate. Oxford: Oxford University Press.
http://dx.doi.org/10.11647/OBP.0055.20
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Because Jack and I had collaborated on a few articles more than fifteen years 
ago, she asked me if I would introduce the book.
Ours was a curious collaboration because we never had the pleasure of 
meeting face-to-face. But on the basis of one telephone call and numerous 
emails we wrote three essays. The first was written for an ill-conceived debate 
organized by Scientific American. Jack had been invited by the magazine to 
write an article defending the need for using animals in biomedical research.3 
Jack thought that it would be best to have an American join him in the debate 
and chose me because I had been very active in the field.
Our opponents were to be two physicians, Neal Barnard and Stephen 
Kaufman, well-known for philosophical objection to using animals and their 
false claims that animal research has been wasteful and misleading. We 
knew that they had a history of depending on gross and clever distortions of 
medical history to support those claims, and what they wrote for the debate 
was no exception.4 Having joined together, Jack and I then tried to persuade 
the editor that his debate would be unwise and harmful because, as planned, 
there would be no chance for rebuttal. Our plea fell on deaf ears even after 
we had seen the contributions of our opponents prior to publication and had 
pointed out to the editor their various distortions of history requiring a reply.
The editor’s answer was that the issue was an important one and should 
be presented to the public as planned. But how was an uninformed public 
to sort out fact from fancy, we asked? Barnard and Kaufman’s philosophical 
objections to using animals in research had been melded into a supposedly 
scientifically sound presentation of medical history.
Regrettably, the debate was published; and, as we had predicted, reference 
to Barnard’s and Kaufman’s article in what had always been a legitimate 
journal began to appear in animal-rightist publications. Although one scientist 
whose work had been misrepresented wrote a letter to the editor describing 
how his statements had been presented wrongly, Jack and I thought that an 
extensive rebuttal had to be published somewhere. We found two outlets 
for presenting our rebuttal: an online journal, H.M.S. Beagle: TheBioMedNet 
3  Botting J H and Morrison A R (1997), Animal research is vital to medicine. Sci Am 276 (2) 
83-85.
4  Barnard N D and Kaufman S R Animal research is wasteful and misleading, Sci Am 276 
(2) 80-82. http://dx.doi.org/10.1038/scientificamerican0297-80 
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magazine,5 and a guest editorial in The American Biology Teacher.6 The former 
is defunct, but science and medical journalist, Andrew A. Skolnick, is kindly 
hosting the article on his website.
We actually based our article in HMS Beagle, ‘UnScientific American: 
Animal Rights or Wrongs,’ on the several emails we had sent to the editor of 
Scientific American detailing Barnard’s and Kaufman’s distortions of medical 
history on several fronts. Our corrections focused on the development of the 
polio vaccine, stroke research, drug side effects, the birth defects induced by 
thalidomide, and the miracle of insulin. These topics are among the many 
that are discussed in this book in incredible detail.
Our guest editorial, ‘Confusion in the Ranks’ allowed us to present our 
arguments to an extremely important audience: biology teachers. Animal-
rightist propaganda had been infecting young minds for many years so we 
thought it critical to counter these efforts. The misleading methods presented 
in Scientific American and elsewhere were listed 
in no particular order of perversity [as we put it]:
1.  Overemphasizing an ultimate clinical discovery while ignoring the 
dependence on years of dedicated background laboratory work of 
others or else dismissing the need to dissect mechanisms after a clinical 
observation
2.  Endowing a particular methodology, such as epidemiology, with 
exaggerated powers
3.  Reporting experimental observations or even the opinions of scientists 
out of context
4.  Using faulty logic
5.  Reversing the conclusions of a particular article by quoting a disjointed 
series of sentences as if they had appeared together in the original
6.  Boldly listing supporting references even if they are not. (6, p. 388)
We then offered something positive: ideas for creating a curriculum module 
around the debate. First among them was the philosophical question of 
whether we are justified in using animals for purposes of our own health 
5  Botting J H and Morrison A R (1998) UnScientific American: animal rights or wrongs: An 
op-ed. HMS Beagle: TheBioMedNetMagazine 25 (Feb 20) 1-7, http://www.aaskolnick.com/
morrison/unscian.htm
6  Morrison A R and Botting J H (1997), Confusion in the ranks Am Biol Teacher 59 388-89. 
http://dx.doi.org/10.2307/4450341 
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and well-being. If the answer is negative, is the individual prepared to live 
without benefitting from medical advances? We then suggested asking 
students how one would develop new drugs or surgical techniques without 
using animals in one or more stages of the process. Finally, we suggested 
researching one of the claims made in the Scientific American debate. We 
noted that the editor had received references from both sets of authors so 
that the magazine should be able to provide them on request. I hope some 
did follow through on this last suggestion. The foregoing illustrates how 
important Jack’s efforts were. I hope that many scientists will make good 
use of them in public education. 
Adrian R. Morrison, DVM, PhD 
Professor Emeritus of Behavioral Neuroscience 
School of Veterinary Medicine, University of Pennsylvania 
Philadelphia, PA, USA
Introduction
The Research Defence Society (RDS) was founded in 1908 by Dr Stephen 
Paget, son of the eminent Victorian surgeon, Sir James Paget. Its role was 
to defend scientists conducting medical research using animals and to 
inform the public about the importance of animal experimentation. In its 
first year it attracted a membership of 2000 which included scientists in 
the pharmaceutical industry, in academia and in research institutes. Past 
presidents of the Society include such distinguished figures as Lord Perry 
of Walton and Sir William Paton.
Dr Jack Botting joined the staff of the RDS as its Scientific Officer in 1991, at 
the height of the antivivisectionist activity being carried out by organisations 
such as the Animal Liberation Front (ALF), the National Anti-Vivisection 
Society (NAVS), the British Union for the Abolition of Vivisection (BUAV) 
and People for the Ethical Treatment of Animals (PETA).
One of the most damaging aspects of antivivisection campaigning was 
that they had started to hijack the scientific argument, claiming that animal 
experimentation was scientifically misleading, “a failed technology” etc., and 
that an examination of the research behind major medical advances showed 
that non-animal techniques were crucial and that the animal experiments 
had contributed nothing, or worse still, held up progress. Antivivisectionists 
were deliberately shifting the debate from the traditional “science vs animal 
welfare” argument to a “scientific” debate giving their arguments a cover 
of scientific respectability. 
To respond to this style of campaigning, Jack was given the specific task 
of reviewing the research behind the major medical advances and writing 
non-technical reviews explaining the role played by animal experimentation. 
His work effectively put an end to this aspect of antivivisection campaigning. 
The articles which Jack wrote at that time have been collected in this book. 
But the activists didn’t stop at spreading misinformation. Some extremist 
groups harassed, threatened and attacked scientists and laboratories involved 
http://dx.doi.org/10.11647/OBP.0055.21
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in animal research, painting graffiti on the houses of researchers and even 
planting bombs under their cars. Colin Blakemore, Professor of Physiology 
at Oxford University, who was recognised for his research in early 2014 with 
a knighthood, was one of those targeted by these groups. A leading vision 
scientist who has used cats for his studies, he has received letter bombs, death 
threats against him and his family, had his car damaged and the windows of 
his home broken. The activists also agitated to close down laboratories which 
used animals and the facilities which bred them. Meanwhile, scientists were 
working to find ways to refine and reduce the use of animals in research, but 
their efforts did not appease the antivivisectionists who were determined 
to shut down animal research altogether.
These antivivisectionist groups vary in size and structure; PETA, for 
example, claims that their membership runs into millions. This particular 
group has a wide campaign portfolio: as well as vivisection, it also protests 
against the use of animals for fur farming, pet ownership, hunting and even 
for food. They and groups like them receive large donations from which they 
obtain a considerable income – PETA receives millions of pounds annually 
from their supporters. 
The current animal rights movement, with its organised activities, has its 
origins in the publication of the book Animal Liberation in 1975, by Australian 
philosopher Peter Singer, which animal liberationists viewed as providing 
their founding philosophical statement of ideas. The following year saw the 
foundation of the ALF, followed in the 1980s by the Animal Rights Militia, 
which, as its name suggests, was an extreme group which sent bombs to 
politicians and animal researchers. In the early 1990s, they and other similar 
groups firebombed scientists and organisations engaged in medical research 
using animals. 
One of the most well-known activists is Greg Avery, who founded Stop 
Huntingdon Animal Cruelty (SHAC) in 1999 and is an alleged member of 
the ALF. He was involved with a 10-month campaign that succeeded in 
closing down Consort Kennels, a facility which bred beagles for medical 
research. From 1996, Avery was in and out of prison on various charges 
before being jailed for nine years in 2008 after being convicted of conspiracy 
to blackmail; imprisoned along with him were his wife and ex-wife. Other 
protests achieved some success: 1999 saw the closure of Hillgrove Cat Farm, 
the last dedicated UK establishment which bred cats, its owner retiring after 
a sustained series of protests and attacks. In 2005 the Hall brothers, owners 
of Newchurch Guinea Pig Farm, shut up shop after a six-year campaign by 
activists; in one two-year period police logged 450 separate criminal acts. 
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The victimisation culminated in the theft of the remains of Christopher Hall’s 
mother-in-law and, although no one was ever convicted of the desecration of 
the grave, four people were jailed for using the theft to blackmail the family.1
The degree of criminal behaviour exhibited by these groups led the British 
government to set up the National Extremism Tactical Coordination Unit 
(NETCU) which aimed to enable the police to deal effectively with animal 
rights extremism. In addition, legislation has been put in place to curb the 
activity of antivivisection groups. These measures, combined with more 
severe sentences handed down by judges, have notably reduced extremist 
action by such groups. 
At the same time, the press coverage given to the more extreme cases led to 
public condemnation of the tactics animal liberation groups were using and 
along with this came an increase in awareness of the issues involved. While 
new animal rights campaigns were set up, other groups were formed, such 
as Speaking of Research, to counter them. In 2003, the work of the RDS was 
reinforced by the establishment of the Coalition for Medical Progress (CMP), 
which also engaged in pro-research communication. At the end of 2008, the two 
organisations merged to form Understanding Animal Research (UAR). The 
announcement of the building of a new animal research facility, the Oxford 
Biomedical Research Institute, resulted in animal rights extremists burning 
down student boathouses at Oxford University in protest. This action led 
to the formation at the beginning of 2006 of the Pro-Test committee and in 
February of that year they held their first rally, which saw over 800 students, 
scientists and members of the public marching through Oxford in support of 
animal research. Two subsequent rallies again attracted hundreds of people 
and, in 2008, Oxford University opened its new Biomedical Sciences Building.2
This tide of public support has been complemented by the pursuit of 
alternatives to animal research by the scientific community. The charity, 
Fund for the Replacement of Animals in Medical Experiments (FRAME), was 
registered in 1969 and has provided a blueprint for similar organisations 
throughout Europe and in the USA, advising the government on the Animals 
(Scientific Procedures) Act, passed in 1986. Medical research was still being 
regulated by the 1876 Cruelty to Animals Act, which was in need of updating. 
FRAME outlined a ‘Three Rs’ approach, advocating the replacement, reduction 
and refinement of experiments on animals and the work of the organisation, 
1  Illman J (2008) Animal Research in Medicine: 100 Years of Politics, Protests and Progress. The 
Story of the Research Defence Society. London: Research Defence Society.
2  Holder T (2014) ‘Standing up for Science: The Antivivisection Movement and How to 
Stand up to It.’ EMBO Reports 15/6, 625-30, http://dx.doi.org/10.1002/embr.201438837
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along with progress in scientific knowledge, has enabled the first of these to 
become a reality. The LD50 test has been substituted by the ED50 test which 
uses fewer animals; the Pyrogen Test using live rabbits has been supplanted 
by the Limulus Amebocyte Lysate (LAL) Assay which uses the blood of the 
limulus crab, and the potency of a batch of insulin is now determined by 
biochemical methods instead of the blood sugar levels of conscious rabbits. 
Animal rights extremism has been significantly curbed due to the measures 
mentioned above, as well as the restraining or imprisonment of many of 
the most zealous activists. 2014 finally saw the end of the campaign against 
Huntingdon Life Sciences (HLS). The sustained attacks on Huntingdon had 
seen not only staff targeted but also investors; they received hoax bombs, had 
their cars torched and one US executive even had his boat sunk. Much of the 
energy of the activists has now been channelled into online campaigns, with 
antivivisection groups campaigning to stop airlines transporting primates, 
having already successfully prevented ferry companies transporting laboratory 
animals across the English Channel.3 
The debates around animal experimentation will continue and animal rights 
activists will continue to campaign. However, the landscape has changed 
considerably and there are several organisations now engaged in countering 
the campaigner’s arguments and disseminating information. In the UK, the 
work of UAR is supported by the charitable organisation, the Biomedical 
Research Education Trust (BRET), which was originally set up by the RDS 
and which supports lectures for schools and societies interested in finding 
out the facts about animal research. In the USA, the groups Americans for 
Medical Progress (AMP) and the Foundation for Medical Research (FMR) 
perform a similar role. Even at the time of writing this introduction one 
of the recipients of the 2014 Nobel Prize for Physiology or Medicine, John 
O’Keefe, spoke in support of the use of animals. In an interview with the 
BBC he said “It is an incontrovertible fact that if we are to make progress in 
basic areas of medicine and biology, we are going to have to use animals.”4
This volume of Jack’s articles is supported by the trustees of BRET and their 
generosity is gratefully acknowledged. I would also like to thank Josephine 
Botting, Nina Botting Herbst and Mark Matfield for skilful editing and Ian 
O’Sullivan for invaluable technical help.
Regina Botting, Ph.D., October 2014 
3  The Independent on Sunday (2014) Animal rights group ends campaign, 24th August 2014.
4  BBC News Website, Interview with John O’Keefe by James Gallagher, 7th October 2014. 
I. TREATMENT OF  
INFECTIOUS DISEASES

1. Smallpox and After: An Early 
History of the Treatment and 
Prevention of Infections
The scientific work that led to the discovery of the causes of infections was 
possibly the major biomedical advance of the nineteenth century. From 
it was derived the aseptic technique of Lister, the use of antitoxins and 
immunisation, and the ultimately successful search for chemicals selectively 
toxic to bacterial cells.
The conquest of most of the infectious diseases is, however, the field subjected 
to the most derisive attack by the antivivisectionists. The scourges that were 
responsible for the high childhood mortality up to the end of the nineteenth 
century were, it is claimed, defeated by improvements in sanitation, nutrition 
and housing, rather than knowledge obtained from animal experimentation.
Improvements in public health undoubtedly contributed to the reduction in 
death from infectious disease. Obviously the easiest way to avoid morbidity is 
to stay away from the cause. However, with one notable exception, the causes 
are still with us. The tubercle bacillus, streptococcus, poliovirus etc. could 
still, even in our sanitary environment, cause lethal or crippling conditions 
if there was no appropriate medical intervention. The fact that 50 million 
prescriptions for antibiotics are written per year in the UK is testimony to 
the continued prevalence of infective disease.
Pasteur and others, in the second half of the nineteenth century, attributed 
the cause of certain diseases to microbes that enter (or infect) the body. Pasteur’s 
subsequent work, on the examination of the relative virulence of microbes 
http://dx.doi.org/10.11647/OBP.0055.01
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after in vitro culture, put a sound scientific basis beneath the empirical practice 
of smallpox vaccination that was current in Europe at the time.
Smallpox
Those who may harbour in their imagination an affinity for the romanticism 
of pre-Victorian times would find the historical descriptions of smallpox 
sobering reading. De la Condamine (1) wrote in 1754:
Every tenth death was due to smallpox, and one fourth of mankind were 
either killed by it, or crippled or disfigured for life. The disease was a river 
that everyone had to cross.
This severe scourge was endemic in China and other eastern countries centuries 
before Christ and was certainly present in Europe in the sixth century.
Bishop Gregory of Tours was surely describing smallpox when he wrote 
in 582 of the epidemic with vesicular eruption (lues cum vesicis) which began 
with sickness, fever and back pains. The fever abated with the copious 
eruption of hard, white vesicles which were very painful. Bad cases were 
fatal (amongst the young especially) on the 12th to 14th day.
The prevalence of the disease in these early times is indicated by the 
first clear description of smallpox by a physician. This was that of Isaacus 
Judaeus, or Isaac the Jew, who lived in the ninth century. Isaac theorised, 
since smallpox attacked everyone, that it was a natural fermentation of the 
blood in children in order to get rid of an impurity acquired in the womb. 
That smallpox continued to be a widespread scourge up to the time of the 
formal record of morbidity and mortality is evidenced by the quotation of 
De la Condamine (see above).
Against this background it is not hard to understand the development of 
the technique of inoculation (or variolation). This was the deliberate infection 
of pustular matter, collected during a mild epidemic, into an incision in 
a healthy child. This practice stemmed from the clinical observation that 
one attack of smallpox conferred protection against the disease and was 
long used by physicians of ancient China and India. It was introduced 
into Europe in 1721 by Lady Mary Wortley Montague, wife of the British 
Ambassador to Turkey. Although efficacious, the procedure was extremely 
dangerous, causing at least three epidemics on the continent and being 
fatal in at least 1-2% of cases (2). That individuals were prepared to accept 
discomfort and such severe risks attests to the inevitability with which 
people accepted smallpox in the era before any statistics were available.
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Vaccination
Jenner’s experiments, published in 1798, obviated the need for variolation 
and set the scene for the eventual eradication of smallpox. The story is 
familiar. Jenner, like others before, was intrigued by the accepted belief that 
individuals who came into contact with the comparatively rare disease of 
cowpox were immune to smallpox. In his classic experiment Jenner inoculated 
a boy with pus from a cowpox lesion on the hand of an infected dairymaid. 
Two months later the boy was inoculated with pus from a smallpox vesicle 
but did not develop the disease. “Vaccination” with cowpox resulted in 
immunity to smallpox. Vaccination gradually spread throughout Europe 
during the next hundred years.
The Vaccine
Initially vaccination was usually effected by the use of “humanised” lymph that 
is a lymph from the pustules of those previously vaccinated. The occasional 
accidental transmission of syphilis and the lack of sufficient vaccine material 
to combat an epidemic led to the use of animals to prepare the vaccine. Horses, 
mules, goats and rabbits were all used at one time to generate the virus. However 
calves became the standard method to prepare the vaccine, due to the facility 
with which the supply could be multiplied at relatively short notice to deal 
with even the most serious epidemic. The potency of the prepared virus was 
tested by the rapidity with which it could produce lesions in rabbits (3), it was 
usually also tested on mice to ensure the absence of tetanus bacilli (3).
The Effects of Vaccination
Where the introduction of vaccination was extended the immediate result 
was “a striking and rapid fall of smallpox mortality” (2). Fortunately the 
recording of local or national morbidity and mortality statistics became 
common at this time and thus the beneficial effect of vaccination was 
immediately apparent.
Sweden
Sweden was one of the earliest countries to vaccinate extensively. Vaccination 
began in Lund in 1801 and 25,000 were so treated by 1805. From 1805 on 
about 20,000 vaccinations per year were performed. Vaccination was made 
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compulsory in 1816. The effect was dramatic. Average annual deaths per 
million population during the decades 1792-1801, 1802-11 and 1812-21 were 
1,914, 623 and 133 respectively (Fig. 1.1).
Fig. 1.1  Smallpox deaths in Sweden, 1774-1900.
Bavaria
Bavaria, in 1807, was the first country to make vaccination compulsory. 
Smallpox deaths were reduced and the disease became more prevalent 
in older persons rather than children. This pointed to the necessity for 
revaccination, which was made compulsory in 1872, after which smallpox 
virtually died out in that country.
Netherlands
The Netherlands adopted compulsory vaccination in 1873 and an attenuation 
in smallpox mortality was immediately apparent.
England
In England vaccination was made obligatory in infancy in 1853 and 
compulsory under punishment in 1867, although it is alleged that poor 
 Smallpox and After 7
technique resulted in unsatisfactory protection. John Simon in 1857 observed 
that in England and Wales there was “not only an appreciable amount of 
utterly incompetent vaccination but a very considerable proportion of 
second-rate vaccination” (6). During the epidemic of 1871 vaccination was 
enforced by inspectors.
This was followed by a wane in smallpox deaths (Fig. 1.2).
Fig. 1.2  Smallpox deaths in England, 1838-1900 (1843-1846: no reliable data available).
Austria and Belgium
Austria and Belgium had no formal vaccination policy until the last decade 
of the 19th century and the high mortality from smallpox reflects this.
The Attack on Vaccination
Most informed opinion would agree with the statement of Zinsser in 1931 
(3) that:
The benefits of vaccination are no longer a question of opinion, and opposition 
to the practice is explicable only on the basis of ignorance.
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However others consider that the decline in smallpox occurred throughout 
Europe despite vaccination (see Ref. 4 for example). One noted opponent 
of animal experimentation uses carefully chosen figures of death rate from 
smallpox (although the actual figures are excluded from the graph) to 
imply that smallpox mortality was declining in England and Wales from 
1840-1900 except when vaccination laws were enforced, when there was 
a dramatic rise (5).
Two factors have enabled those that decry the value of vaccination 
to muster some spurious evidence to support their claims. Firstly it was 
wrongly believed that inoculation with cowpox virus would provide 
life-long protection against smallpox (the protection lasts about ten 
years). Secondly was the epidemic nature of smallpox, and the fact that 
a devastating pandemic occurred in Europe between 1870 and 1875. The 
epidemic began in France and lasted about two years in each country. The 
occurrence of a sudden epidemic at a time when widespread vaccination 
was underway is eagerly seized upon as an irrefutable demonstration 
that vaccination was redundant. However mortality statistics for the 
years 1870-75 provide clear evidence for the benefits of vaccination, since 
mortality rates in the countries with vaccination were demonstrably less 
than where vaccination was not practised at that time. In England the 
epidemic peaked in 1871 with a death rate of 1,012 per million, in Sweden 
(where vaccination was started in 1801) 936 per million died in 1874. In 
Belgium and the Netherlands, where vaccination was not practised the 
rates were a striking 4,168 and 4,355 per million respectively at the height 
of the epidemic.
Further proof of the efficacy of vaccination (and of the necessity for 
revaccination) emerges from the examination of the age distribution of 
those dying from smallpox (data from Ref. 6). Before vaccination in England, 
80% of smallpox deaths were in the younger age groups (under 10 years). 
As the vaccination of babies spread the ratio reversed, that is those in the 
older age groups formed the highest proportion of those contracting and 
dying of smallpox (these individuals had outgrown the immunity conferred 
by vaccination and of course had not acquired the long-lasting immunity 
secondary to a mild smallpox infection).
Were it required, additional evidence of the protection by vaccination is 
provided by the comparison of mortality to smallpox in adjacent countries, 
one of which had enforced vaccination whilst the other had not (e.g. Belgium 
and the Netherlands, and Austria and Bavaria).
 Smallpox and After 9
The WHO Eradication Programme
In the first half of the twentieth century Europe and North America gradually 
became smallpox free due to extensive vaccination and containment measures 
(7). Occasional relaxation of vaccination laws always led to outbreaks which 
had to be suppressed by vigorous vaccination programmes. Zinsser (3) 
cites an outbreak in Kansas City in 1921 which led to 1,090 cases and 222 
deaths. 200,000 people were vaccinated before the epidemic ceased. In 1922 
in Denver there was a virulent outbreak of 805 cases with a death rate of 
over 30%. No order requiring vaccination was issued until November 21, 
1922. The result was that there were only 81 cases in December as against 
252 in November of that year.
The success of vaccination in eliminating smallpox from countries 
where it had been endemic raised the possibility of the global eradication 
of smallpox. This was proposed at the Eleventh World Health Assembly in 
1958. After 8 years it was evident that technical and material assistance from 
the WHO would be required and this was initiated in 1967. Freeze-dried 
vaccine that met the WHO standards was used and a simplified vaccine 
technique was devised (the bifurcated needle) that made the programme 
easier to carry out.
Eradication programmes began in 1967, the last of the remaining 30 
endemic countries to start the programme was Ethiopia in 1971 (7).
South America
In 1967 smallpox was being reported almost solely in Brazil. Over 4 years 
83.3 million people were vaccinated (90% of the population). Surveillance 
was begun in July 1969 (which accounts for the apparent increase in 
incidence at that time) and in 1970 a steady decline occurred until April 
1971 when the last case reported.
Africa
At the institution of the vaccination programme (1967) smallpox was 
endemic throughout South Saharan Africa. By 1972 smallpox incidence 
had decreased virtually to zero except in Sudan and Ethiopia. After 1971 
vaccination and surveillance was increased in these two countries with 
consequent decrease in cases.
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Asia (Mainland)
China had become smallpox free after extensive vaccination in the 1950s 
and, at the time of the eradication programme, Burma and Iran had only 
limited outbreaks imported from Asian countries with endemic disease – 
Afghanistan, India, Nepal and Pakistan.
In these endemic areas surveillance and vaccination resulted in 
attenuation of the disease which was somewhat slower than in other areas, 
due partly to the geography and partly to the persistence of variolation, 
which continued to be practised by itinerant shamans, particularly in 
Afghanistan and Pakistan.
Indonesia
The programme in Indonesia was started in July 1968 in Java and Bali 
and was later extended to the remaining islands. By the end of 1971 there 
were only a few cases in limited foci in Java and one focus in Sulawesi 
(see Fig. 1.3). 
Fig. 1.3  Smallpox incidence in Indonesia, 1966-1971.
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Eradication
The last recorded case of smallpox was reported in Somalia in 1977 (8). In view 
of the long history of the disease this was an astonishing achievement which 
throws into sharp relief the criticisms of those who claim that vaccination 
was ineffective (4) and dangerous. The diminution of the disease over a 
hundred years in both developed and Third World countries immediately 
after the institution of a vaccination programme either attests to the value 
of the procedure or is a remarkable coincidence.
As to the dangers of vaccination, the statement by Sharpe (5) – that 
“vaccination was stopped in 1940 when the considerable risks were thought 
to outweigh the benefits” – is typical hyperbole. Serious complications of 
vaccination, according to the WHO (7), were so infrequent that “very large 
populations must be studied in order to assess the relative risks involved.” 
In one extensive study in the USA in 1968 (7) there were 9 deaths in over 14 
million vaccinations. Five of these occurred either in eczematous patients 
(eczema was considered a contraindication in non-endemic areas) or in 
patients with immunological defects.
The Scientific Origins of Immunisation
Whilst the acceptance of vaccination was spreading across Europe, Pasteur 
and his colleagues were carrying out experiments that were to give rise to 
the techniques for providing active artificial immunity to many diseases. It 
is of significance, and somewhat ironic, that the crucial experiments were 
those carried out into the cause and treatment of diseases of animals – chicken 
cholera and anthrax.
Chicken cholera
Chicken cholera was a lethal disease that occurred in epidemics in poultry 
yards. Due to the emerging prominence of the “germ theory” at that time it 
was thus naturally thought that the cause was a microbe. Pasteur found and 
described the microbe as: “tiny bodies, extremely slender and constricted in 
the middle, which would at first sight be taken for isolated dots.”
Pasteur (Fig. 1.4) succeeded in cultivating the microbe outside the 
body in a neutral, sterilized broth made of ground up chicken meat. Small 
amounts of the broth sprinkled on the food given to chickens caused the 
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disease, and Pasteur proceeded to demonstrate that the microbe flourished 
in the gut of the infected chickens, and passed on the infection through the 
faeces. The microbe was fatal to rabbits on inoculation but when injected 
into the skin of guinea pigs produced a local abscess. Such infected (but 
apparently generally healthy) guinea pigs however could spread the disease 
to both rabbits and poultry (as Pasteur remarked – how many obscurities 
in the history of contagions will one day be cleared up by even simpler 
experiments).
Fig. 1.4  Louis Pasteur (1822-1895), microbiologist. Wellcome Library, London, CC BY.
The crucial discovery made by Pasteur was that cultures of the chicken 
cholera microbes, left for some time, lost their ability to transmit the disease 
to hens. This was a chance observation due to cultures being left over a 
vacation. It was typical of the thoroughness of Pasteur that he decided to see 
if the “ineffective” cultures had produced any change in the condition of the 
chickens. On administration of a fresh culture these hens proved resistant 
to the disease. The same operation on hens obtained fresh from the market 
caused death in them all from cholera.
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It was known that recurrence of a virulent disease after survival of a 
severe attack was rare. Resistance was conferred by the challenge. Pasteur 
had found a way of producing the resistance without the risk of the disease.
Anthrax
Although the development of a “vaccine” against chicken cholera was 
of enormous scientific significance the disease itself was not of great 
importance. Because of long experience of the disease poultry farmers 
kept birds in small groups and killed sick hens immediately, before the 
disease could spread. Anthrax on the other hand was a disease of sheep 
and cattle that was of enormous importance. Each year 5% of cattle and 
10% of sheep died of anthrax in France. In some particular areas of France 
and the Argentine the mortality to farm animals was so great the land 
had to be left unused.
Using the culture techniques with which he had become expert Pasteur 
addressed the problem of the prevention of anthrax.
Small bodies, termed bacteridia, had sometimes been detected in the 
blood of animals suffering from anthrax, but the weight of scientific opinion 
considered the disease to be due to something invisible termed “virus” 
(as was the case for smallpox). Pasteur found that the bacteridium would 
grow freely in neutralised urine. By successive subculture he produced a 
culture diluted from the original virulent one by many million times. That 
this culture could still produce anthrax in guinea pigs proved that the 
bacteridium was the cause, since all else had been diluted out.
By a series of elegant but simple experiments Pasteur showed that the 
anthrax bacteridium infected sheep through the alimentary canal and also 
explained how the disease persisted in particular “accursed fields” (champs 
maudits) where cattle or sheep were bound to contract anthrax if they were 
allowed to graze.
Koch had shown that anthrax bacteridia could form spores in conditions 
of high oxygen levels and temperature. Pasteur demonstrated the presence 
of anthrax spores in the fine top soil of the accursed fields. The spores were 
brought to the surface (sometimes from the buried bodies of anthrax sheep 
or cattle) by earthworms. Presumably the animals ingested the anthrax 
spores from soil contamination of the grass or clover upon which they 
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grazed. Extracts of the soil produced anthrax in guinea pigs even if the 
soil had been heated to 90oC (which kills off other soil bacteria). Pasteur 
also produced anthrax in guinea pigs by inoculation of the soil from the 
intestine of earthworms.
An Anthrax Vaccine
In order to develop an attenuated strain of bacteridia (similar to the innocuous 
but immunogenic culture of chicken cholera) Pasteur investigated the 
vitality and virulence of cultures treated in various ways. The bacteridium 
grew only between 16 and 44oC. When cultured at fairly high temperatures 
(42-43oC) a very virulent strain grew rapidly but Pasteur found that the 
virulence waned, so that the culture became harmless to guinea pigs after 
12 days, but would kill mice. After 4 weeks even mice and baby guinea 
pigs survived challenge with the culture.
Pasteur was thus able to produce “vaccines” of graded strength depending 
upon the duration of the high temperature incubation, and he used these 
to protect animals against a challenge with a virulent anthrax culture. The 
stage was set for a field trial. 
Pasteur proved the effectiveness of his vaccine with a convincing 
public demonstration at Pouilly-le-Fort in 1881. Under the supervision 
of a vet 25 sheep were inoculated with Pasteur’s vaccine, 25 were not so 
treated. On May 31st all 50 sheep were inoculated with a virulent culture 
of anthrax bacteridia. The trial was a spectacular success. On June 2nd all 
the vaccinated sheep were in good health. Of the non-vaccinated, 22 were 
dead and three dying. The experiment was repeated in 10 cows with the 
same definitive result.
Of course criticism persisted, particularly from some veterinarians 
who were offended at the intrusion of a scientist in what they considered 
their preserve. But when the vaccine was shown also to protect animals 
against inoculation with blood from an animal dying from anthrax, and 
“not a mixture of unknown nature made up in a laboratory, and whose 
constitution no one knows but the makers” – all opposition disappeared.
In France, between 1882 and 1893 nearly 4 million animals received 
anthrax vaccine, and loss of cattle and sheep from the disease fell to low 
levels. The use of Pasteur’s vaccine spread throughout Europe and the World. 
By 1914 40 million doses had been sent out from the Pasteur Institute alone.
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By a simple animal experiment, of a style and to an extent that could 
never be reproduced in humans, Pasteur had shown indisputably that 
immunisation did protect against infective disease. This protection induced 
against an animal disease should be held as irrefutable evidence for the 
value of immunisation – which, of course, is repudiated by the animal rights 
organisations. It is also evidence that animals themselves benefit from such 
research. It may be alleged by opponents of animal research that protection 
against anthrax merely solved an economic problem for milk distributors 
and wool merchants. However, it undoubtedly prevented animal suffering 
and such a claim of vested interest cannot be levelled at the research that 
resulted in a vaccine that conferred protection against canine distemper.
An earlier version of this chapter was published as: Smallpox and after – an 
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2. Rabies
On the 17th of June, 1981 an Englishwoman travelling in India was bitten on the 
leg by a dog. The wound was immediately cleansed by her husband using whisky 
as an antiseptic. She later attended a local clinic where the wound was again 
washed and packed with antiseptic powder. The woman returned to England 
in July and the wound was redressed in her local hospital. By the middle of 
August she became constantly tired and complained of aches and shooting pains 
in the back. She was anxious and depressed, and appeared to catch her breath 
when trying to drink. By the 19th of August she found it impossible to drink 
more than a few sips. She could not bear the touch of the wind or her hair on her 
face and had moments of apparent terror. The following day she was confused, 
hallucinating, incontinent of urine and quite unable to eat or drink. For the next 
two days she was intermittently hallucinating and screaming with terror until 
she collapsed and had a cardiac arrest. Although she was resuscitated in the 
ambulance whilst being carried to intensive care, she died two days later, on 
24th of August 1981, without recovering consciousness. The unfortunate woman 
had been infected by rabies virus in the saliva from the, obviously rabid, dog 
(Fig. 2.1). The typical symptoms and signs of rabies encephalitis that appeared 
two months after the initial infection had been misinterpreted as hysteria
Fig. 2.1  Study of a rabid dog from an oil painting by J.T. Nettleship.  
Wellcome Library, London, CC BY.
http://dx.doi.org/10.11647/OBP.0055.02
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Such case reports of rabies make frightening reading. The initial phase of the 
disease may start some months (in some cases years) after the infected saliva 
has entered a puncture wound, thus the two events may not be associated. The 
delay is due to the slow passage of the virus along the sensory nerves to the 
brain and spinal cord. The initial symptoms resemble those of less serious viral 
diseases – weakness, headache and loss of appetite. Most patients then move 
into the so-called furious phase. There is an increased sensitivity to sensory 
stimuli and a horrifying aversion to liquids (hydrophobia), during which 
patients may retch and vomit so violently that the lining of the oesophagus 
may tear. Patients scream in alarm during periods of wild agitation, which 
alternate with periods of lucid calm. Eventually the patient sinks into a 
coma and dies. Once the central nervous system symptoms appear, death 
is inevitable, and the period before coma is terrifying for the patient.
Though causing the death of many wild and domesticated animals, 
control measures meant that rabies did not in fact kill as many people as 
other contagions rife until the early twentieth century. Nevertheless, because 
of its dreadful symptoms, it has been called “the most severe of all the 
communicable diseases.” (1)
Rabies is still endemic in most parts of the world. Its incidence is under-
reported partly for political reasons, and partly because it may be unsuspected 
as a cause of death. In India, Pakistan and Bangladesh there may have been 
as many as 50,000 deaths per year in the 1970s (2). Sri Lanka, The Philippines 
and Thailand each lose approximately 1,000 citizens per year due to rabies 
and the incidence of the disease is also high in China, Iran and Colombia.
Rabies in Britain
In Britain rabies was certainly known in 1000 AD and probably much 
earlier. In the mid-eighteenth century the situation was so bad that a two 
shilling reward (then a considerable sum) was offered for the destruction 
of each stray dog. In the early nineteenth century, packs of hounds had to 
be destroyed (including the Quorn, a well-known hunt in England) and 36 
persons were alleged to die annually from rabies, although this was probably 
an underestimate.
Outbreaks of rabies continued throughout the nineteenth century in 
various centres in Britain, and thousands of rabid animals, mainly dogs, 
were destroyed (Fig. 2.2). By 1864 rabies was widespread in animals in and 
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around London. The Metropolitan Streets Act was passed in 1867, enabling 
police to seize all vagrant dogs, and rabies then declined (2).
Fig. 2.2  Slaying of a rabid dog. Wellcome Library, London, CC BY.
Due to the imposition of strict quarantine laws, rabies was eradicated from 
Britain in 1903 (There was however an outbreak that originated in Plymouth 
in 1918 from a dog illegally brought back from the continent. About 300 dogs 
became infected and 358 persons had to be given anti-rabies treatment (3)).
Rabies in Europe
In the nineteenth century rabies was widespread in Continental Europe, 
with extensive outbreaks occurring in various species. In an outbreak in 
1803, many people, dogs and pigs were bitten by rabid foxes in France, and 
the foothills of the Jura Alps were littered with the bodies of rabid animals. 
Between 1800 and 1841, 800 dogs had died of rabies in the veterinary hospital 
at Lyon alone. By the middle of the century, 60% of the dogs taken to this 
hospital were rabid (2).
Bites from rabid wolves were commonplace. In 1851 a single rabid wolf 
bit 46 persons and 82 head of cattle in one day in the vicinity of Hue-Au-Gal. 
Many people died and all the cattle had to be destroyed (2). By 1869 rabies 
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had become common even in large towns. In that year a rabid cat passed 
on the disease to a woman in Paris.
Pasteur and his Research on Rabies
Against this background of rabies endemic in the woods, mountains and by 
then even the large cities of France, Pasteur launched his researches into the 
nature and treatment of the disease. Pasteur had up to 1880 worked on the 
prevention of animal diseases but had always intended to seek “the causes 
of putrid and contagious diseases that affect man.”(4)
Rabies, an animal disease transmissible to humans, was thus an eminently 
suitable field of research. Pasteur also had had an early experience of the 
horror of rabies. As an eight-year-old boy he had witnessed victims of the 
bite of a rabid wolf arriving at the blacksmith’s forge in his home town of 
Arbois in eastern France, to have their wounds cauterised (5). A procedure 
of doubtful value but the sole preventive treatment for rabies at that time.
Pasteur was convinced that rabies did not occur spontaneously in dogs, 
but that each case derived from another. Obvious today, this view was not 
commonly held in the 1880s. The saliva of rabid animals was an obvious 
source of the infective organism and Pasteur attempted to infect rabbits by 
inoculation of saliva from patients dying of rabies. He also, with some bravery, 
collected saliva from rabid dogs for the same purpose. The deliberately 
infected animals died. From his researches, Pasteur did not believe that any 
of the visible micro-organisms in saliva were the cause of rabies, nor was he 
convinced that the rabbits always died of rabies (rabbits with rabies sink into 
a “painless kind of paralysis” rather than the “rage” seen in dogs (4)). Further, 
the latent period before the disease became evident varied tremendously, 
making the experiments long and unpredictable.
It is tempting to believe that Pasteur sensed intuitively that the sometimes 
very long incubation period of rabies was because the infective organism 
took a long time to reach the central nervous system via the peripheral 
nerves. At all events, Pasteur decided that using the brain and spinal cord 
of infected animals was the best way of transmitting the disease for his 
particular experimental purposes.
Placement of portions of the brain of a dog dead from rabies under the 
skin of rabbits reliably produced the disease, but there was still a prolonged 
latent period. The crucial experiment was to place the infected tissue onto 
the surface of the brain of rabbits. This was achieved by removal of a small 
disc of bone from the skull of a rabbit under chloroform anaesthesia and 
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placing the infected brain tissue just under the membrane surrounding 
the brain (the dura). This technique always resulted in the production of 
rabies within 20 days. Pasteur shortened the incubation period to 6-7 days 
by increasing the virulence of the virus, as he had previously done with 
anthrax, by repetitive passage through rabbits. Thus, Pasteur had prepared 
a very active virus with an absolutely predictable ability to cause the disease 
within a short time (he termed this his virus fixe). The way was now open 
to explore methods to attenuate the virus, as Pasteur had done with the 
microorganisms responsible for chicken cholera and anthrax.
Pasteur’s Vaccine
Pasteur removed the spinal cord of a rabbit killed by the virus fixe and stored 
it in an aseptic flask in dried, filtered air in the dark at constant temperature. 
Under these conditions, portions of the cord gradually lost their ability to 
infect until, after 12 days, they appeared innocuous. By inoculating many 
rabbits at different times, Pasteur was able to collect a series of cords ranging 
in potency from the ineffectual to the highly virulent. Dogs were inoculated 
with portions of the cords suspended in a small volume of broth, starting with 
a non-virulent sample and gradually, over 12 days or so, using samples of 
increasing virulence until the dogs were ultimately shown to be resistant to 
challenge with the virus fixe. Pasteur demonstrated that 50 dogs so treated were 
unaffected by bites from rabid dogs and were even resistant to administration 
of the virus fixe to the surface of the brain. Early this century, modifications 
of the Pasteur vaccine were used to vaccinate dogs. A consequent fall in the 
incidence of canine rabies was reported from Morocco, Hungary, Finland, 
Algeria, Yugoslavia and various parts of the USA (6).
The most intense canine vaccination programme was started in Japan in 
1918. From 1921, a phenol-inactivated virus prepared by Fermi was used as a 
vaccine. By 1934 1.5 million dogs had been vaccinated. The annual number of 
rabies cases in dogs dropped from 1,041 in 1918 to 60 in 1930 (6). In the 1950s, 
vaccination was made compulsory and all stray and feral dogs were seized 
and destroyed. As a result, the last case of canine rabies in Japan occurred 
in 1956, though the disease had existed there since the 10th century (2).
Treatment of Human Rabies
The virus fixe vaccine of Pasteur was potentially too toxic for routine prophylaxis 
in humans. At the outset of his researches into rabies Pasteur had suggested 
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that, because of the long incubation period, protection by vaccination might 
be possible after the bite of a rabid animal. He obtained evidence for this 
by allowing pairs of dogs to be bitten by a rabid animal; one was then 
vaccinated the other untreated. In each case the untreated dog died, the 
vaccinated animal lived.
Not everyone accepts that the experimental studies proved that post-
exposure vaccination was effective in preventing rabies. Webster (7) considers 
that all the early studies (including those of Pasteur) were faulted by poor 
controls. The studies of Fermi, who used a simpler, phenol inactivated 
virus as a vaccine, are however generally accepted as demonstrating a 
post-exposure prophylaxis.
Notwithstanding the subsequent debate over the experimental studies, 
it is difficult not to accept that post-exposure prophylaxis developed by 
Pasteur was beneficial in humans. The first patient publicly recorded as 
being treated by Pasteur probably provides the best known case history in 
medicine. Joseph Meister, a nine-year-old from Alsace, was brought to Pasteur 
on July 6th 1885. He had been attacked on July 4th by a dog, thrown to the 
ground and bitten fourteen times. When found, his wounds were covered 
with the animal’s saliva. The dog subsequently attacked his owner and was 
shot; the body had shown evidence of rabies (2).
Pasteur and his colleagues decided that they must treat the boy, since 
the extent and nature of the wounds meant he was highly likely to develop 
rabies. 60 hours after the attack, Joseph Meister was injected with an infected 
cord that had been desiccated for 15 days. He received 13 injections over the 
next 10 days, the final injection being a virulent sample. The boy survived 
and was subsequently employed at the Pasteur Institute.
Three months later a second patient was successfully treated and the news 
of these two successes, which spread with remarkable rapidity, resulted 
in a steady flow of potential rabies cases to Paris. In 1886 Pasteur reported 
the results of treating 350 cases of rabies. Only one had died, a child whose 
treatment was delayed 5 weeks after being bitten. The most conservative 
contemporary statistics as to the likelihood of rabies developing after dog 
bites in Paris range from 16 to 40 per hundred persons bitten (8), although 
some authorities claim the figure was 50% (2).
By the end of 1886, 2,000 people had been treated, including 38 Russians 
bitten by rabid wolves (three of these died, bites from rabid wolves having a 
particularly high mortality). Pasteur noted however, that the treatment was 
not always successful, particularly when the face was bitten. Nonetheless, 
the value of Pasteur’s crude vaccine can be assessed by examination of the 
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detailed reports that appeared each year from the Pasteur Institute. In 1898 
Pottevin reported a total of 20,166 patients treated at the Pasteur Institute 
with only 96 deaths – a mortality of 0.48% (2).
Criticisms by the Antivivisectionists
Pasteur’s researches were acclaimed, and not only within France. In 1886 the 
British government appointed a Committee to examine Pasteur’s method; 
it reported favourably and in 1889 a donation of 40,000 francs was made by 
the government to the Pasteur Institute (4). Anti-rabic institutes, using the 
Pasteur technique, were opened in many parts of the world.
There is no doubt that contemporary opinion regarded the experimental 
work on rabies as prodigious. It is sad that a century later, those that seek 
to belittle the contribution of animal experimentation to medical progress 
find it necessary to disparage a researcher of the stature of Pasteur. Thus 
one critic states that Pasteur’s vaccine “turned out to be a failure.” (9) His 
attempted justification is the uncertainty that rabies will inevitably follow 
a bite from a rabid animal, implying that in the early clinical studies those 
that were inoculated after a bite would not have developed rabies anyway.
Obviously a controlled trial, whereby vaccine treatment is deliberately 
withheld from some patients, would be unethical. Thus the only way to 
assess the effectiveness of the vaccine is to examine data of the incidence 
of rabies following bites before development of the vaccine, or data from 
studies where patients refused the vaccine. Fleming, in 1872 (10) described 
the clinical course of 198 patients bitten by rabid dogs. Of 132 who had the 
wound cauterised, 41 died (31%), of the remaining 66 that were not cauterised, 
55 died (84%). The mortality in treated patients after the development of the 
vaccine was between 0.2 and 1.3%.
The most emphatic data was that recorded by the Pasteur Institute of 
Southern India, Madras (11). Of 28,898 cases treated over 16 years, 0.7% were 
treatment failures. Of 423 persons bitten by rabid dogs in Madras and who 
received no treatment, 148 died of hydrophobia – a 35% mortality.
There is little doubt that the vaccine was effective, but by modern day 
standards it was certainly not safe. Even the later phenol or glycerin-
treated vaccines, because of their high nerve-protein content, caused severe 
neurological complications for 1 in 2,000 patients (2).
Due to the remarkable progress in the prevention and treatment of 
disease over the last 100 years, patients today enjoy a high expectation of 
safe treatment. Thus the dangers of the early anti-rabies vaccines now seem 
24 Animals and Medicine
grievous. This is another reason that their value, and hence the significance 
of the experiments that produced them, is peremptorily dismissed in animal 
rights propaganda.
It should require (for the unbiased reader) only a superficial examination 
of contemporary records to understand the import of Pasteur’s research. A 
horrific and inevitably fatal disease had but one treatment – vaccination. 
Despite its risks, at the time such treatment was not only acceptable but 
eagerly sought.
Local Wound Treatment
Even 2,000 years ago it was realised that bite wounds from rabid animals were 
probably the portal of entry of the factor responsible for rabies. Irrigation of 
the wounds with various noxious substances and cauterization were common 
until the availability of standard viral preparations enabled experimental 
studies to be undertaken to establish optimum wound treatment. These 
studies are well reviewed by Cabasso (2). Typically, guinea pigs were infected 
with the virus through a wound in the neck or hind limb, or mice had the 
virus implanted in the hind-limb or foot pad. The effectiveness of various 
techniques in preventing the development of the disease was then assessed.
Fortunately, the earliest studies resulted in the rejection of cauterization 
and fuming nitric acid to irrigate the wound (these techniques were common 
even in the early 20th century). Washing with 20% soap solution was found as 
effective as these traumatic and painful measures. Of the many other chemicals 
used in the experimental studies, quaternary ammonium compounds were 
found to be valuable, with benzalkonium chloride being particularly effective. 
Of some practical significance, ethyl alcohol was surprisingly efficacious 
even in concentrations as low as 20%.
The present recommended wound treatment in humans stems from these 
animal studies. Dead tissue should be removed and the wound flushed with 
soapy water or a 1-2% solution of benzalkonium chloride. If the wound is 
deep the viricidal benzalkonium chloride must be used, if it is not available 
then 40-70% ethyl alcohol is the best alternative. Passive immunisation with 
anti-rabies antibodies is also used.
Passive Immunisation
Since vaccination results in the production of antibodies in the treated person, 
it was not surprising that immune serum, i.e. serum from vaccinated animals, 
was tested to see whether it could protect infected animals.
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Habel in 1945 (described in Ref. 2) obtained a serum from rabbits hyper-
immunised with mouse brain fixed virus. Given to guinea pigs previously 
infected with rabies the antiserum had a significant, dose-dependent protective 
effect, the benefit being greatest if the antiserum was given soon after infection. 
Similar protection was seen in mice challenged with mouse-adapted virus 
where the development of rabies was prevented if the serum was given 
within three hours.
These experimental studies were confirmed and extended by Koprowski 
(12) who raised anti-rabies antibodies in rabbits and sheep to protect infected 
hamsters. Koprowski also made the highly significant observation that small 
doses of anti-rabies globulin and vaccine given together completely protected 
guinea pigs against rabies, whereas given alone they were ineffective. This 
apparent synergistic effect of the vaccine and anti-rabies serum was followed 
up by the World Health Organisation’s Expert Committee on Rabies, which 
instituted a field trial with vaccine and anti-rabies antibodies raised in horses 
(anti-rabies equine serum). The test was carried out in Iran where there was 
a high fatality rate amongst humans bitten by wolves. Careful, controlled 
studies such as those of Koprowski cannot ethically be carried out in humans, 
nonetheless the few cases initially treated were encouraging. In 1954 a chance 
of obtaining definitive evidence arose when a rabid wolf entered a village 
and bit 29 persons. The wounds were all severe. A six-year-old boy was 
bitten in the head, his skull was partially crushed and penetrated deeply 
by the wolf’s teeth; he presented with meningeal lesions and convulsions.
Of the 17 patients given antiserum plus vaccine, one died (6%). Of those 
with severe head wounds given vaccine only, 75% died. The boy with the 
crushed skull was given six injections of the equine antiserum and, remarkably, 
was one of the survivors (2). Serological tests on all the victims confirmed 
emphatically that concurrent use of antiserum greatly increased the beneficial 
effects of the vaccine. Combined use of anti-rabies antibodies with the modern 
vaccines is now routine for post-exposure prophylaxis against rabies, as is 
administration of the antibody preparations to the potentially infected wound.
Modern Vaccines and Immunotherapy
As indicated previously, useful as the nervous tissue vaccine was, it was not 
without risk, particularly because of its nerve-protein content. Improvement 
in safety was achieved firstly by the culture of the virus in embryonated 
hen or duck eggs (1940-56) and then by culture on hamster kidney cells 
(1960). Though such vaccines were free of protein of nervous origin they still 
contained potentially harmful factors (2). The development of the human 
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diploid cell (HDC) line provided an improved method of culturing the virus 
and preparing the safest vaccine (HDCV), which was first used in Iran in 1972.
Similarly, the equine antiserum, though dramatically effective when 
used in conjunction with the vaccine, could cause anaphylactic shock in a 
few patients (although the possibility of this occurring could be tested by 
conjunctival or intradermal administration of a small amount of serum). 
Hence today rabies immune globulin of human origin (RIGH) is available. 
This is obtained from immunised donors by repeated bleedings, using 
plasmaphaeresis, whereby whole blood is removed, the cells separated from 
the plasma (retained for patient use), resuspended in saline and reinfused 
into the donor (2).
We have thus perfected the treatment of rabies. Today post-infection 
prophylaxis is effective and safe, using vaccines grown on human cells and 
antisera obtained from human plasma. Objectors to animal experiments 
use this fact to dismiss the contribution of the early animal experiments to 
the treatment of rabies. This is at best naive. Modern experimenters have 
been able to refine treatments using modern techniques and human tissue 
because they could harvest the yield of the experiments of giants such as 
Pasteur and his colleagues.
Rabies Eradication?
A significant step towards the possible eradication of rabies is the development 
of a novel vaccine using vaccinia virus (which was responsible for smallpox 
eradication). The vaccine is produced by inserting the gene coding for the 
protein conferring immunity to rabies into the genome of vaccinia virus (VV). 
The modified VV is used to infect cultured cells which correctly express the 
rabies antigen. This antigen has potently induced rabies virus-neutralising 
antibodies in rabbits and mice and protected the animals against challenge 
with a lethal strain of rabies virus (13).
This vaccine is active orally and has been used in bait to immunise raccoons 
in the USA and foxes in Europe. Innocuous to mammals, the vaccine is 
undergoing field trials in Belgium and France. Widespread immunisation of 
feral and domesticated animals would be the first step towards the ultimate 
eradication of rabies.
An earlier version of this chapter was published as: Rabies – a century of 
research brings eradication closer. RDS News October 1993 8-12.
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3. Lockjaw: Prevalent but 
Preventable
Tetanus is one of the most dreadful diseases which has been produced in 
nature to torment mankind. No one who has seen a case can ever forget it. 
The poor victim, thrown every few minutes into the most violent spasms, bent 
backwards to such an extent that only his head and heels touch the bed, his 
teeth tightly clenched, unable to eat or drink, his face expressing the fiendish 
torture he is undergoing, at last is mercifully released by death.
Sir David Bruce (1920) (1)
Although tetanus was described at the time of Hippocrates, for over 2000 
years there was no advance in our understanding of the disease. At the 
end of the nineteenth century the prevalent, rather naive view was that it 
was caused by “inflammation travelling up an injured nerve to the central 
nervous system.” (2)
The infective nature of tetanus was demonstrated by Carle and Rattone, 
who in 1884 took pus from a lesion of a patient with tetanus and injected it 
into rabbits, where it produced signs typical of the disease (3).
The Causative Organism
Tetanus frequently followed wounds where the skin had been deeply 
punctured, particularly if the lesions were contaminated with soil or other 
foreign matter such as splinters etc. Nicolaier, in 1884, established that the 
infective organism was present in the soil. He produced the disease in mice, 
rabbits and guinea pigs by inoculation of various samples of soil under the 
skin (4). Soil from richly manured areas, such as grazing land and the ground 
around stables, was particularly potent.
http://dx.doi.org/10.11647/OBP.0055.03
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The identification of the bacterium responsible for tetanus was delayed 
because of the enormous variety of organisms present in manure-contaminated 
soil. Kitasato in 1889, provided definitive evidence of the identity of the 
causative bacterium by the use of heat (800 for one hour) to destroy non 
spore-bearing organisms, followed by culture in the absence of oxygen. The 
pure culture of “drumstick-like” anaerobic bacteria (subsequently known as 
Clostridium tetani) produced the typical symptoms of tetanus on inoculation 
into animals (5).
Tetanus Toxin
As with diphtheria, the tetanus bacillus is not invasive. It stays in the area 
of damage, grows and exudes a toxin which produces the symptoms of 
the disease. Bacteria-free filtrates of broth cultures, prepared according to 
the method of Kitasato, were shown to be potently toxic to animals, a few 
hundredths of a microlitre proving fatal to mice of 10g body weight (6).
The absorption of the toxin accounts for all the pathology of tetanus. In 
animals, after a latent period of 1 to 3 days, spasm occurs in the muscles 
at the site of the inoculation. However, should the toxin be administered 
intravenously, generalised muscle spasm occurs (7). This suggested that the 
toxin exerts its action in the central nervous system having reached there by 
transport along the motor nerves. This was proved by Bruschettini (8) who 
showed that toxin injected into muscle in rabbit could be recovered from 
motor nerves supplying that area. Similar animal experiments demonstrated 
that toxin injected into the sciatic nerve could, after a period, be recovered 
from the spinal cord of the animal. The fact that “local tetanus” in animals 
could be prevented by sclerosis or actual section of the nerve, confirmed 
that passage along motor nerves lying near to the focus of the tetanus 
infection was the means by which the toxin entered the central nervous 
system, where it caused its toxic actions. These experiments had profound 
implications for the use, and the route of administration, of the antitoxin 
which was developed later.
Tetanus Antitoxin
In view of the scientific climate in the late 19th century it was predictable 
that researchers should try to ascertain if animals could be stimulated to 
produce a substance that could neutralise tetanus toxin, and thus combat 
tetanus infection. It was perhaps also predictable that the production of a 
tetanus antitoxin in animals (after serial injections of gradually increasing 
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amounts of tetanus bacillus filtrates) was demonstrated by von Behring and 
Kitasato, who also produced the diphtheria antitoxin (9). The antitoxin was 
able to protect animals against large doses of tetanus toxin or large numbers 
of tetanus bacilli.
Toxin was obtained by filtration of suitable cultures. The potency of the 
toxin was standardised by making serial dilutions and determining the minimal 
lethal dose (MLD) after subcutaneous injection into white mice of 20g body 
weight. Multiples of this MLD, perhaps rendered less noxious by treatment 
with terchloride of iodine, were administered to a horse in increasing doses 
at intervals of 8 days or more. Eventually the horse had generated sufficient 
antibody to withstand challenge with very high doses of tetanus toxin. The 
antitoxic serum was obtained by bleeding from the jugular vein and was 
preserved with small concentrations of phenol or tricresol. The preparation 
was standardised by measurement of the volume needed to protect animals 
(mice or guinea pigs) against lethal doses of toxin, and diluting the antitoxin 
solution accordingly (7).
Prophylaxis with Antitoxin
It soon became clear from experimental studies that tetanus antitoxin could 
only neutralise toxin that had not yet entered the motor nerves. Roux and 
Borrel in 1898 (10) demonstrated that rabbits with sufficient antibody in their 
plasma to protect them from huge doses of tetanus toxin given intravenously, 
readily succumbed to minute doses of toxin given by intracerebral injection. 
Nevertheless much animal data attested to the prophylactic value of tetanus 
antitoxin. The horse is particularly susceptible to tetanus infection, and 
tetanus following surgery or injection in this animal was commonplace. 
There were many reports at the turn of the century as to the prophylactic 
value of tetanus antiserum in the horse. A study on several hundred horses 
used for the production of various antisera in a large laboratory in the USA 
showed a 10% death-rate from tetanus despite rigid aseptic technique and 
disinfection. After routine prophylactic use of antitoxin before any surgical 
procedure, death-rate was reduced to 1% (2)
Antitoxin Prophylaxis in Humans
Although hundreds of thousands still die from tetanus infection each year, 
it was during war that deaths from tetanus reached epidemic proportions. 
Missiles such as musket balls, bullets or shrapnel, blasted through soil-
contaminated clothing produce the deeply penetrating wounds in which 
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clostridium tetani bacteria flourish. Thus military medicine provides the first 
clinical evidence for the efficacy of tetanus antitoxin.
According to Larrey, in Napoleon’s campaign the tetanus case mortality 
was 82% (cited in 1). During the American civil war case mortality was 89.3% 
(11, p. 203), 82% during the Franco-Prussian war of 1871 (on the German 
side) (1) and 90% on the British side in the Crimean war (1). The 1914-18 
war was the first real testing ground for the then freely available tetanus 
antiserum (Fig. 3.1).
Fig. 3.1  Incidence of tetanus per 1,000 wounded in the British Army, 1914-1918.
Evidence from animal studies that the antitoxin would be effective as 
prophylaxis against tetanus was clear. Faced with evidence of a tetanus case 
mortality averaging 85%, one might have expected the British Army Medical 
Service in 1914 to have recommended routine administration of the antiserum 
to all wounded personnel. This was not the case however. For almost the first 
two months of the war no antiserum was used, with the result that incidence 
of tetanus was high. The reason for this lapse of clinical judgement was that 
the most recent experience of the traumas of active service was that of the 
Boer War. Tetanus during that campaign was rare since the veldt was clean, 
unlike the highly cultivated soil of Northern Europe. Although this error 
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undoubtedly caused needless deaths during the first few weeks of the war, 
it also provided evidence of the clinical benefit of the antitoxin through the 
dramatic fall in incidence of tetanus after the belated adoption of routine 
anti-tetanus prophylaxis (1).
Evidence for the value of tetanus antitoxin in preventing the development 
of tetanus after serious wounds is undoubted, although never in fact subjected 
to definitive test. Without question, in medical units where all wounded were 
given antitoxin at the moment of entry to the field hospital, the incidence 
of tetanus was at most one third of that where the antitoxin was given only 
where the case was considered “suspicious”(12). Bazy describes a clinical 
situation involving 200 soldiers with similar wounds, where “on account 
of certain circumstances” (unspecified by the author) only 100 received 
antitoxin. Of these, only one developed tetanus, and that very soon after 
the injection, suggesting that the disease had already taken hold. Of the 
100 left unprotected, 18 developed tetanus. Thus the “certain circumstances” 
that obtained in Bazy’s study, whilst unfortunate for 18 subjects, provided 
something akin to a partially controlled clinical trial to demonstrate the 
efficacy of tetanus antitoxin (12).
Therapy with Antitoxin
The value of antitoxin to treat tetanus once the central nervous effects of 
the disease are manifest is less easy to establish. The heterogeneity amongst 
patients with tetanus and the ethical problem of withholding a potentially 
life-saving treatment mean that a properly controlled trial is hard to conduct. 
One such, assessed by sequential analysis, did show a significant benefit 
from administration of 200,000 units of antitoxin (13). The small number of 
patients in this trial (38 pairs) has meant that the results are not accepted 
everywhere.
In view of the knowledge of the nature of the progress of infection by 
tetanus (derived solely from animal experiments) one might have supposed 
that injection of antitoxin direct into the nervous system would be attempted, 
since this is where the toxin is exerting its pathological effects. Indeed, in a 
particularly rigorous experiment, Sherrington (14) showed that intrathecal 
injection of antiserum to rhesus monkeys could reduce mortality to a 
substantial dose of toxin from 100% to 48%, even if the injection of the antidote 
was delayed until overt signs of tetanus were apparent.
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It appears, however, that physicians were loath to administer a foreign 
protein (i.e. equine antitoxin) into the human central nervous system. Some 
trials carried out in India (15) demonstrated that the equine antitoxin given 
intrathecally was beneficial if administered less than 24 hours after start of 
symptoms, and a report from Irwin Hospital showed that intrathecal injection 
of human tetanus immune globulin reduced mortality from “mild” tetanus 
from 21% to 2% (15).
It is clear that tetanus antitoxin is prophylactic if administered in repeated 
doses to patients at risk of infection. However, once the disease has taken 
hold, antitoxin will be of use only to neutralize toxin that has not yet entered 
the nervous system, or if given intrathecally, to negate the effect of toxin that 
is in the nervous system but not yet fixed to the tissues. Complete control of 
the disease could only be achieved by effective immunisation programmes.
Immunisation against Tetanus
Effective immunisation against tetanus became possible when Descombey 
(16) demonstrated that tetanus toxin was rendered innocuous after prolonged 
incubation with formaldehyde (thus forming “toxoid”). Bergey and Etris (17) 
showed that three doses of toxoid, given over a period, could protect guinea 
pigs against injection of several thousand times a lethal dose of tetanus toxin. 
Since the 1930s toxoid, or toxoid precipitated with alum or other agents, has 
been widely used in humans.
Preparation of Toxoid
Tetanus vaccine is prepared as prescribed by the World Health Organisation 
(18). Tetanus toxin is obtained from a liquid medium in which a high-yielding 
strain of clostridium tetani has been cultured. The toxin is converted to the 
non-toxic “toxoid” by treatment with a dilute solution of formaldehyde 
for days or weeks. During this time the product is continually tested for 
toxicity in animals. The complete conversion of toxin to toxoid is established 
by injection of suitably diluted samples into 5 guinea pigs. The sample of 
toxoid passes this formal “specific toxicity test” if no guinea pig shows 
sign of paralysis or any other sign of tetanus within 21 days. Potency tests 
(protection of guinea pigs against challenge with a subcutaneous injection) 
and a test for innocuity (intraperitoneal injection to mice and guinea pigs) 
are also stipulated by the WHO monograph and national pharmacopoeias.
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The Success of Tetanus Immunisation
Routine vaccination against tetanus has been the norm in developed countries 
for three or four decades. Effectiveness of the procedure is generally assessed 
by the presence of high antibody titres in the blood. Due to the consequent 
rarity of the condition in the developed world, as with antitoxin, one has to 
look to war to provide evidence of the efficacy of vaccination.
Unfortunately, during war reliable data is not always accurately recorded. 
Nevertheless a good account of the incidence of tetanus in the US Army is 
reported by Long and Sartwell (19). All US troops were immunised with 
tetanus toxoid from 1941. During World War I, when troops were non-
immunised, out of 523,158 wounded 70 developed tetanus. During World 
War II  2,734,819 soldiers were wounded, yet only 12 cases of tetanus occurred, 
and six of these occurred in subjects who were not in fact immunised, for a 
variety of administrative reasons. In the Pacific theatre incidence of tetanus 
was high amongst non-immunised troops and civilians. In a group of 550 
wounded Japanese prisoners of war in the Marshall Islands, 26 developed 
tetanus, and tetanus caused approximately 400 deaths of civilians injured 
in the war zones of Manilla and Saipan. Other comparative data attest to 
the protective value of vaccination against tetanus (20, 21)
Neonatal Tetanus
Current estimates of mortality from tetanus are 800,000 deaths per year 
from neonatal tetanus, and 120,000 to 300,000 deaths from non-neonatal 
tetanus (22). The cause of neonatal tetanus is generally due to infection of 
the umbilical scar caused by poor obstetric technique. Tetanus accounts for 
approximately 50% of neonatal deaths and 25% of infant deaths (22). As 
noted by Habig and Tankersley, “this high incidence is additionally tragic 
because the disease is largely preventable by appropriate immunisation.” (23)
Conclusive proof of the value of tetanus toxoid in the prevention of 
tetanus is provided by a double-blind controlled field trial for the prevention 
of tetanus neonatorum in Colombia (South America), where in 1966 the 
estimated death rate from the condition was 11.6 per 100 births. Over 2.5 
thousand women were initially involved in the trial. The control group 
received injection of a polyvalent influenza-virus vaccine, the test group 
aluminium-phosphate-adsorbed tetanus toxoid. In children born to women 
in the control group, incidence of neonatal tetanus was 7.8 per 100 births 
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(27/347). None of the 341 children born to mothers previously given 2 or 3 
doses of tetanus toxoid developed the disease. Non-tetanus mortality in the 
two groups was similar (5.5 and 4.1% respectively) (24, Table 1).
THE USE OF TETANUS TOXOID FOR THE PREVENTION OF NEONATAL TETANUS. 
Report of a double-blind controlled field trial covering 1618 women in a rural area of Colombia. 
From Newell, Duenas Lehmann, Leblanc & Garces Osorio (1966) Bulletin of the WHO 35 863-71.
Control Vaccinated
Total births 347 341
Tetanus mortality (%) 27 (7.8) 0 (0)
Non-tetanus mortality (%) 19 (5.5) 14 (4.1)
Management of Tetanus
Knowledge obtained through animal experimentation has not only contributed 
to development of tetanus antitoxin and toxoid, but also to other modes of 
treatment. Antibiotics (penicillin and metronidazole) may be given to prevent 
the growth of clostridium tetani and so prevent further accumulation of toxin. 
Should the disease have taken hold and convulsions started, neuromuscular 
blocking drugs must be used to prevent spasm, and breathing maintained by 
positive pressure ventilation (25). The development of both antibiotics and 
neuromuscular blocking drugs depended totally on animal experimentation.
The Action of Tetanus Toxin
Many potent toxins of plant and animal origin have proved to be valuable 
tools to elucidate cell and organ function. Botulinus toxin and black widow 
spider venom are two notable examples. Tetanus toxin is no exception. It has 
been shown to prevent the release of chemical transmitters from nerves by 
a highly selective action on a protein present in the outer membrane of the 
vesicle that encloses the stores of transmitter in nerve endings. Presumably 
the toxin has a particular affinity for those nerves in the spinal cord that 
release inhibitory transmitters. Disruption of activity of these nerves would 
cause overactivity of motor nerves and generalised spasm. Recent research 
in rat tissue (26) shows that tetanus toxin is a zinc endopeptidase enzyme 
that selectively destroys the membrane protein, synaptobrevin. Use of the 
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toxin will help to unravel the various functions of the different constituents 
of the vesicular membrane. With such tools we shall eventually elucidate 
the esoteric, intracellular processes controlling the storage and release of 
chemical messengers from nerve cells. We may also, incidentally, expose new 
methods of treatments for tetanus, for example the use of zinc endopeptidase 
inhibitors such as the antihypertensive drug, captopril.
Tetanus toxin was isolated 30 years before chemical transmission of nerve 
action was even raised as a possibility. The fact that some 60 years on, we 
are anticipating the use of this toxin in the elucidation of intricate molecular 
processes governing release of neurotransmitters from individual nerve cells 
is an example of the remarkable exponential nature of the progress of research.
Tetanus Today
Tetanus still occurs, even in developed countries. Typically it strikes females 
over 50 years of age, frequently infected after a minor cut or abrasion sustained 
while gardening. This susceptibility is due to the fact that routine tetanus 
immunisation of infants began only in the 1950s. Thus, those too old to have 
benefited from this, and who did not receive the vaccine as a member of the 
armed forces, would be vulnerable. Three recent cases have been reported 
in patients over 60 (27). This argues for vaccination for those unprotected 
and who are at risk by virtue of their job or hobby.
Tetanus vaccination appears to have been ignored by the animal rights 
lobby. No attack upon its usefulness can be found after a brief examination 
of recent antivivisection literature. This is probably due to its undoubted 
efficacy, its remarkable safety (side effects are virtually non-existent) and 
to its widespread use to protect animals against the disease. The Index of 
Veterinary Specialities lists 20 vaccine preparations containing tetanus toxoid, 
alone or in combination with vaccines against other animal diseases (28).
An earlier version of this chapter was published as: Lockjaw: prevalent but 
preventable. RDS News April 1994 6-9.
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4. Pertussis Vaccine, Unfairly 
Maligned – At What Cost?
Whooping cough prophylaxis, as pertussis vaccine, is routinely administered 
to infants together with diphtheria and tetanus as the DPT combined 
immunisation.
After a short catarrhal phase, whooping cough begins with a dry nocturnal 
cough. This progresses to prolonged bouts of coughing which often end with 
a sharp intake of breath. The coughing fits may induce vomiting and, in 
severe cases, convulsions. Frank damage to the nervous system may occur, 
this is due to haemorrhage and lack of oxygen in the brain caused by the 
raised venous pressure that occurs during the paroxysms.
The symptoms persist for weeks and may be complicated by pneumonia, 
bronchitis and collapse of the lung. Admission to intensive care is frequently 
required. The patient may be left in a debilitated condition with an increased 
susceptibility to pulmonary infections. Whooping cough is without doubt 
an extremely distressing disease for both the patients and carers.
Prior to vaccination, mortality to whooping cough was the highest for any 
childhood disease. In Europe and the USA between 1900 and the 1920s the 
annual death rate was between 10 and 11 per 100,000 (mostly children under 
3 years). In 1931, a standard textbook of bacteriology stated: “[whooping 
cough] may be looked upon as one of the major causes of death in civilised 
countries.” At this time it was responsible for 1.3% of all deaths in England 
and Wales (1). Today, whooping cough is still a significant cause of child 
mortality in developing countries. In 1991 it was estimated that, world-wide, 
pertussis caused the deaths of approximately 340,000 children each year (25).
The causative organism of whooping cough was described in 1900 when 
Bordet and Gengou observed small, ovoid bodies in the sputum of a child 
http://dx.doi.org/10.11647/OBP.0055.04
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with the disease. Cultivation of the bacillus (Bordetella pertussis) was not 
achieved until 1906 when the same workers managed to grow the organism 
on a composite medium of glycerin extract of potato, agar and defibrinated 
rabbit blood (2). 
Toxins obtained from these cultures were lethal to rabbits after intravenous 
injection. Subcutaneous injection produced a non-suppurating local necrosis 
(1). The pathological effects in humans are presumably due to local necrosis 
caused by toxins released by the bacilli growing on the ciliated cells lining 
the bronchi and trachea. A thick, ropy exudate is formed and the attempted 
ejection of this, together with a systemic effect of pertussis toxin, is the cause 
of the paroxysmal cough.
The Vaccine
It was natural that researchers should attempt to develop a vaccine that 
would protect against such a distressing disease with a high child mortality. 
Clinical trials began in the 1920s to determine the protective effect conferred by 
extracts of killed Bordetella pertussis. The vaccines were generally considered 
to confer some degree of protection, although the studies were not always 
well-controlled (3).
To assess the potential of the various vaccines against whooping cough, 
a series of rigorous trials under the control of the Medical Research Council 
began in England after World War II and were completed in 1959. This 
whole investigation was of impeccable quality and reflected great credit on 
the relevant committee of the MRC.
It soon became apparent that the candidate vaccines varied in ability 
to protect against the disease. It was thus decided to assess the correlation 
between the efficacy of the vaccines in children and the potency in the 
“mouse protection test.” In this test, groups of 15 mice were injected with 
graded doses of vaccine, and 10-14 days later challenged intracerebrally with 
a virulent strain of the bacillus. From the proportion of mice dying in each 
group an estimate of the efficacy of the vaccine could be obtained. In a study 
of 25 vaccines there was a high degree of correlation between the activity 
in the mouse test and the effectiveness of the vaccine in the field (4). These 
meticulous observations thus provided a quick method of assessment of new 
vaccine preparations, and the final report of the MRC trials recommended (5): 
“Only those pertussis vaccines which have been shown, by the intracerebral 
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mouse protection test, to have adequate potency in relation to the British 
Standard Pertussis Vaccine should be used in whooping cough prophylaxis.”
The MRC trials, double-blind and randomised as they were, showed 
definitively that vaccination against pertussis was effective. Immunisation of 
infants was therefore officially recommended in 1957, although immunisation 
had already spread throughout some areas of England and Wales during the 
1940s and early 1950s as local health authorities gradually adopted a pertussis 
immunisation programme and replaced diphtheria/tetanus vaccine with 
diphtheria/tetanus/pertussis vaccine in their routine procedures (6) (Fig. 4.1).
Fig. 4.1  Studies on pertussis immunisation, 1937-1942. 1.0 Saur 1938; 2.0 Park 1937; 3.0 
Kendrick Eldering 1939; 4.0 Doull-Shipley 1939; 5.0 Kramer 1938; 6.0 Silverthorne 1939; 
7.0 Siegel 1938; 8.0 Siegel 1938; 9.0 Singer 1940; 10.0 Howell 1938; 11.0 Kendrick Eldering 
1939; 12.0 Kositza 1940; 13.0 Lapin et al 1939; 14.0 Lapin et al 1939; 15.0 Perkins 1942.1
The beneficial effect of routine vaccination against whooping cough is well 
illustrated by the drop in incidence in England and Wales as the vaccination 
acceptance rate rose to around 80% (Fig. 4.2).
1  Data taken from J H Lapin (1943) Whooping Cough. London: CC Thomas, from which 
complete references may be obtained.
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Caption: Fig. 4.2  Whooping cough notifications in England and Wales, 1940-1990.
Clear confirmation that the drop in incidence was not fortuitous coincidence 
is provided by the upturn in incidence as the vaccine acceptance rate 
unfortunately dropped between 1975 and 1983 (7). Elsewhere, in countries 
such as Fiji, where the vaccination programme was not interrupted, the 
disease was practically eliminated (8) (Fig. 4.3).
Fig. 4.3  Whooping cough in Fiji, 1950-1980.
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Questions of Safety
Undoubtedly, the killed, whole cell pertussis vaccine is highly reactogenic. 
Redness and soreness at the site of injection and fever are common. Incidence 
of serious reactions such as persistent screaming, convulsions or shock 
accompanied by collapse have been variously estimated as 1 in 5000 to 1 in 
50,000 injections (9), although these studies were never controlled and thus 
neglected the natural incidence of these events. For example, a first convulsion 
may occur naturally in approximately 1 child in 400 aged between 3-9 months. 
Thus one child in 10,000 in that age group, given 3 doses of vaccine might 
by chance have a first convulsion within 3 days of an injection (7).
The great contention that has dogged discussion of the safety of pertussis 
vaccine for the last two decades is whether it occasionally produces irreversible 
brain damage. The history of the rise and fall of this canard should be 
mandatory study for both medical students and science writers.
There were sporadic reports of an alleged association between pertussis 
vaccination and serious brain damage but these were paid little heed since 
control studies were never performed and most informed authorities did 
not assume a causal relationship (9). The discussion was kept within the 
medical establishment and thus did not affect the acceptance rate of pertussis 
vaccination by the public.
A crucial event was the publication in 1974 of a paper that stated that 
over an 11 year period, 36 children were admitted to a large London hospital 
with acute neurological illness that had started within 28 days of an injection 
of pertussis vaccine (10). The authors made no claim that the vaccination 
caused the illness and in some of the cases there were probable diagnoses 
that excluded an assumption of a causal relationship. This report might well 
have remained accessible only to those capable of assessing the significance 
of these observations in conjunction with other valuable epidemiological 
studies. Unfortunately the mass media gave them much publicity with 
the result that the general public and some general practitioners (but not 
consultant paediatricians) were reluctant to accept pertussis immunisation.
Between 1977 and 1983 the question of whether or not pertussis vaccine 
caused irreversible brain damage continued to be argued. On one side 
allegations of an incidence of 1 in 60,000 to 1 in 10,000 were quoted (11); on the 
other the possibility was described as “not proven” or very rare (1 in 135,000 
to 1 in 300,000) (12, 24). The problem was the temptation (to some) to accept 
that any neurological defect that developed after vaccination was necessarily 
caused by it. Natural incidences of neurological problems in infants were 
ignored. The diagnostic problems of assigning a severe encephalopathy to 
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vaccination were well illustrated by the clinical account of 3 children who 
developed mental handicap, symptoms of which appeared 6 hours, 2 days 
and 1 week respectively after “the whooping cough jab” (12). These children 
might well have remained designated as “vaccine damaged” but for follow up 
studies one and a half to four years later, which showed two of the children 
had suffered prenatal damage and the third had X-linked Menkes disease 
inherited from his maternal grandmother. In the same paper the pertinent 
point was made that if, as some suggested, 1:20,000 children vaccinated 
with pertussis suffered brain damage, then there should be enough affected 
children for each specialist in paediatric neurology to have an appreciable 
case load of children with a characteristic disease indubitably associated 
with vaccination. This was not the case.
The relative danger of forgoing vaccination for a perceived risk of, say a 
1 in 135,000 chance of serious neurological damage, were well illustrated by 
Grist in 1977 (13). He claimed that 135,000 cases of whooping cough “would 
entail 30 cases of encephalitis..., many cases of convulsions, 170 deaths and 
13,500 illnesses requiring hospital admission; many children would have 
pneumonia, bronchitis, and lung damage, and most of them would experience 
distressing symptoms for many weeks.”
The safety of pertussis vaccine has now been established following the 
comprehensive survey by Pollock and Morris (14) which found no evidence 
that DPT caused major neurological damage. This has been confirmed by 
two recent large scale studies from Britain (15) and the USA (16). The first 
concludes “(the) study has clearly shown that illnesses leading to death or 
brain damage after diphtheria, tetanus, and pertussis vaccine, if they occur 
at all, are extremely rare.” The second, which involved 218,000 children, 
“did not find any statistically significant increased risk of onset of serious 
acute neurological illness in the 7 days after DTP vaccine exposure for young 
children.”
The reassurance provided by these thorough studies comes years too late 
for the 102,000 children who became seriously ill (32 died) in the epidemic 
of 1977-79, which coincided with the dramatic decline in vaccine acceptance 
due to misplaced publicity of brain damage incorrectly attributed to the 
vaccine. As others have noted with some cynicism (17, 18), the good news 
of the establishment of the safety of pertussis vaccine has apparently gone 
unnoticed by the media. Fortunately, the information was actively promoted 
by the Department of Health with the result that confidence in the vaccine 
returned and the acceptance rate has risen to 92%.
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The Antivivisection Argument
The heated epidemiological arguments over the safety of pertussis that waged 
for 10-15 years provided an opportunity for the promulgation of persuasive 
propaganda by those opposed to animal experiments. Sharpe, for example 
(21), quotes only data from Stewart, who was virtually the sole advocate of 
the rejection of the vaccine on grounds of safety. This view was emphatically 
but courteously attacked in the medical journals by both neurologists and 
paediatricians (12, 13, 19, 20). This contention was quite overt and was not 
only carried out in the correspondence columns of the British Medical Journal 
and the Lancet, but also featured in editorials and leading articles. These 
discussions are ignored by Sharpe, as is the substantial study by Pollock and 
Morris (14) (which absolves the vaccine) and the scholarly and well-balanced 
review by Miller, Alderslade and Ross (9), both of which appeared 5 years 
before the publication of Sharpe’s attack on animal experimentation, The 
Cruel Deception. The misrepresentation that results from selection of evidence 
solely supporting one’s prejudice is in itself a deception.
Sharpe also questions the benefit produced by pertussis vaccination. He 
presents a graph (with no scale or actual figures) which shows a steep fall in 
mortality due to whooping cough from 1860 onwards (23). He thus claims 
that the disease had ceased to be a problem before the advent of antibiotics 
or vaccination. Mortality certainly had fallen due to great improvements 
in the techniques applied to the care of infants with respiratory disease. 
Application of specialist nursing, techniques of aspiration, the availability 
of intensive care units, oxygen etc., all contributed, as did the availability of 
antibiotics to combat secondary infections. Nonetheless to suggest that the 
disease was of little significance is a travesty.
The incidence of the disease did not diminish until vaccination. Even 
if mortality was reduced, whooping cough was a severe and dangerous 
disease in a substantial proportion of affected children, as the epidemic of 
1977-79 showed. The problem was well illustrated by the Royal College of 
General Practitioners special report on the nature of this epidemic in a large 
population of West Glamorgan (22). 2,295 cases were reported, two children 
died of apparent cot death, 64 unvaccinated children had to be admitted to 
hospital, 24 needed aspiration, 25 intensive care, 10 required oxygen. Two 
had encephalitis (one died), 14 had convulsions, 224 had acute bronchitis, 
8 had collapsed lung, 17 developed asthma; there were 26 cases of apnoea. 
Whooping was present in 45% of cases, the paroxysms were followed by 
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vomiting in 66%. Severe cyanosis after paroxysms occurred in 430 cases. 
The avoidance of morbidity and mortality of this magnitude would appear 
a sound justification for the adoption of pertussis immunisation.
The Future
The anxiety over the possible severe adverse effects of the whole cell pertussis 
vaccine, needless as it was, nevertheless reduced public confidence in the 
vaccination programme. It is thus important to restore this confidence by 
the development of a vaccine which contains the antigenic fractions, and no 
active pertussis toxin or extraneous matter that is likely to cause the local 
reactions and fever.
A number of candidate vaccines have been produced based on antigenic 
fractions of precipitates of centrifuged suspensions of bacteria (23). The 
possible value of these vaccines can be rapidly assessed by their ability to 
protect mice against intranasal challenge with B pertussis or direct challenge 
with pertussis toxin. The possibility of reversion to frank toxicity, which has 
been observed with some potential pertussis vaccines, can be excluded by 
two simple tests in mice; the histamine sensitisation test or the measurement 
of leukocytosis-promoting activity (23). An in vitro test is now available for 
pertussis toxin based on the morphological changes it produces in Chinese 
hamster ovary cells.
An earlier version of this chapter was published as: Pertussis vaccine, unfairly 
maligned – at what cost? RDS News April 1994 10-13.
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5. Vaccination: The Present and 
Future
Meningitis
The reduction of morbidity and mortality through development of new or 
improved vaccines continues. In October 1992, vaccination against infection by 
Haemophilus influenzae type B (Hib), a major cause of meningitis, was included 
in the childhood immunisation programme in Britain. The effect was immediate, 
for Hib infections fell by 70% in the period January to March, 1993 (1).
The introduction of the vaccine in Britain was triggered by the outstanding 
success of the experiment in Finland, where the introduction of the vaccine 
in 1986 reduced the incidence of Hib menigitis, which had been steadily 
rising since the 1960s, to zero by 1991 (2) (Fig. 5.1).
Fig. 5.1  Hib meningitis in Helsinki. Actual cases, 1970-1990.
http://dx.doi.org/10.11647/OBP.0055.05
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Similar benefit had been reported in three regional studies of Hib meningitis 
in the USA, where falls in incidence of between 80-90% occurred over a two 
year period following vaccination against Hib (3) (Fig. 5.2).
Fig. 5.2  Decline of Hib Meningitis in USA children under 5 years, 1980-1993.
Prior to vaccination, 1500 cases of Hib infection occurred every year in the 
UK (mostly in children under one year), over half resulting in meningitis. 
Despite the effectiveness of antibiotics against the bacillus, it killed 65 children 
and caused permanent brain damage, deafness etc. in a further 150 each year.
The drive to produce a prophylaxis against this potentially devastating 
disease was considerable, but initial efforts were stymied by the nature of 
the antigen. This is a polysaccharide present in the capsule of the bacterium, 
a linear polymer of ribose, ribitol and phosphate (PRP). Antibodies to PRP 
were effective at passively immunising animals, but PRP vaccines could 
only produce a poor, short-lived immunity in children under one year, that 
is those at greatest risk.
After much experimentation the immunogenicity of PRP was increased 
by coupling it to a protein. This general technique had been suggested by 
the work of Landsteiner (of blood group fame) and had been shown to be 
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effective in protecting mice against infection with pneumococci (4). Conjugates 
of PRP with bovine or human albumin, haemocyanin and diphtheria toxoid 
were shown to be powerfully immunogenic in mice and rabbits (4). From 
these experimental studies four effective vaccines were developed for 
human use, based on PRP linked to diphtheria toxoid, tetanus toxoid or a 
membrane protein from meningococci. Each vaccine was of course subject 
to the standard animal tests for innocuity.
Malaria
In terms of extent, malaria is one of the most serious infectious diseases. Actual 
numbers of those affected are difficult to establish, due to the remoteness of 
some of the areas where the disease is endemic. A recent estimate suggested 
that malaria causes 3 million deaths per year in Africa alone, one third 
of these being children under 5 years of age (5). The parasite is generally 
developing resistance to antimalarial drugs, as is the anopheles mosquito 
to insecticides. An effective vaccine has thus long been sought and may 
now have been found since the prototype vaccine SPf66 has been shown 
to produce a “strong immune response” in a recent trial in Tanzania (5). 
SPf66, developed by Patarroyo at the University of Bogota, was perfected 
by experiments in aotus monkeys (6).
The Future
What next? Will research to produce new vaccines become redundant? Hardly. 
The spectre of AIDS still looms, other fatal diseases emerge and old diseases 
re-emerge as problems.
Tuberculosis is on the increase in certain areas and paediatricians are 
questioning the policy of some health authorities to discontinue routine 
BCG vaccinations, this despite the advice of the British Thoracic Society to 
continue to offer BCG to all 10 to 14-year-olds and neonates in areas where 
the incidence of tuberculosis is high (7).
An emergent problem is posed by hantaviruses. An estimated 200,000 
people world-wide become infected with hantaviruses each year, between 
4,000 and 20,000 die as a result (8). Hantaviruses, which produce haemorrhagic 
fever and chronic nephropathy, normally infect rodents, but can easily 
spread to humans under certain conditions. In October 1993, the US Center 
for Disease Control and Prevention confirmed that there were 42 cases (with 
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26 deaths) of a new disease, hantavirus pulmonary syndrome. This had 
presumably arisen due to the sudden proliferation of the rodent population 
in SW states caused by unusual social and climatic changes (9). Hantavirus 
infections are virtually untreatable. The development of a vaccine is the only 
way to combat the threat of an epidemic.
The denial of the importance of animals in research into the nature and 
treatment of infective disease, and the insistence of animal rights groups that 
economic and social change is the sole cause of the decrease in morbidity 
and death from infection cannot be sustained. The consequent questioning 
of the effectiveness of vaccination, and the promulgation of unsupportable 
allegations of the toxicity of vaccines, is at best unjustified and in some 
instances thoroughly irresponsible (see for example 10).
VACCINES INTRODUCED FOR HUMAN USE.  
From Cryz SJ (1991) Vaccines and Immunotherapy. New York: Pergamon.
1880 Rabies
1890 Typhoid, cholera, plague
1920 Diphtheria, pertussis, tetanus,tuberculosis
1930 Yellow fever, scrub typhus
1940 Influenza, pneumococcal pneumonia
1950 Poliomyelitis
1960 Measels, mumps, rubella
1970 Meningococcal meningitis
1980 Adenovirus, Hepatitis B, Hib meningitis
An earlier version of this chapter was published as: Vaccination: the present 
and future. RDS News April 1994 14-15.
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6. The Conquest of Polio and 
the Contribution of Animal 
Experiments
Any individual old enough to have even occasional recall of a childhood 
before World War II must be aware of the impact of antibacterial agents and 
vaccination on infective disease.
With the advent of prontosil and hence the sulphonamides, followed 
by the antibiotics, death from common bacterial infections has become a 
comparative rarity. Similarly, the leg braces and iron lungs (Fig. 6.1) – a 
mark of the epidemics of poliomyelitis that were a regular feature of Europe 
and North America throughout the first half of the twentieth century – are 
now seen only in the countries which have not yet implemented the polio 
vaccination programme instituted by the WHO.
Fig. 6.1  The iron lung before vaccination, 1952? Image in the public domain.
http://dx.doi.org/10.11647/OBP.0055.06
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Those who assert that animal experiments have contributed nothing to the 
treatment of infectious disease claim that improvements in hygiene and 
sanitation are solely responsible for the lower death and morbidity from 
infectious disease this century.
It is undoubtedly true that improvements in social conditions lessen the 
possibility of contraction of certain bacterial diseases, and that improvements 
in nutrition may increase resistance. It is, however, undeniable that the annual 
death rate from puerperal sepsis was steady at approximately 190/100,000 
births from 1860 to 1938, but with the development of sulphonamides 
and antibiotics this had fallen to half that value within two years, and to 
approximately 5/100,000 by the 1960s (1).
Similarly, the death rate from lobar pneumonia in middle-aged men 
averaged a steady 60/100,000 from 1910-1940, but with the application of 
bacterial chemotherapy had fallen to below 6 by 1970 (2).
However, of all the contentions of the animal rights movement, its 
attempts to reject the contribution of animal experiments towards the 
reduction in death and paralysis from poliomyelitis are the most unacceptable. 
Thus it is claimed:
The significance of poliomyelitis had dropped as better sanitation, better 
housing, cleaner water and better food had been introduced in the second 
half of the 19th century. (3)
This statement is quite untrue. For 4,000 years ‘infantile paralysis’ was a 
sporadic disease, with a very low background occurrence. A dramatic change 
occurred at the end of the nineteenth century, when epidemics began to 
occur in Scandinavia (1868-1881) and later in Vermont, USA (1894). The 
1905 epidemic in Sweden (1031 cases) established the change in nature of 
the condition from an obscure, endemic, sporadic disease to one with a 
regular, almost predictable occurrence in developed countries (4) (Fig. 6.2).
What explanation can account for this apparent paradox, that poliomyelitis 
only became a serious problem in those countries (e.g. in late nineteenth 
century Scandinavia) that boasted the highest standards of hygiene and 
sanitation? In fact poliomyelitis can be relatively innocuous if contracted 
when one is very young. Symptoms may be confined to a temperature 
and headache – a so-called “inapparent infection” – yet this can confer 
life-long immunity. It is thus obvious that infants brought up in unsanitary 
 The Conquest of Polio and the Contribution of Animal Experiments 59
conditions are likely to become infected whilst very young, suffer a slight 
illness and become immune. As hygiene and sanitation improve children 
become shielded from infection during infancy, and thus may contract the 
condition at an age when they are particularly vulnerable to the severe, 
paralytic form of the disease. The infection can then easily spread among 
such non-immune persons and the epidemics, typical of the first half of 
the 20th century, will result (4).
Fig. 6.2  Comparison of infant mortality rates and the incidence of poliomyelitis.
Animal experiments, of course, were crucial in the elucidation of the nature 
of poliomyelitis and inevitably in the formation of a vaccine. Although it 
was suspected that polio was an infectious disease, definitive proof was 
provided in 1908, when Landsteiner and Popper (5) managed to induce 
the condition in monkeys by injecting homogenates of the spinal cord of 
a 9-year-old boy who had died of acute polio. Since the samples of spinal 
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cord were shown to be free of bacteria, Landsteiner and Popper surmised 
that poliomyelitis was caused by a virus too small to be detected by 
microscopic techniques at that time (in actual fact poliovirus is one of the 
smallest viruses). The infection was transferred from monkey to monkey 
and thus provided a model of the disease from which much information 
was gleaned.
It is unfortunate that Landsteiner, at that time working in Vienna, was 
not able to continue in this field, since the enormous expense of maintaining 
a sufficient monkey colony to pursue this study was beyond his available 
funds. (Landsteiner was awarded the Nobel Prize in 1930 for his work on 
the classification of blood groups).
From 1908 until the 1940s the induction of polio in monkeys was the 
only means of study of the disease. With this model it was established that 
three strains of the virus existed, that the route of infection was via the nose 
and mouth, and that the virus stayed and multiplied in the gut before, in 
more serious cases, migrating via the blood stream to the motor neurones 
of the spinal cord, where the destruction resulted in permanent paralysis.
Of great significance was the observation that nasal washings from 
patients with a relatively trivial infection caused severe paralysis when 
administered to the experimental monkey, thus indicating that individuals 
could, in some circumstances become immune. This undoubtedly served 
to encourage those endeavouring to develop a vaccine.
From an early date attempts were made to grow the virus in culture, just 
as bacteria were cultured in broth. Viruses of course can only replicate in 
cells, thus tissue culture was the only possible means of fostering the virus 
outside the whole animal. Progress was slow since there were few groups of 
workers who could afford to maintain a monkey colony. The problem was 
eased when, after much effort, a strain of poliovirus was transferred to the 
Cotton rat, and subsequently to the mouse. The maintenance of the poliovirus 
in mice was significant because it meant that it was now possible to use a 
sufficient number of animals to provide clear evidence for the existence and 
virulence of the poliovirus. Thus the way was paved for intensive efforts to 
grow the virus in culture. As animal rights literature claims:
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[…] the most crucial breakthrough in preparing the vaccine came in 1949 
when Enders and his colleagues showed how poliovirus could be grown 
in human tissue culture. (6), 
and
animal research supporters are wrong to say that without animal experiments 
there would never have been a vaccine against poliomyelitis because: an 
early breakthrough in the development of poliomyelitis vaccine was made 
in 1949 with the aid of a human tissue culture. (3)
It is certainly true that Enders and his co-workers (7) made a significant 
advance in showing that the poliovirus could be grown in culture and 
for this they were awarded the Nobel Prize in 1954. However, for animal 
rights groups to imply that this work was a significant departure from 
animal experimentation is absolutely wrong. Further it has to be said 
that anyone who implies as such (if they have any scientific pretensions) 
are either deluding themselves or deliberately attempting to mislead the 
general public.
The poliovirus could not be seen, how was it therefore possible to establish 
that the virus was replicating in culture? Only by an animal experiment. The 
primary inoculum seeded by Enders was a suspension of brain tissue from 
a mouse that had been infected with the Lansing strain of poliovirus. (The 
identity of the virus was verified by the “character of the disease it produced 
in white mice following intracerebral injection”). Subcultures to fresh tissue 
were prepared at 8-20 day intervals. Replication of the virus was proven 
when at the end of 67 days culture the primary inoculum had been diluted 
by many millions. Even so, the culture fluid still: “on inoculation into mice 
and monkeys, produced typical paralysis.” Thus, animal experiments were 
crucial in these significant results. It is probably superfluous to add that 
the incubation fluid used by Enders et al. was “balanced salt solution (3 
parts) and ox serum ultrafiltrate (1 part).”
The ability to grow the virus in cell culture ensured the rapid development 
of a vaccine, and widespread vaccination was introduced in 1955 in the 
USA and Europe (Figs. 6.3 and 6.4).
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Fig. 6.3  Deaths from poliomyelitis in the USA, 1948-1967. Data from Vital statistics of 
the USA; US Dept of Health, Educ. & Welfare.
Fig. 6.4  Deaths from poliomyelitis in England and Wales, 1938-1973.  
A.M. Ramsey and R.T.D. Emond, Infectious Diseases, London: Heinemann, 1978.
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As a result, the disease has been virtually eliminated from these areas. It has 
been estimated that 1.5 million cases of polio were prevented in the decade 
1980-1990 due to the immunisation programme (8). Although one opponent 
of animal experiments claims: “Proof that the introduction of the (polio) 
vaccine was not the success it was made out to be comes from undeniable 
statistics” (3), mortality and morbidity figures do not in any way support 
this. Furthermore, the collective medical experience of the WHO maintains 
that the vaccination programme would eradicate poliomyelitis by the end 
of the decade (8) (Fig. 6.5).
Fig. 6.5  Polio in Latin America, confirmed cases per year, 1969-1989.  
Data from Medical & Health Annual, 1991, Chicago: Encycl. Britannica Inc.
An earlier version of this chapter was published as: The conquest of polio and 
the contribution of animal experiments. RDS News October 1991 4-5.
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7. Diphtheria: Understanding, 
Treatment and Prevention
Diphtheria levies a toll of clinical incidence of 10% of all born with a mortality 
of 5 to 7 per 1000; immunisation reduces this to an incidence of 1% and 
zero mortality.
Report of Medical Officers of Health, 
Diphtheria Immunisation in Infancy, 
The Medical Officer (1932) 48 188.
In the sanitary 1990s it is hard to envisage the experiences of physicians 
working in the fever hospitals a century ago. Yet this is the only way to 
appreciate the progress made in the treatment and prevention of infective 
disease. An inability, or unwillingness, to undertake this exercise largely 
explains the misrepresentation by some of the value of early treatments of 
infections. These treatments stemmed from basic research into causative 
agents and mechanisms of toxicity.
A prime example is diphtheria. The melancholic effect of having to 
watch a succession of children die either from suffocation or, as the disease 
progressed, from paralysis and heart failure, was wretched enough. Add 
to this the demoralisation and sense of impotence caused by the lack of 
effective treatment, then one can appreciate how dispiriting the practice of 
medicine could be at that time.
Diphtheria was formally described by Bretonneau in 1826, although 
epidemics among children of “malignant sore throat destroying life by 
suffocation and sometimes leaving paralytic sequelae” had been described 
http://dx.doi.org/10.11647/OBP.0055.07
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since earliest times. The epidemics tended to be cyclical “often lasting for 
many years, and followed by intervals of quiescence” (1).
The primary lesion of the disease occurs in the upper respiratory tract. 
It is a thick, leathery, bluish-white pseudomembrane composed of bacteria, 
dead cells and fibrin. Should the lesion occur in the laryngeal region, the 
airway may become occluded and intubation would therefore be necessary. 
The emergence of the germ theory triggered the start of the scientific 
investigation of the aetiology of diphtheria. Klebs in 1883 described a bacillus 
obtained from the pseudomembranes of diphtheria patients. The straight 
or slightly curved rods described by Klebs we know today were indeed 
Corynebacterium diphtheriae, although Klebs’ study was purely morphological. 
A year later Loeffler isolated and cultured the bacillus from 13 undisputed 
cases of diphtheria. When the cultures were inoculated onto injured mucous 
membranes of various animals, pseudomembranes developed, resembling 
those in patients. Nevertheless, Loeffler’s report was somewhat reserved, 
since he was unable to explain the systemic symptoms of diphtheria.
In both animals and man infected with the supposed causative organism 
there are severe systemic disturbances and even organ degeneration, but the 
bacillus could be found only in the local lesion. 
The anomaly was resolved in 1888 by the observation by two of Pasteur’s 
colleagues, Roux and Yersin, that the broth used to grow the cultures of 
bacillus diphtheriae remained toxic for guinea pigs after the bacteria had been 
removed by filtration. The filtered broth was also shown to be toxic for rabbits, 
dogs, cats and horses (2). Thus the systemic symptoms of the disease were 
due to the absorption of a toxin exuded during the growth of the bacilli on 
the mucous membrane. This observation was very important, since studies 
on hog cholera in 1885 had demonstrated that administration to an animal 
of very small concentrations of a bacterial product could eventually produce 
immunity to that infection. Consequently in 1890, von Behring and Kitasato 
were able to show that administration of very small amounts of diphtheria 
toxin to animals resulted in the presence in their plasma of a factor which, 
when mixed with the toxin, rendered it innocuous to animals (3).
The subsequent observation that this plasma, when actually administered 
to animals, could protect them from fatal doses of diphtheria toxin paved 
the way for the use of “diphtheria antitoxin” to treat diphtheric patients. 
According to most accounts the first clinical use of the antitoxin was in Berlin 
on Christmas Eve 1891, when von Behring administered it to a seriously ill 
girl who subsequently recovered (Fig. 7.1).
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Fig. 7.1  1909 photo of Emil von Behring (1854-1917). Wellcome Library, London, CC BY.
Diphtheria Antitoxin
To produce an effective antitoxin, a potent toxin was required. Typically, 
a virulent strain of bacillus was grown on a shallow layer of medium and, 
after 6-8 days, the formed toxin was obtained by filtration. The toxin could 
only be standardised by a biological assay. This was the measurement of the 
volume of filtrate that would kill a guinea pig of 250g body weight within 
5 days. The lethal volume was required to be below 0.1cc for the toxin to be 
of adequate strength (4).
The antiserum was usually produced in horses. Gradually increasing 
subcutaneous doses of toxin were administered over a period of 2-3 months. 
At the end of this time the horse plasma contained possibly 1,000 antitoxin 
units per cc and the animal could continue to provide antitoxin for 2-4 years.
The antitoxin in turn required standardisation. This was achieved by 
comparing its ability to render a sample of toxin innocuous to guinea pigs, with 
that of a stable, standard sample of antitoxin provided by a central source (4).
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Serotherapy in Diphtheria
After the first successful treatment of diphtheria with the antitoxin by von 
Behring, the use of equine diphtheria antitoxin spread rapidly. Even today 
serotherapy is the only way to avoid the severe effects of systemic intoxication.
Early on it was realised that to be effective the antitoxin had to be 
administered early, since the toxin could only be neutralised before it became 
bound to the tissue elements where it caused toxicity. Rabbits given a tenfold 
lethal dose of diphtheria toxin could be saved by a relatively small dose of 
antitoxin if it was administered shortly after the poison. If the injection of 
the antitoxin was delayed, then increasing doses were required to prevent 
death. If the administration of the antitoxin occurred after one hour, then 
no dose would save the animal (4). 
Clinical Effects of the Antitoxin
In 1894, Roux and co-workers published their report of the striking benefit 
produced by antitoxin treatment of diphtheric cases admitted to the Hospital 
for Sick Children in Paris (5) (Fig. 7.2).
Fig. 7.2  Effect of antitoxin on case mortality.
The serum was administered to every case proved by bacteriological examination 
to be diphtheric, during February to July 1894. Between 1890-1893, before 
treatment, 3,971 children were admitted, 2,029 of whom died, a case mortality of 
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51%. During the first 6 months of serum treatment 448 children were admitted 
of whom 109 died, a case mortality of 24.3%. During the same period, Trousseau 
Hospital in Paris was not using the antitoxin, 520 cases were admitted there, 
316 died, a case mortality of 60%.
In some cases, where the lesion extended to the laryngeal region, tracheotomy 
was required. Case mortality in these instances was 73% in the Hospital for 
Sick Children prior to the use of antiserum. During the trial period this was 
reduced to 49%, whereas at the Trousseau Hospital the contemporary mortality 
in such cases was 86%.
After Roux’s signal paper, the use of diphtheria antitoxin spread throughout 
the developed world. Wherever it was used there occurred a reduction in case 
mortality. Although there was nothing akin to a double-blind clinical trial (case 
mortalities were compared to those prior to the adoption of the antitoxin) the 
circumstantial evidence was compelling. Amongst many anecdotes is the oft 
quoted report of the problem at Baginsky’s clinic in Berlin, where they were 
unfortunate to run out of the antitoxin and the case mortality immediately 
rose from 15.6% to 48.4% (6).
Based as it was firmly upon experiments in animals, predictably the use of 
the antiserum came under attack from the antivivisection community. Even 
as recently as 1934, Beddow Bayly alleged that the antitoxin could not work, 
since the disease was not caused by the Klebs-Loeffler bacillus but by “drain 
poison” (7). Strangely, in the same publication he asserts, through selective 
quotation, that the apparent drop in mortality following the use of antiserum 
occurred because of diphtheria diagnosis by bacteriological means, i.e. by 
demonstration of the presence of the bacillus in throat swabs. The result of 
this was that very mild cases, which previously would have been recorded 
as minor sore throat, were diagnosed as diphtheria. Beddow Bayly asserted 
that the inclusion of these mild, self-limiting cases falsely reduced the case 
mortality. Firstly, this ignores the fact that the reduction in mortality immediately 
followed the introduction of the antitoxin treatment, whereas the bacillus had 
been described 10 years previously. Secondly, it takes no heed of the striking 
reduction in mortality of cases which required tracheotomy, and thus were of 
undoubted severity. Finally, there were many studies that demonstrated the 
necessity to administer the antiserum as early as possible, mortality increasing 
as the treatment was delayed from the first to the fifth day of the disease. As 
Sir Charles Martin, an authority on the treatment of diphtheria, emphasised: 
“If the antitoxin were a remedy of no value, whether it were administered on 
the first or the fifth day of the disease would be immaterial” (8).
Acceptance of the antitoxin was lukewarm in Great Britain. It was not widely 
used until the publication in 1898 of the report by the Special Committee, set 
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up by the Clinical Society, to investigate the efficacy of antitoxin treatment of 
diphtheria (9). The report compared 633 treated cases with 3,042 cases that 
did not receive antitoxin. The 50-page report concluded:
•  General mortality is reduced by one-third
•  Mortality in tracheotomy falls by one-half
•  Extension of the membrane to the larynx very rarely occurs after 
administration of the antitoxin
•  Duration of life in the fatal cases is prolonged
•  The number of fatal cases is less when antitoxin is used early in the 
illness than in those that do not receive it until a later period.
Even after large doses there were no serious ill effects. Rashes occurred in one 
third of cases. Pain and swelling of the joints were produced in a number of cases.
Immunisation against Diphtheria
As emphasised by Cobbett in 1933 (10), the benefit produced by the antitoxin 
was “by no means to be despised,” but it was only able to reduce the overall 
case mortality to a certain percentage. This was partly due to the practice of 
relying on bacteriological diagnosis before administration of the antitoxin, thus 
delaying the early use of the remedy, when it is most efficacious.
In 1890, von Behring and Kitasato had mooted the possibility of generating 
active immunity against diphtheria, and had actually produced immunity in 
guinea pigs by the use of a “detoxified” diphtheria toxin. Some years later, von 
Behring (11) produced a long-lasting immunity in guinea pigs, monkeys and 
asses by using a carefully balanced mixture of toxin and antitoxin (a technique 
which had been used with success in New York for the generation of antitoxin 
in horses). The toxin/antitoxin mixtures were used in limited studies by von 
Behring to protect humans against diphtheria, but widespread immunisation 
only began with the development of formalin-inactivated toxin, introduced 
independently by Glenny and Hopkins (12) and Ramon (13).
The formalin-inactivated toxoid (and the later alum precipitated and 
adsorbed diphtheria toxoids) were required to be standardised for antigenic 
potency by measuring their ability, 28-30 days after inoculation, to protect 
guinea pigs against a challenge with a 20-fold LD50 of a suitable diphtheria 
toxin. Innocuity tests also had to be performed to exclude dermal toxicity 
(intracutaneous injection to rabbits or guinea pigs – observed for 48 hours) 
and delayed, systemic toxicity (parenteral administration to guinea pigs – 
observed for 6 weeks) (14).
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The adoption of immunisation against diphtheria occurred in piecemeal 
fashion, its initiation depending on the awareness and energy of individual 
Medical Officers of Health. There was also a vociferous opposition both from 
the antivivisection movement and the National Anti-Vaccination League.
From early studies in restricted populations it emerged that sanitary measures 
of isolation would be of limited value in the containment of diphtheria, since 
the Health Committee of the League of Nations demonstrated that 97% of 
infections were not contracted from clinically evident cases of the disease, but 
from the more numerous healthy carriers of virulent bacilli (8).
The dramatic impact of immunisation was cogently illustrated by the well- 
controlled investigation of the incidence of cases of diphtheria at Greenwich 
Hospital School, where immunisation abolished the disease despite the fact 
that infective but healthy carriers were present in constant numbers both 
before and after the inoculation programme.
Similarly, striking evidence for the benefits of immunisation against 
diphtheria comes from the clear protection of nursing and auxiliary staff 
afforded by inoculation of those deemed to be at risk (i.e. those with a positive 
Schick test) in diphtheria hospitals (15). Non-immunised staff were 14 times 
more likely to contract the disease as the inoculated.
Fig. 7.3  Diphtheria death rate in New York, 1920-1930.
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Even in field trials, the benefits of inoculation were clear, for example in 
New York (described in 1932 as the “best immunised city in the world” (16; 
Fig. 7.3)) and in Birmingham, which was one of the earliest English cities 
to institute diphtheria immunisation in 1926. Here a marked decline in 
incidence of diphtheria was seen by 1931, when almost 10% of children had 
been vaccinated (17) (Fig. 7.4).
Fig. 7.4  Incidence of diphtheria in Birmingham (children 5-14 years), 1920-1935.
Despite the clear medical evidence of the protection offered by inoculation, 
the Anti-Vaccination League fought a vigorous rearguard action, disagreeing 
with immunisation “by filthy concoctions produced from the artificially 
diseased blood of the lower animals being injected into the clean blood stream 
of human beings” (18). (The vaccine of course was simply the formalin-treated 
toxin, it was not obtained from an animal). Much was made of the supposed 
toxicity of the vaccine (19), although at the time this battle was at its height 
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(1932), 150,000 persons in Great Britain and Ireland had been immunised 
against diphtheria without any ill-effect, let alone fatality (20).
The success in local health districts of inoculation against diphtheria 
resulted in the acceptance across Britain of the immunisation of pre-school 
children in 1940. The drop in incidence of the disease after this is an impressive 
illustration of its efficacy (Fig. 7.5).
Fig. 7.5  Diphtheria death rate in Great Britain, 1925-1955.
The success of the many local experiments into the protection offered by 
diphtheria immunisation means there can be no doubt that this technique 
is effective in reducing the incidence and mortality of the disease. However, 
as the WHO statistics show (21), in several European countries significant 
declines in death rates have been registered, despite the fact that in these 
countries only a few vaccination programmes were carried out in limited 
areas. It is thus possible that a concurrent change may have taken place in 
the pathogenicity of Corynebacterium diphtheriae, or human resistance may 
have increased.
It is known that with the increase in the number of resistant individuals 
as a result of immunisation, the toxinogenic C diphtheriae becomes replaced 
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by nontoxinogenic strains in carriers. It is possible this could account for 
the general decline in diphtheria morbidity.
Could Diptheria Return?
The report of a serious case of diphtheria in a Finnish man, contracted during 
a trip to Russia, has resuscitated interest in the need for booster vaccinations 
(22). This particular patient entered hospital during Easter 1993, developed 
neurological symptoms (paraesthesia of right mandibular area and loss of 
power in all four extremities) and signs of myocardial toxicity. He was still 
in hospital at the time of the publication of the case (July 1993). The absence 
of the toxinogenic strains in countries where inoculation was widespread 
means that one does not acquire booster protection by natural infection. It 
may thus be necessary to reinforce protection, particularly for those travelling 
to countries endemic for diphtheria. The non-toxic, antigenic cross reacting 
materials (CRM), obtained after random mutagenesis of the TOX gene, may 
be developed as suitable alternatives to the toxoid vaccines (23), which may 
cause untoward reactions in adults.
The occasional case of diphtheria that occurs intermittently in Europe, 
serious as each is, serves as a reminder of how far we have progressed from 
the dire situation in the diphtheria wards one hundred years ago.
An earlier version of this chapter was published as: Diphtheria – understanding, 
treatment and prevention. RDS News January 1994 8-12.
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II. DEVELOPMENT OF  
LIFE-SAVING PROCEDURES

8. Development of Dialysis to 
Treat Loss of Kidney Function
The kidney regulates the water, acid/alkali and ion balance of the body, and 
removes toxic products of metabolism and ingested poisons. It is thus not 
surprising that when the kidney fails to function properly the consequences 
are dire. Urine production falls and toxins build up in the plasma ultimately 
producing coma. Cardiac arrhythmias may be induced through build-up of 
potassium ions in the plasma. Death results if the condition is severe and 
untreated.
Acute renal failure is a sudden decline in renal function as a result of 
poisoning or reduced cardiac output (due to severe haemorrhage, shock, 
septicaemia, myocardial infarction etc.). Chronic renal failure (CRF), due to 
pyelonephritis, glomerulonephritis, hypertension or diabetes, is characterised 
by a more gradual loss of function. The chronic disease can be controlled 
to some extent by a low sodium, low protein diet. But both for acute renal 
failure, and for the 5,000 patients per year in the UK that develop chronic 
renal failure, the life-saving technique of dialysis is essential.
Haemodialysis
The crucial discovery in the development of dialysis techniques was that of 
Thomas Graham, who in 1854 showed that colloids and crystalloids could 
be separated in aqueous solution. Graham demonstrated the movement 
of urea and sodium chloride, but not colloids, through a semipermeable 
membrane (treated parchment, 1). Over the next 50 years, collodion became 
the most popular material for the formation of a semipermeable membrane 
and Richardson must receive credit for being the first to suggest that 
http://dx.doi.org/10.11647/OBP.0055.08
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animal blood could be “dialysed” by passing it through a colloidal tube 
surrounded by saline (2).
The first practical demonstration of the continuous dialysis of blood outside 
the body (i.e. in an “extracorporeal circuit”) was performed by Abel and his 
co-workers (3). They took blood from arteries of chloretone-anaesthetised 
dogs and rabbits and passed it through a series of celloidin tubes immersed 
in saline (celloidin was a brand of collodion). The blood was then returned 
to the animal via a cannulated vein. The animals made complete recoveries 
after being subjected to this “vividiffusion” for 2-3 hours.
Abel did not actually develop the apparatus as a prototype machine 
for treating renal failure. His main interest was the measurement of the 
plasma concentration of physiologically active substances such as hormones. 
Detection of these in the plasma was difficult since they were often lost during 
precipitation of the plasma proteins, to which they could adhere. Abel thus 
hoped that this form of dialysis would extract active substances as fast as 
they entered the blood, without at the same time removing proteins and 
cells. Nevertheless Abel stated in his paper that the machine might act as 
an “artificial kidney” which might be used to tide over a dangerous crisis 
in one of the:
numerous toxic states in which the eliminating organs, more especially the 
kidneys, are incapable of removing from the body at an adequate rate, either 
the autochthonous or the foreign substances whose presence in excessive 
amount is detrimental to life processes.
Abel prevented coagulation in the extracorporeal circulation by the use of 
the anticoagulant extracted from leeches, hirudin (Hirudin, at $27.50 per 
gram, appears to have been the 1913 equivalent of some of the contemporary, 
expensive recombinant-produced proteins. Abel therefore extracted hirudin 
for himself from leeches bought from cupping barbers at the rate of $6 per 
hundred).
Anticoagulants and Cellophane
It was difficult to extract large quantities of hirudin for use in haemodialysis, 
and the early preparations were very impure and caused severe cardiovascular-
respiratory side effects and allergic reactions. This meant that such preparations 
could only be used for animal studies. The absence of a suitable anticoagulant 
to prevent blood clotting in the extracorporeal circuits prevented the clinical 
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use of haemodialysis. The despair and frustration experienced by military 
physicians during World War I, observing the inevitable death of troops 
from renal failure following severe traumatic damage, ensured the continued 
experimental investigation of the technique. More efficient dialysis membranes 
were prepared, and the design of dialysis machines was modified so that a 
smaller volume of blood was required to fill the extra corporeal circuit. A 
significant event was the commercial manufacture of long lengths of cellophane 
tubing. Although prepared originally as sausage casings, their potential as 
dialysis membranes in artificial kidney machines was soon recognised.
The discovery of the anticoagulant that occurred naturally in mammals, 
heparin, was a turning point in the clinical use of dialysis. Heparin was 
isolated from dog liver by McLean in 1916, when he was actually trying to 
prepare clotting factors (4). Haas produced a batch of heparin in 1925 and 
showed that it performed well during dialysis in his animal studies (5). But 
as with hirudin, the early extracts of heparin were very impure and could 
not be used in patients. However, the relative abundance of heparin, large 
amounts of which could be extracted from beef liver and lung, meant that 
biochemists were free to experiment with purification techniques. In 1937 
Murray(6), using purified extracts (250 units/mg) produced by Charles and 
Scott, showed that injection of heparin into dogs, rabbits, guinea pigs and 
mice rendered their blood incoagulable for long periods with no apparent ill 
effects. A sample of double the purity (500 units/mg) was then administered 
to patients with “no deleterious effects” (6).
Heparin was thus used as the anticoagulant in the first successful treatment 
of a patient in acute renal failure by the Dutchman Willem Kolff in 1945.1 
Although she was completely comatose when the treatment was initiated, 
the use of the artificial kidney designed by Kolff brought her out of the 
coma. Renal function improved and she survived. The life-saving potential 
of dialysis was realised (5).
Heparin must still be prepared from animal sources, viz the lungs of 
oxen or the intestinal mucosa of oxen, sheep or pigs. Like many substances 
1  “One of my first patients was a young man suffering from chronic nephritis and slowly 
dying of renal failure. He was hypertensive, had headaches, became blind, and was 
vomiting every day. His old mother was the wife of a poor farmer, her back bent by 
hard work, dressed in her traditional Sunday black dress, but with a very pretty white 
lace cap. I had to tell her that her only son was going to die, and I felt very helpless.” Dr 
Willem Kolff, the first person to treat a patient with an artificial kidney. Written in a 
letter to Dr F. D. Moore, quoted in F. D. Moore, Give and Take: The Development of Tissue 
Transplantation. Philadelphia: Saunders.
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extracted from animal tissue, the safety of each batch must be ensured by 
testing samples on an anaesthetised animal to ensure the absence of substances 
that may lower blood pressure (7).
Alternative Anticoagulants
Even in the presence of heparin, blood platelets can deposit on the dialysis 
membranes and thus cause a thrombocytopenia (fall in platelet levels) in the 
patient. Some low molecular weight fragments of heparin are anticoagulant 
and are said to produce less of a fall in platelet levels. Such compounds may 
be of use in dialysis in patients with a high bleeding risk.
Epoprostenol (prostacyclin) is an endogenous prostanoid made by the 
innermost cells of the blood vessels. Its ability to prevent platelet aggregation 
in vivo was demonstrated in a number of species (8). Epoprostenol was 
shown to be capable of replacing heparin in dialysis in anaesthetised dogs 
(9). Subsequent tests in dialysis patients showed that with small amounts 
of epoprostenol, the dose of heparin could be reduced to avoid problems in 
high-bleeding-risk patients. Epoprostenol thus has a guaranteed place in the 
management of dialysis where haemorrhage may be a problem.
Rather belatedly, highly purified samples of the first anticoagulant, hirudin, 
have now become available. Studies in dogs, rabbits and rats showed hirudin 
to be well-tolerated with low toxicity. The cardiovascular-respiratory effects 
seen in dogs with the partially purified hirudin were not seen with the highly 
purified preparations (10). Subsequent tests of the purified hirudin samples 
in healthy volunteers showed that they were also innocuous to humans 
(11). (It is of interest that the pharmacokinetic data, i.e. plasma half-life and 
urinary excretion of unchanged hirudin, were virtually the same in both 
animal and human studies).
Since hirudin can now be produced in recombinant form, it is possible 
that it may, after 100 years, find a use in dialysis.
Peritoneal Dialysis
Wegner, in 1877, was the first to conduct experiments into the effect of placing 
solutions of various concentrations into the peritoneal space (12). He noted 
that if a particular volume of a concentrated sugar solution was injected into 
the peritoneum of rabbits, a larger volume could be subsequently withdrawn.
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Changes in volume and osmotic pressure of fluids placed in the peritoneal 
space were further studied by Starling and his co-workers between 1894 and 
1895. In the same species they noted that on injection of hypotonic solutions 
their volume in the peritoneum decreased within hours, but when an isotonic 
solution was used, the volume remained the same for 2-3 hours (actually the 
fluid began to be absorbed after this time). The inevitable conclusion was 
that the serous surfaces of the peritoneum behaved as an inert membrane, 
the volume of fluid within the peritoneal cavity being dependent on the 
osmotic pressure on either side of the membrane (13).
It was natural to assume that small molecules might cross the peritoneal 
membranes, the rate of passage depending on the relative concentrations 
in the blood or the peritoneal fluid. From the 1920s to 1930s, experiments 
on rabbits, dogs and monkeys showed that the peritoneal membranes were 
permeable to most low molecular weight substances (including urea) and 
even some proteins (13). Warming the solutions placed in the peritoneum, 
and increasing the movement of the gut were found to accelerate the diffusion 
of substances out of the blood into the fluid in the peritoneum.
The conclusion derived from these animal experiments was that if fluid 
was placed in the space surrounding the highly vascular intestines, the 
membranes between the blood and the injected solution acted in the same 
way as the artificial membrane in vividiffusion. That is, they allowed low 
molecular weight substances to diffuse across to an area of low concentration.
Peritoneal Dialysis in Uraemic Animals
It was a natural assumption that it would be possible to remove waste 
products from the blood into suitable solutions injected into the peritoneum. 
Experiments were therefore performed on uraemic animals. Solutions were 
either placed in the peritoneum, left for a sufficient time and then replaced 
with a fresh solution, or a continuous method was used. In this case the 
solution was caused to flow into the peritoneum through one catheter and 
allowed to drain out through a second.
Ganter in 1923 performed peritoneal dialysis on guinea pigs and rabbits 
with anuria (and hence uraemia) induced by ligation of the ureters. Constant, 
intraperitoneal injection of 50 ml samples of a physiological salt solution 
produced a marked clinical improvement. The animals became less lethargic 
and began walking around in search of food (14).
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Later investigations were virtually restricted to tests on bilaterally 
nephrectomised dogs. Such experiments clearly demonstrated that peritoneal 
dialysis could prolong the life of uraemic dogs from a control level of 3-5 
days, to 13 (15), 70 (16) and even 111 days (17). Through such experiments 
the optimal formulations of the dialysis solutions were derived and possible 
complications of the procedure exposed. One such was peritonitis, and as 
a consequence antibiotics were added to dialysis fluids used for patients 
from 1957 onwards.
These early animal experiments laid the basis for the use of peritoneal 
dialysis for the removal of toxins from the blood of patients. The use of 
peritoneal dialysis gradually intensified from 1945 onwards with constant 
refinements being added to the technique. Continuous ambulatory peritoneal 
dialysis (CAPD), in which waste products and water are continuously 
removed whilst patients carry on with their normal activities, became freely 
available in the UK in 1980.
Fig. 8.1  In the 1960s, the NHS only supplied dialysis for acute kidney failure; patients with chronic 
kidney failure had to pay about £7,000 for machines and technical support. However, today kidney 
dialysis machines like these are widely available. © Science Photo Library, all rights reserved.
Anaemia During Dialysis: Erythropoietin
Another problem associated with renal failure is anaemia. This is not 
secondary to the dialysis, but to the fact that the diseased kidney is not able 
to produce a factor that normally promotes the maturation of red blood cells, 
erythropoietin (EPO). Our knowledge of the importance of EPO and other 
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agents in the prevention of anaemia stems originally from studies of the 
circulating haemopoietic factors that appear in the blood of anaemic rabbits 
(18). The kidney was shown to be the main site of formation of EPO after 
experiments in rats and rabbits which demonstrated a sharp fall in plasma 
EPO activity after nephrectomy, but no change after removal of other organs 
(19). Defective production of EPO in patients in chronic renal failure can 
render some patients dependent on regular blood transfusions. EPO can 
now be prepared by recombinant methods and it is highly effective for the 
treatment of the anaemia of chronic renal failure, removing the requirement 
for transfusion within weeks.
Dialysis without question saves the lives of patients with acute and 
chronic renal failure. The basic animal research, performed around the turn 
of the century, exposed the possibility of removal of toxic metabolites from 
the blood by diffusion across semipermeable membranes. Without those 
experiments, the 100 patients per million population per annum (20) that 
develop CRF would have no future. However, while dialysis is life-saving, 
the treatment for CRF with the best prognosis is a kidney transplant (21). 
Transplantation is also the most cost effective treatment (20).
An earlier version of this chapter was published as: Development of dialysis 
to treat loss of kidney function. RDS News January 1995 8-11.
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9. The Contribution of Animal 
Experiments to Kidney 
Transplantation
Haemodialysis is life-saving and curative in acute renal failure. By reversing 
the build-up of metabolic products normally excreted by a functioning kidney, 
dialysis enables the temporarily affected kidneys to heal and resume normal 
function. In chronic renal failure however, the burden of regular dialysis is 
necessary unless a healthy kidney from a donor can be grafted.
Chronic Renal Failure
Chronic renal failure (CRF) due to glomerulonephritis, pyelonephritis or 
polycystic kidney disease is quite common, particularly in young adults. 
Depending on the composition of the population, between 50 and 100 persons 
per million will develop chronic renal failure each year (1).
In the absence of treatment, the deterioration in kidney function results 
in anaemia and weakness. Since water cannot be excreted, fluid accumulates 
in the tissues and consequent lung oedema causes breathing difficulties and 
strain on the heart, an organ probably already compromised by high blood 
pressure, which is a common feature of kidney failure. The build-up of waste 
products results in inflammation of various tissues leading to pericarditis, 
colitis, diarrhoea, gastritis and persistent vomiting. Peripheral neuritis can 
result in paralysis (2).
Experiments in Transplantation
The miserable clinical picture of the patient, often young, sinking inexorably 
into coma, and from coma to death was a potent stimulus to research. The 
http://dx.doi.org/10.11647/OBP.0055.09
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possibility of treating CRF by grafting a healthy kidney was a natural 
experiment to attempt. However, the transplantation of a large organ such as 
the kidney, which receives its blood supply via a single, large artery, requires 
the connection (or anastomosis) of the renal artery and vein of the donor 
kidney with a suitable artery and vein in the patient. This was no simple 
task since the arterial anastomosis had to be secure enough to withstand 
systolic blood pressure.
This formidable problem was resolved by the French surgeon Alexis 
Carrel (Fig. 9.1), who in 1902 described a method for suturing together the 
cut ends of blood vessels (3). 
Fig. 9.1  Alexis Carrel, 1912 Nobel Laureate in Physiology or Medicine.  
Wellcome Library, London, CC BY.
Carrel initially fixed three sutures equidistant around the end of each vessel 
and applied tension, thus forming a triangle. Corresponding sides of the 
triangulated vessels were then sewn together using extremely fine needles 
and the thinnest linen thread as used by the lace makers of Valenciennes (Fig. 
9. 2). Carrel performed many anastomoses, of various types, in cats and dogs. 
These healed and functioned well for many months (4). It is noteworthy that 
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Carrel emphasised the importance of protecting the endothelial cell layer 
during the procedure. A fact he found by experiment, but obvious today in 
view of the many important factors known to be synthesised and released 
by these cells.
Fig. 9.2  Carrel’s vascular anastamosis. From A. Carrel (1902), ‘La Technique operatoire 
des anastomoses vasculaire et la transplantation des visceres’, Medecine de Lyon, 98, 859.
Carrel used his suturing technique to experiment with kidney transplantation 
in dog and cat. His anastomoses enabled a kidney, removed and transplanted 
to a different site in the same animal (an autograft), to function adequately 
provided that the organ was not deprived of a blood supply for too long. 
However, a kidney grafted from another animal of the same species (a 
homograft or allograft) functioned for only a few days. After that it would 
become oedematous and cease to work. After many experiments, Carrel 
became convinced that it was not the surgery that caused the problem, 
since autografts always functioned reasonably well. He concluded that the 
changes that occurred in the kidney transplanted from a different animal 
of the same species were due to “biological factors” from the host. Thus the 
phenomenon of rejection was exposed (5).
Rejection
Carrel was the first scientist in America to be awarded the Nobel Prize. 
This was in 1912 for work on “vasculature suture and transplantation of 
organs.” He returned to France at the outbreak of World War I. Although 
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he went back to the USA in 1919, he did not return to the problem of kidney 
transplantation, but worked on the in vitro cultivation of organs and tissues.
The inevitability of the rejection of homografted kidneys was confirmed 
in 1923 by Williamson, a surgeon working at the Mayo Clinic Foundation. 
Williamson’s experiments in dogs were similar to those of Carrel. They were 
slightly more sophisticated, however, in that he analysed the urine produced 
by the kidney homografts and autografts, and noted that there was very little 
difference until rejection began in the homograft. Williamson also examined 
microscopic sections of the homografted kidneys and was thus the first to 
describe the histological picture of the kidney during rejection (6).
The seemingly insuperable problem of the refusal by a host to tolerate 
the presence of an organ from another animal from the same species caused 
a hiatus in transplantation research. It was not for another 20 years that the 
dreary clinical picture, and the frustration of the physician attempting to treat 
CRF, again stimulated research into the possibility of kidney transplantation.
There were some sporadic attempts to transplant kidneys into seriously 
ill patients. The thigh was usually chosen as the transplant site. This was 
anatomically inconvenient, but the ease of access meant that the kidney 
could be easily examined and removed without major surgery. As might 
have been predicted, long-term survival was not attained.1
Perfection of the Surgery
Although, in experimental animal studies, autografted kidneys worked 
adequately, they did not function in a completely normal way. This was probably 
due to the absence of the nerve supply, lymphatic drainage and various other 
factors. The surgeon Joseph Murray joined the Brigham Hospital in Boston in 
1951, and initially worked in the laboratory to determine the optimum surgical 
technique for kidney transplantation. Murray demonstrated in dog that the 
best place for the graft was in the abdomen, behind the peritoneal membrane 
and connected to the blood vessels of the pelvis. The ureter could then be 
1  One surprising example of a homotransplanted kidney surviving for 175 days without 
any immunosuppressive therapy is described by Moore (The case of “Dr. W” in Ref. 7). 
The patient ultimately died as a result of severe hypertension, the kidney showing no 
classical sign of rejection. There is no explanation for this random success. It was an early 
example of the occasional apparent acceptance of a graft that occurs in both animal and 
human experiments, perhaps due to a chance close tissue matching.
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sutured to the bladder, instead of to the skin, as in the early transplants (the 
latter technique frequently resulted in infection). By 1954 Murray had several 
dogs living for over 2 years on a life-sustaining renal autograft (7).
Armed with a perfected technique, and impressed with the knowledge 
that a kidney allograft in a dog with both kidneys removed would excrete 
urine and support life until rejection, the surgeons at the Brigham began 
in earnest to attempt transplantation in patients with CRF. Without any 
attempt to tackle the problem of rejection these were obviously not successful. 
Nevertheless important lessons were learned. As in the animal studies, the 
transplanted kidney could restore the uraemic patient to normal and Murray’s 
placement of the kidney in the abdomen, and the anastomosis with pelvic 
vessels perfected in dog, worked well in patients. The necessity of sometimes 
removing the diseased kidneys to prevent hypertension was established, 
and the pathological changes occurring in the kidney during rejection were 
observed and shown to be similar to those in the animal studies.
The Mechanism of Rejection: An Immunological 
Phenomenon
Clues to the mechanism of the rejection of homografted tissue had actually 
appeared in the literature long before surgeons were seriously considering 
kidney grafting for CRF.
In 1916 Little and Tyzzer (8) had shown that tumours that arose 
spontaneously in one strain of mice could be transplanted to other individual 
mice within that strain, but not to mice of a different strain, who would reject 
them. Gorer, in 1937 (9), used similar experiments to demonstrate that the 
rejection of a tumour inherent to one mouse strain by mice of another strain 
was due to tissue antigen(s) (designated by Gorer as antigen II). This could 
raise tumour-destructive antibodies that would also agglutinate red cells of 
the tumour strain of mice.
The definitive analysis of the immunological nature of graft rejection 
was provided by Medawar (Fig. 9.3) and his co-workers. The need to treat 
severe burns incurred by both service personnel and civilians during World 
War II prompted the British government to sponsor a study of skin grafting. 
Medawar, in conjunction with a plastic surgeon, studied the use of skin 
autografts and homografts for burns. Initially both grafts seemed to take, 
92 Animals and Medicine
but after a few days the allograft began to darken and die. Further allografts 
from the same donor were rejected even more rapidly. This became known 
as the “second set phenomenon” and was the observation that caused 
Medawar to conclude that the rejection of allografts was brought about by 
active immunisation (10).
Fig. 9.3  Sir Peter Medawar, painting by Sir Roy Calne. All rights reserved.
On his return to Oxford University after the war Medawar continued with 
his classic experiments which ultimately resulted in his Nobel Prize of 
1960. Medawar and his colleagues set up an animal model to examine the 
mechanism of rejection of skin grafts under tightly controlled conditions. 
He grafted skin between rabbits and established the control data of average 
times to rejection. Repeated grafts from the same donors were rejected much 
more quickly, whereas grafts from a second donor lasted as long as the initial 
grafts. Medawar thus had illustrated clearly the specificity of graft rejection. 
He also made careful histological examinations of the grafts and described 
their invasion by the white blood cells. This established beyond doubt the 
immunological nature of the rejection reaction (7).
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Prevention of Rejection: An Impossible Goal?
During the 1930s the concept of genetic individuality had emerged. Loeb, in 
his book The Biological Basis of Individuality, stated that any transplant between 
individuals would inevitably fail, since there were differences in the genetic 
make-up of everyone. Twenty years later, Loeb was invited to an international 
conference on transplantation. He declined, since he considered that “the 
subject matter of the conference was useless to pursue and a waste of time 
because the goal was impossible”(11). Unfortunately such emphatic assertions 
tend to be recorded in perpetuity. Since today there are patients with kidney 
transplants of more than 20 years standing, this provides a lesson for those 
tempted to make definitive statements based on intuition rather than evidence.
Experimental work during the 1950s increased our knowledge of immune 
mechanisms and strengthened the view that the rejection reaction might be 
capable of modification, so that transplants could succeed.
The fact that two genetic types could coexist in the same organism, without 
rejection of either, emerged from studies in cattle twins. Twinning is rare 
in cattle, and identical twinning is virtually unknown. In a study of cattle 
twins, Owen (12) noted that each twin carried blood cells of two different 
types. The fact that each was tolerated was presumed to be the result of an 
admixture of bloods between the twins in utero (Lillie, in 1916, had shown 
that in bovine twins there was often a union of the circulatory systems 
between the two placentae) (13).
The inevitable conclusion of these observations was that exposure to 
genetically dissimilar cells during fetal life rendered cells of that type tolerable 
in later life.
Other animal experiments consolidated this conclusion. Cannon and 
Longmire (14) transplanted skin between newly hatched (one-day-old) chicks 
of different breeds, producing adult red hens with patches of skin growing 
white feathers (in later experiments they also reversed the position of the 
skin, so that the white feathers were projecting in a different direction to 
the rest of the plumage). Delaying the skin graft for three days reduced the 
success rate to 1%, at 14 days all grafts were rejected.
Medawar also experimented with younger and younger animals, and in 
1953 published a significant paper describing what he termed as “actively 
acquired tolerance” (as opposed to actively acquired immunity) (15). Medawar 
and his co-workers anaesthetised a mouse (CBA strain), pregnant and near to 
term. By a careful incision they exposed the abdominal body wall. The fetuses 
94 Animals and Medicine
were sequentially brought into view by gentle manipulation of the abdomen 
and injected with a suspension of cells from adult mice of a different strain 
(A-line). Eight weeks after birth, each member of the CBA litter received a 
skin graft from an A-line mouse. The grafts took satisfactorily and resulted in 
the much-photographed mice carrying patches of fur of an entirely different 
colour. Medawar had thus shown that exposure of mice in utero to tissue of 
a genetically different strain produced a tolerance to that tissue.
Although “actively acquired tolerance,” as experimentally accomplished 
by Medawar, had no immediate application to the problem of rejection 
of kidney grafts, this work demonstrated that the immunological barrier 
was not insuperable. This was immensely encouraging for the surgeons 
endeavouring to achieve long-term survival of transplanted kidneys. (One 
such surgeon recorded his debt to Medawar in his account of the history of 
organ transplantation (16)).
The Identical Twins: A Vindication of the Surgery
It was evident that rejection of grafts would be unlikely if the organ or 
tissue came from an identical twin, since such monozygotic twins were also 
genetically identical. As everyone possesses a pair of kidneys, the surgeons 
at the Brigham Hospital had long considered that the donation of one kidney 
from a healthy twin might well be life-saving for the other suffering from 
CRF. The opportunity to put this to the test arose in 1953, when “Mr R H” was 
admitted to the Boston Public Health Service Hospital with chronic nephritis. 
His illness was severe and the outlook poor. Upon learning that the patient 
had a twin brother, his physician contacted the Brigham Hospital to suggest 
that this might be a case for a successful transplantation. Having ascertained 
that the tissue of the twins was interchangeable (by cross grafting patches of 
skin), and after establishing that the potential donor had a healthy urinary 
system, the question as to whether the transplant should be attempted was 
seriously addressed by the scientific and surgical team at the Brigham.
At a meeting on 20 December 1954 it was decided to proceed with the 
operation and, in view of Doctor Murray’s experience with dogs, to place 
the donated kidney in the abdomen with the ureter anastomosed directly 
to the bladder (7).
The operation was performed on December 23, 1954. The transplanted 
kidney began to produce “crystal clear normal urine” before the surgeons 
even had time to sew the severed ureter to the bladder. The patient recovered 
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rapidly after the operation. His heart, which had been enlarged, returned 
to normal size, fluid cleared from his lungs and he was returned to health. Mr 
RH married the nurse who had tended him in hospital and raised a family.
To attempt this first identical twin transplant was a brave action by the 
medical team at the Brigham. It showed unequivocally that in man, as in 
dog, this operation was feasible and that the transplanted organ performed 
normally. Attention then turned to the apparently insuperable problem of 
maintaining grafts from genetically different donors.
Whole Body Irradiation
Intense radiation was known to be particularly toxic to the mediators of 
rejection, the white blood cells. In view of the implacability of the problem 
it was not surprising that even this drastic procedure was examined as a 
means of prolonging survival of grafted kidneys. High levels of x-radiation 
were shown to prolong the life of skin homografts in rabbits, but at the cost 
of shortening the life of the host, since damage to the bone marrow rendered 
the animals susceptible to infection (17). Researchers tried to combat this 
problem by subsequent administration of homologous and heterologous 
bone marrow cells. The survival time of mice exposed to lethal x-radiation 
was increased by such treatment. Subsequently, skin grafts between rabbits 
showed extended survival after x-radiation and injection of hybrid bone 
marrow prior to grafting (18).
A successful renal graft was achieved in an irradiated dog at the Mary 
Imogene Bassett Hospital in Cooperstown. The animal was infused with 
bone marrow from the donor animal. Unfortunately the lack of an effective 
immune system resulted in the death of the animal from pneumonia after 
49 days. However the grafted kidney functioned excellently for this period, 
with no sign of rejection (19).
The results of these animal experiments did not really augur well for 
the value of x-radiation in patients in need of a kidney graft. However, dire 
situations produce drastic action. X-radiation followed by administration 
of bone marrow from numerous relatives was used to prevent rejection of 
a kidney graft in a woman who had her only kidney removed to stem a 
life-threatening haemorrhage. After some while her platelet levels dropped 
and, perhaps predictably, she died of haemorrhage 32 days after the 
irradiation. Of great significance however, at the post mortem the kidney 
showed no sign of rejection (7).
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Despite one apparent success, where the kidney was donated from a 
fraternal twin, and hence only a low level of radiation was used, the toxic 
effects of the radiation in patients, as in the animals, rendered this technique 
too dangerous. Nevertheless, the continued functioning of the transplanted 
kidneys did encourage the surgeons to believe that prevention of rejection 
was achievable (7).
Success with the First Immunosuppressants
A paper of great significance in transplant research is that of Robert Schwartz 
and William Dameshek of Tufts University Medical School. These workers 
showed, in 1959, that the anticancer drug 6-mercaptopurine (6-MP) given 
to rabbits, prevented the formation of antibodies following the injection of 
human serum albumin (20). In other words, 6-MP was capable of suppressing 
an immune response. Within one year Schwartz and Dameshek had extended 
this work to show that 6-MP could triple the survival time of skin homografts 
in rabbits (21).
The British surgeon, Roy Calne demonstrated the value of 6-MP in delaying 
the rejection of kidney allografts in dogs. In his first series of experiments, 
although 6 mg of 6-MP per day prevented rejection, the animals died within 
10-14 days. In a second series, the animals were bilaterally nephrectomised 
(and thus had to depend solely on the graft) and were given 5 mg of 6-MP 
initially. This was reduced to 2.5 mg after 2 days. Incredibly, two dogs 
survived for 21 and 47 days respectively. Without 6-MP dogs so treated 
would survive only 4 to 8 days, and ultimately die of kidney failure. Both 
of the test dogs died of pneumonia. The kidneys, however, showed no sign 
of rejection and were secreting concentrated urine to the end (22).
Calne at this time joined the active team at the Brigham Hospital for a 
sabbatical, where a collaboration was formed with the synthetic chemists at 
the Burroughs Wellcome Research laboratories in Tuckahoe, New York. These 
researchers, under the leadership of Dr George Hitchings, synthesised new 
analogues of 6-MP and produced azathioprine, orally active and less toxic than 
6-MP. With azathioprine it was possible to keep bilaterally nephrectomised 
dogs alive for up to 12 months (Fig. 9.4), dependent only on their grafted 
kidney (7). This experimental work led to the use of immunosuppressant 
drugs in patients with kidney grafts. From 1963 onward one-year survival 
of related donor transplants reached 80%.
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Fig. 9.4  The first long-surviving dog, Lollypop, treated with the immunosuppressant 
azathioprine following a kidney graft. All rights reserved.
Corticosteroids, such as cortisone and the newer synthetic analogues, soon 
began to be used in conjunction with azathioprine. Corticosteroids were 
known to inhibit antigen-antibody reactions and were subsequently shown to 
produce a threefold increase in the survival time of dog kidney homografts (23).
In the late 1970s cyclosporin was extracted from the fungus Tolypocladium 
inflatum, and purified as a potential antifungal agent. It was however, 
shown to be rather better as a potent immunosuppressant in animal tests. 
It suppressed the appearance of plaque-forming cells in the spleens of mice 
immunised with sheep red blood cells, and doubled the survival time of 
skin allografts in mice. Cyclosporin has become established as a front-line 
immunosuppressant drug.
Antilymphocyte Serum
Since the lymphocyte is the cell primarily responsible for rejection, it is not 
surprising that antilymphocyte serum (ALS) has been developed as a potential 
antirejection agent. Metchnikoff in 1899 was the first to prepare ALS by 
injecting guinea pigs with extracts of rat or rabbit lymph nodes (25). The sera 
produced caused agglutination of rat or rabbit white cells. Woodruff clearly 
demonstrated the benefit of ALS in transplantation by showing it produced 
a ten-fold increase in survival time of skin homografts between albino and 
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hooded rats (26). Despite problems of standardisation, ALS raised in horses 
is used in acute rejection crises. Poor tolerance to horse proteins, manifested 
by some patients, necessitates the occasional use of ALS raised in rabbits.
Tissue Typing
The genetic basis of rejection had been exposed by the mouse tumour 
transplant experiments of Little and Tyzzer (vide supra). The use of inbred 
strains of mice differing at only a single genetic locus from the original 
strain (congenic strains) enabled Gorer and Snell to establish the genetic 
locus (the “H” locus) for transplantation antigens. This work on the murine 
counterpart of human leucocyte antigens (HLA) hastened the understanding 
of transplantation antigens and emphasised the need for adequate tissue 
typing to ensure the best chance of long-term survival of kidney grafts (27)
The Future
Despite the emphatic progress made in organ transplantation, there is still 
need for improvement in antirejection therapy. Tacrolimus (FK 506) was 
introduced in 1989 but seems to share the same toxic effects as cyclosporin. 
Using transplant models in rodents, dogs and monkeys various groups of 
researchers have produced many candidate antirejection drugs (28). It is 
estimated that at the moment there are 10 novel non-peptide drugs and 15 
monoclonal antibodies in various stages of clinical and preclinical testing (28). 
From this research will no doubt come further, step-by-step improvements 
in immunosuppressive therapy.
The continual improvements in methods to prevent rejection have resulted 
in an increase in patients on the waiting list for a transplant. The shortage 
of donors has thus become the major problem, exacerbated by the fall in 
donors resulting from improved road safety measures.
This problem would be eased if kidneys from another species 
(xenotransplants) could be used. A colony of transgenic pigs has now been 
produced which possess human genes intended to protect the transplant 
against the acute, complement driven, rejection process that normally occurs 
with xenotransplants. The first transplant from a pig to a human will no 
doubt be attempted within the next decade.
About 2,000 patients per year receive a kidney transplant in the UK (Figs. 
9.5 and 9.6). Over two-thirds of these can expect their grafts to survive 
for at least a decade (1). In his admirable history of tissue transplantation, 
Francis Moore (then Professor of Surgery at Harvard) stated that none of 
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the advances in kidney transplantation could have occurred without the 
extensive research in animals (7). Any dispassionate historian would agree. 
Without the pioneering work on anastomoses by Carrel, the early experiments 
on graft placement by Murray, together with the experimental trials with 
antirejection drugs, we would still today regard the diagnosis of CRF as a 
death sentence.
Fig. 9.5  A donor human kidney is perfused with saline prior to transplantation.  
© Science Photo Library, all rights reserved.
Fig. 9.6  Surgeons performing a kidney transplant operation. Of the 2,000 patients a year 
in the UK who receive a transplant, two thirds can expect their graft to survive for at least 
10 years (Ref. 1). © Science Photo Library, all rights reserved.
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Three Nobel Prizes have been awarded (Carrel in 1912, Medawar in 1960 and 
Murray in 1990) for work that has assisted in the success of transplantation. 
Many might argue that even more scientists in this field merit such recognition.
ANIMAL EXPERIMENTS AND KIDNEY TRANSPLANTATION
1902 Anastomosis of blood vessels Dog, cat
1950
Autotransplantation of kidney
Perfection of placement surgery
Dog, cat
Dog
1953 “Actively acquired tolerance” Mouse
1955
Immunosuppressant effect of high dose 
radiation
Rabbit, dog
1959 Immunosuppressant drugs Rabbit, dog
1963 Antilymphocyte serum Mouse, rabbit, horse
1965 Tissue typing Mouse
1989 New immunosuppressants, antibodies Mouse, dog, monkey
An earlier version of this chapter was published as: The contribution of animal 
experiments to kidney transplantation. RDS News April 1995 8-14.
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10. Cardiopulmonary Bypass: 
Making Surgery on the Heart 
Possible
In the early seventeenth century William Harvey established that there 
is continuity between arteries and veins, and that the heart pumps blood 
through these vessels in a circular fashion. Harvey developed his hypothesis 
by observation of the relatively slowly beating hearts of cold blooded animals, 
such as snakes, rather than those of warm-blooded animals, which beat too 
fast to detect the pattern of their motion. In his use of further observational 
and quantitative techniques to substantiate his theory, Harvey manifested 
an exceptional intellect and imagination.
Even Harvey, however, could not have imagined the progress in the 
treatment of cardiovascular problems that was to occur in the following three-
and-a-half centuries. Today, a patient’s heart and lungs can be temporarily 
supplanted by a mechanical pump and oxygenator. The heart can be 
stopped for many hours, opened and subjected to intricate surgery, such 
as the replacement of a heart valve with a manufactured prosthesis or with 
animal tissue. At the end of the operation the repaired heart and the lungs 
are re-plumbed into the circulation where they resume their normal function.
This technique of open heart surgery involves opening the chest and 
the catheterisation of the great veins carrying the blood returning to the 
heart from the system. This deoxygenated, venous blood is collected in a 
reservoir, then passed through an oxygenator. The freshly oxygenated blood 
is pumped back into the arterial circulation through a convenient artery. 
Thus, an adequate supply of oxygenated blood is maintained to the vital 
organs. The heart and the lungs are therefore out of the circulation, having 
been “bypassed” by the mechanical pump, functioning as the heart, and the 
oxygenator, standing in for the lungs.
http://dx.doi.org/10.11647/OBP.0055.10
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The heart is rendered quiescent and kept viable by cooling and by perfusion 
of the coronary arteries with a “cardioplegic” solution, which prevents 
the heart beating and also supplies the heart with requisite nutrients and 
electrolytes. The artificial heart-lung circuit is filled with blood of the same 
group or with a synthetic priming solution, and clotting is prevented within 
this extracorporeal circuit by the use of heparin. The sudden increase in 
apparent blood volume when the patient is connected to the extracorporeal 
circulation requires appropriate adjustment of anaesthetic level. Under 
these conditions the heart can be operated on for many hours. Even long 
and delicate procedures such as the replacement of a heart valve can be 
performed at a leisurely pace.
It is hardly imaginable that anyone could believe that a procedure of 
this complexity, with many potential difficulties, such as the development 
of lethal air or clot embolism, could have been achieved without many pilot 
experiments in relatively large mammals (Table 1). However, animal rights 
literature asserts that it is a “fiction” to say that open heart surgery depended 
on animal experiments (1).
ANIMAL EXPERIMENTS AND OPEN HEART SURGERY
1916-35 Discovery and purification of heparin Dog, pig, ox
1933-53








The first use of cardiopulmonary bypass in a patient was by Gibbon in 
1953. However, Gibbon had started experimental work on the technique 19 
years previously. As is frequently the case, a particular clinical experience 
prompted Gibbon to consider this possible surgical innovation. In 1930 one 
of his patients died because of obstruction of the pulmonary artery with a 
massive embolus. This naturally provoked the thought that the blockage could 
have been successfully removed, and her life preserved, if even a portion of 
the patient’s circulation could have been taken over by an extracorporeal 
heart and lungs (2), thus bypassing the obstruction in the pulmonary artery.
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It was 4 years before Gibbon and his wife had the opportunity to test 
this technique in the Surgical Research Laboratories of the Massachusetts 
General Hospital. They found, to their surprise and delight, that it was 
possible to take over part of the pulmonary circulation of the cat by an 
artificial, extracorporeal circuit for four hours, with the cardiorespiratory 
function being adequately maintained (3). Repetition of the experiments 
under sterile conditions demonstrated that substitution of the heart and 
lungs of a cat for 20 minutes by mechanical devices was followed by recovery 
and survival for more than 250 days in 3 out of 13 animals. The remainder 
survived for between 1-23 days. In control experiments, simple occlusion of 
the pulmonary artery for 3½ minutes, with no bypass, produced permanent 
cerebral damage. Death always followed a 6½ minute occlusion (4).
During these early experiments on cats, Gibbon tested various types of 
pump and oxygenator. It was established that a pulsatile flow (such as occurs 
with the heart) was not essential for the proper functioning of the perfused 
organs. This meant that a comparatively simple roller pump could be used 
as a mechanical heart (perhaps surprisingly, roller pumps were found not 
to cause excessive breakdown of red blood cells). The oxygenator originally 
used by Gibbon was a rapidly moving hollow cylinder constantly gassed 
with a 95% oxygen, 5% carbon dioxide mixture. The withdrawn venous blood 
was trickled against the inner surface of the cylinder where it was spread 
into a thin film by centrifugal force. Oxygenated blood was collected at the 
bottom of the cylinder from which it was pumped back into the animal. 
Gibbon opted for this method of oxygenation since, unlike other techniques, 
it did not cause undesirable frothing.
Gibbon also established that, contrary to belief, large arteries (such as the 
femoral) could be catheterised and ligated, for the return of the blood to the 
circulation, without compromising the tissue normally served by the artery (2).
Refining the Technique
There was a hiatus in research from 1939-1945. Gibbon and others then began 
extensive experiments in dogs to perfect a technique whereby complicated 
and time-consuming operations could be performed inside the chambers of 
the heart, without the problems associated with complete occlusion of the 
vessels carrying blood back to the heart.
In a comprehensive paper, Gibbon described a series of experiments in 
dogs to test whether exclusion of the heart and lungs from the circulation 
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and prolonged passage of the blood through an artificial lung would have 
any deleterious effect (5). Initial experiments merely involved passing venous 
blood through the pump and cylinder oxygenator for 80-180 minutes, with no 
occlusion of the vena cava. This experiment was simply to see if the passage 
of the blood through the extracorporeal circulation for a prolonged period 
produced any ill effects. These animals lived less than 12 hours, dying in 
coma. Post mortem examination showed that death was caused by multiple 
small clots throughout all the organs. Further experiments demonstrated 
that the lungs could filter out these microemboli under some conditions, but 
attempts to pass the blood through the lungs prior to its return to the entire 
system proved abortive. 
Gibbon therefore included a metal filter into the extracorporeal circuit (300 
x 300 micron mesh, thread thickness 140 micron). The apparatus including 
the filter was then used in 6 dogs for 21/2 hour periods. All 6 dogs recovered 
rapidly after the operation and no haemolysis was induced by the filter. The 
animals were sacrificed between 42 and 106 days after the operation.
No sign of any infarction or damage was seen at autopsy. One of the dogs 
was observed to have but one kidney, yet even this animal had recovered 
with no renal complication.
Armed with the experience of these pilot experiments, Gibbon and his 
co-workers embarked on full scale heart and lung bypass experiments with 
the whole of the blood returning to the heart being passed through the 
extracorporeal apparatus for up to 113 minutes. In initial experiments the 
mortality in the dogs was 60%, death being due to haemorrhage or anoxia. 
More sparing use of the anticoagulant, heparin, and the administration of 
carefully chosen amounts of its antagonist protamine at the conclusion of 
the bypass reduced the haemorrhage. The apparatus was modified to enable 
the withdrawal of greater amounts of blood from the vena cava. Oxygen 
saturation of the blood was improved by placement of wire mesh over the 
surface of the rotating drum, this prevented filming and promoted greater 
exposure of the blood to oxygen. These modifications resulted in complete 
recovery of most animals. A few deaths occurred due to pericardial effusion.
The next step was to actually open the heart during bypass. Gibbon and 
co-workers carried out experiments on 29 dogs in which the septum between 
the atria was pierced under direct vision through the opened auricle. In 24 of 
these dogs the septal defect was then closed. Fourteen of these dogs survived 
and the defect became completely healed and covered in endothelium on 
both sides (6).
 Cardiopulmonary Bypass 107
Air entering the heart and hence the coronary circulation whilst the heart 
was opened was a frequent cause of death during these experiments. However, 
in 12 experiments a small plastic cannula was placed in the left ventricle via a 
stab wound. Suction was continuously applied to this cannula, thus any air 
entering the ventricle was removed. Air embolism of the coronary arteries 
did not occur in any of these experiments (6).
The First Use of Cardiopulmonary Bypass in 
Patients
Thus, twenty years of experimentation enabled the considerable problems 
associated with the development of an artificial heart and lung machine to 
be exposed and progressively solved. By the early 1950s the mortality in 
experimental animals was down to 12%.
Gibbon was ready to perform the first open heart operations on patients, 
aided by the heart-lung machine, in 1952-53. The first was on a 15-month-old 
baby with severe congestive heart failure (7). The cause of the condition 
was thought by the referral physicians to be a hole in the interatrial septum. 
When the atrium was opened however, no septal defect was found. The baby 
died soon after the operation and the post mortem revealed a huge patent 
ductus arteriosus. Sadly, this defect could easily have been corrected had it 
been looked for during the operation (Fig. 10.1).
Fig. 10.1  The recently transplanted heart of a baby boy, showing the tubing still connecting 
it to the heart-lung machine. The donor heart was preserved by injecting it with chilled 
cardioplegic solution. © Science Photo Library, all rights reserved.
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The second operation was performed on 6 May 1953. The patient was an 
18-year-old girl who, although symptomless until December, 1952, had at 
that time developed right heart failure. Cardiac catheterisation revealed an 
atrial septal defect. 
The patient was connected to the heart-lung circuit for 45 minutes during 
which time the heart was opened and the septal defect closed with a silk 
suture (7). The patient made a complete recovery and was alive and well at 
least 5 years later (2; Fig. 10.2).
Fig. 10.2  In open heart surgery the heart-lung machine takes over the function of the heart 
with a pump and the function of the lungs with an oxygenator. This means that surgery, 
often taking several hours, can be carried out in relative safety to replace diseased arteries 
or defective valves. © Science Photo Library, all rights reserved.
Elective Cardiac Arrest
During the early open heart operations the flow of blood to the heart muscle 
continued through the coronary vessels. The persistent leakage of blood into 
the heart chambers from the coronary circulation necessitated the constant 
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removal of this blood by suction, in order to maintain a clear field. The heart 
continued to beat, providing another hindrance to the cardiac surgeon.
In order to enable the operator to achieve the goal of “the unhurried correction 
of cardiac abnormalities under direct vision” (8), experiments were made to 
see if it was possible to stop and restart the heart at will, at the same time 
ensuring that no damage occurred to the heart muscle.
Melrose and his colleagues (8) achieved “elective cardiac arrest” in 
anaesthetised dogs on a heart-lung machine. Potassium citrate solution 
infused into the heart caused arrest within 5 seconds. After a token operation, 
blood was allowed back into the coronary vessels. Upon reperfusion with 
blood the hearts frequently went into ventricular fibrillation. Restoration of 
normal rhythm with a defibrillator was only possible in 70% of the experiments.
These researchers therefore performed further experiments on isolated, 
perfused hearts of rabbits to determine the optimal concentration of potassium 
necessary to stop the heart, and the allowable duration of the period of arrest. 
They concluded that potassium ions could be used to stop the heart pumping 
during bypass operations, and that hearts could recover spontaneously after 
15 minutes arrest without becoming damaged. They also demonstrated that 
administration of calcium salts or adrenaline to restore heart beat was not 
only unnecessary but dangerous (adrenaline had frequently been used in 
the clinical setting to restart an arrested heart).
The Development of Cardioplegic Solutions
During the following decade the problems associated with ischaemia 
produced in the arrested heart were investigated and gradually solved. This 
was achieved almost entirely by studies on the rat heart.
One of the most important factors in the prevention of damage to the 
ischaemic heart is to stop the heart as rapidly as possible. High magnesium, 
zero calcium, acetylcholine, neostigmine and tetrodotoxin were all investigated 
for their ability to produce rapid cardiac arrest (9). Raised potassium 
concentration was found to be the method of choice, although preservation 
of the heart was found to be better with the chloride salt, rather than the 
citrate used by Melrose and his colleagues. Citrate had some toxic effect 
possibly due to chelation of calcium.
In a series of painstaking, carefully controlled studies lasting several years, 
Hearse and his colleagues at St Thomas’s Hospital developed a cardioplegic 
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solution that enabled hearts to be safely subjected to ischaemic periods 
of 4-5 hours. Their technique was simple. Rat hearts from freshly killed 
animals were perfused in an in vitro circuit. The hearts were subject to a 30 
minute period of ischaemic arrest at 37°C. The post-ischaemic recovery of 
function (expressed as a percentage of the pre-ischaemic activity) was only 
3%, indicating severe and irreversible myocardial injury. However, prior 
perfusion of the coronary vessels with a solution of potassium chloride (to stop 
the heart) caused a 10-fold improvement in recovery (i.e. to 30% of control).
Continuing with this technique, Hearse and his colleagues altered the 
concentration of various ions and other compounds within the cardioplegic 
solution (Fig. 10. 3). 
Fig. 10.3  Effect of additives on recovery of rat heart from ischemia. Data from D. Hearse (1988), 
‘The protection of the ischaemic myocardium: surgical success v clinical failure?’, Progress in 
Cardiovascular Diseases, 30, 6, 381. The graph shows the beneficial effects of sequential addition of 
protective agents to cardioplegic solution. The protective solution was infused before a 30-min 
period of ischaemia of the isolated perfused rat heart. Without cardiac arrest the hearts only 
recovered 3% of their pre-ischaemic activity. With the progressive addition of various ions and 
chemicals recovery reached over 90%. Concentrations (mmol/L): potassium (K, 16); magnesium 
(Mg, 16); adenosine triphosphate (ATP, 10); creatine phosphate (CP, 10); procaine (7.4).
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Surprisingly, it became clear that myocardial protection during ischaemia was 
not merely a matter of potassium arrest, for major differences in protection 
existed between solutions only slightly different in formulation. Ultimately 
the cardiac function, following even prolonged periods of ischaemic arrest, 
was restored to more than 90% of pre-ischaemic levels by the infusion of 
cardioplegic solutions of optimal composition prior to the ischaemia. Reducing 
the temperature of the solution to below 28°C (“cold cardioplegia”) produced 
even greater improvement (10; Fig. 10.4).
Fig. 10.4  Hypothermia and ischaemic injury. Data from Hearse (1988). The graph shows 
the beneficial effects of hypothermia on the ischaemic heart. Rat hearts were subjected to 
60 minutes of ischaemia at various temperatures. Their recovery was measured 15 minutes 
after the end of the ischaemic period and expressed as a percentage of the activity before 
ischaemia. Hypothermia produced good protection if the temperature was kept below 24°C.
Further experiments, usually upon isolated, perfused rat hearts, have 
investigated the increase in efficacy produced by the inclusion of other 
chemicals in the standard cardioplegic solutions. Creatine phosphate, 
adenosine triphosphate, glucose, glutamate, aspartate, calcium antagonist 
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drugs, procaine, glucocorticoids and many other substances have been 
shown to produce some degree of enhanced protection of the ischaemic 
myocardium in experimental studies.
Cold cardioplegia is routinely used in cardiopulmonary bypass operations 
throughout the world. Over 30,000 such procedures are carried out in the UK 
each year, with under 5% mortality. The “St Thomas’ Hospital No. 1 solution” 
is almost exclusively used in the UK and widely used in Europe. In the USA 
St Thomas’ solution No. 2 (Plegisol) is approved by the FDA (11; Table 2).
ST THOMAS’ HOSPITAL CARDIOPLEGIC SOLUTIONS.  
From Ledingham, Braimbridge & Hearse 1987 J Thorac Cardiovasc Surg 93 240.
Composition (mmol/L) Solution No 1 Solution No 2
Sodium chloride 144 110
Potassium chloride 20 16
Magnesium chloride 16 16
Calcium chloride 2.4 1.2
Sodium bicarbonate -- 10
Procaine hydrochloride 1 --
Cardioplegic solutions have also been used to preserve hearts prior to 
transplantation. With such a technique hearts have been successfully 
preserved for periods in excess of 15 hours (10).
The normal crystalloid cardioplegic solutions in present use, when 
cooled, provide good intraoperative protection for most patients. Clinical 
evaluation of solutions with various concentrations of the additives 
mentioned above will ultimately provide the best cardioplegic solution 
even for the high risk patient.
An earlier version of this chapter was published as: Cardiopulmonary bypass 
– making surgery on the heart possible. RDS News July 1995 8-12.
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11. Artificial Heart Valves: From 
Caged Ball to Bioprosthesis
The heart is a dual pump. The right side receives blood from the body into 
the right atrium. From this chamber it passes to the right ventricle, a muscular 
pump capable of driving the de-oxygenated blood through the lungs via the 
pulmonary artery.
Freshly-oxygenated blood returns to the left side of the pump via the 
pulmonary vein. From the left atrium blood passes into the left ventricle, an 
organ powerful enough to pump blood through all the organs of the body.
The heart therefore pumps by a reciprocal mechanism. Blood enters a 
chamber via one orifice, then is pumped out through another. This means that 
valves are necessary to ensure that flow continues in the desired direction. 
Thus when the ventricles are contracting to direct blood to the lungs or to 
the general circulation, valves between the atria and ventricles are closed by 
pressure. This ensures that flow is directed through the pulmonary artery or 
the aorta. When the ventricles stop contracting, regurgitation of the blood 
back into the heart is prevented by valves that close the openings of these 
vessels (Fig. 11.1).
Valvular Defects
The cardiac valves are amazingly effective. They are flexible, economical on 
space, delicate in design yet remarkably strong. They survive great fluctuations 
of pressure every second throughout life and ensure a unidirectional flow 
of blood through the heart. It is therefore not surprising that if heart valves 
are affected by disease quite severe pathology ensues.
Lack of adequate patency of a valve (stenosis) or valvular incompetence 
can be due to congenital malformation, infection or atheromatous changes.
http://dx.doi.org/10.11647/OBP.0055.11
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The pathology produced is that expected when 
an abnormal load is imposed on a chamber of 
the heart, or a back pressure created through 
the lung circulation.
Thus if the aperture of the mitral valve is 
narrowed, the left atrium and right ventricle bear 
the brunt of the defect. Both become enlarged 
(hypertrophied) and dilated. If regurgitation 
occurs, due to valvular incompetence, then the 
left ventricle will be involved and it too will 
hypertrophy. The pulmonary circulation may 
become engorged, with dilatation of the vessels, 
thickening of the alveolar walls and reduced 
oxygen transfer.
With serious defect of the mitral valve, death 
could be due to a variety of causes; maybe 
congestive heart failure, or cerebral embolism 
from a thrombus arising in a fibrillating atrium.
Similarly, in aortic valve disease, regurgitation 
results in gross enlargement of the heart (even to 
a weight of 1kg) with left ventricular hypertrophy 
and compensatory dilatation. Stenosis will 
produce a slowly developing hypertrophy. A 
patient with aortic valve disease will be prone 
to dizziness and fainting and will most likely 
die from congestive heart failure.
Damage to the tricuspid will tend to oppose 
the return of the blood to the heart, whereas 
defects of the pulmonary aortic valve will cause 
hypertrophy of the right ventricle (Fig. 11.1).
Treatment for Valvular Disease
Before the 1950s there was little one could do for 
serious valvular disease once it was established. 
In 1832 Corrigan stated: “cure of inadequacy of 
the aortic valve is probably beyond the reach 
of medicine” (1).
Fig. 11.1  Diagrams from: ‘On 
Breathlessness, especially in 
relation to cardiac disease?’ An 
address given by Lauder Brunton 
to the Willesden and District 
Medical Society and published 
in The Practitioner in June, 1905. 
Image in the public domain.
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Even much later, White in his 1951 treatise (2) suggested nothing further 
than to advise the patient “to protect himself against strenuous exertion or fatigue.”1
The development of the cardiopulmonary bypass technique, together 
with cardioplegia (see Chapter 10) provided a completely new outlook for 
the patient with valvular disease. The ability to open the heart and operate 
within it for perhaps hours, raised the possibility that defective heart valves 
could be excised and replaced with artificial substitutes.
Artificial Heart Valves: Early Designs
Natural heart valves are exquisitely designed. The mitral, for example, consists 
of two flaps of tissue, the free margins of which are anchored to the floor of 
the ventricle by thin strands of connective tissue called chordae tendineae. It 
offers virtually no impedance to the flow of blood into the left ventricle, yet 
prevents completely blood being forced back into the left atrium during the 
powerful contraction of the ventricle that sends blood throughout the system. 
It is an extremely effective valve yet takes up little space, being thin, pliable 
but totally unyielding to the pressures it is designed to resist.
It is not surprising that the earliest attempts to design a prosthetic valve 
tried to mimic the anatomy of the mitral valve with artificial materials.
One of the most intensive investigations was carried out at the University 
of Minnesota Medical School (3). The remarkable strength of cardiac valves 
is due to their collagen content. The team at Minnesota digested the valves 
of cattle and human cadavers with a proteolytic ferment that removed all 
protein except collagen. This enabled them to study the distribution of 
collagen fibres and their orientation along lines of stress.
Armed with this information, they manufactured valves from Silastic 
rubber-coated Teflon or Dacron felt. Imitation chordae tendineae were prepared 
by braiding strands of the felt prior to applying the rubber coating. It would 
of course be unthinkable to attempt to implant such a prosthesis into a patient 
without evidence that it could actually function. Therefore, as with all the 
various types of valve prostheses that were being made, they were put into 
dogs after excision of the mitral valve. The artificial flaps were sewn onto 
the mitral ring and the imitation chordae pulled through the wall of the heart 
and anchored outside at a suitable tension.
1  White did however refer to some palliative surgical interventions for some valve defects. 
For example, construction of an anastomosis between the aorta and pulmonary artery to 
ensure oxygenation of blood in severe stenosis of the pulmonary aortic valve.
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This surgery was rather difficult. The prosthesis was emplaced successfully 
in only 7 out of 10 dogs. Only 2 of the 7 survived for a reasonable period (12 
and 14 days). Small thrombi were observed on the atrial side of the prosthesis, 
particularly around the sutures.
It was soon realised that attempts to design a valve anchored by artificial 
chordae was going to be too difficult. If the chordae were made too long the 
valve flaps everted into the auricle, if too short, the valve was incompetent. 
Workers at the Mayo Clinic thus designed a “flexible cusp” valve (4). This, 
in essence, consisted of a firm plastic (Mylar) ring, to this was attached a thin, 
flexible sheet of plastic, strengthened by transverse “slats” of firm plastic. The 
flexible cusp was slightly larger than the ring, so that when forced against 
the ring by pressure it closed the orifice. The solid slats preventing the cusp 
being everted through the ring.
The comparatively simple design of the flexible cusp valve meant that the 
insertion of the prosthesis was relatively easy. Thus the dogs in whom it was 
tested were walking around within 5 hours of the operation and the valves 
appeared to function well initially. However the incessant movement and 
stress to which heart valves are subjected revealed the fragility of man-made 
materials compared to the archetype. Damage to the experimental valves 
occurred, in some cases as early as 5 days. Such poor durability precluded 
use in humans, where one would need to anticipate years of function.
Despite the disappointment of the lack of long-term success with these 
and the many other prostheses tested in the early 1960s, the experiments 
produced useful information. It was realised that for durability more robust 
materials were required. Thus the tendency for fatigue fracture was minimised 
by using woven material such as knitted Teflon. The increased durability 
resulted in increased post-operative survival, some dogs living for 72 days. 
The availability of even a few short-term survivors enabled the study of the 
anticipated problem of valve thrombosis.
Clot formation is bound to occur upon foreign surfaces, and within 
the heart or blood vessels where there is damage to the inner surfaces, for 
example where there are sutures. The workers at the Mayo Clinic noted 
that in their dogs clots tended to form at the suture lines then spread over 
the surface of the valve. The use of “non-irritant” suture, such as siliconised 
silk, or covering the sutures with Ivalon or natural valve tissue produced 
minimal benefit. Similarly, experiments with 9 different materials for the 
manufacture of the valve (including gold plated Mylar) had no significant 
effect on thrombosis formation. However it was established that valve design 
should ensure that there were no “nooks or crannies” where blood could 
stagnate and hence tend to clot (4).
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There were many attempts to develop flexible, non-rigid artificial valves 
made of a wide variety of materials including, besides various compressed 
plastics and knitted Teflon, biological tissue such as pericardium and auricular 
wall. None was really reliable enough for human use.
There was undoubtedly a pressing clinical demand for an effective 
prosthetic valve. Eventually, it was realised that attempts to design a flexible 
prosthesis that would mimic faithfully the function of an endogenous valve 
would be abortive, at least without the advantages possessed by the original 
designer i.e. omniscience and unlimited time.
The Caged-Ball Valve
The cardiac surgeon Starr believed that one could not depend on the long-
term flexibility of plastic materials emplaced in the heart, and opted for 
the development of a total replacement prosthesis that would not require 
extensive adjustment and manipulation in the theatre.
Starr developed a simple caged-ball valve (5). It consisted of a Teflon cloth 
ring to which is attached a lucite cage enclosing a Silastic ball. The ring was 
sewn into the mitral orifice of a dog, with the caged portion projecting into 
the ventricle. When the ventricle contracted the pressure increase forced the 
ball against the ring, effectively closing the orifice.
Compared to the other relatively delicate prototypes being tested at 
the time, Starr’s ball valve must have seemed cumbersome, yet it was 
haemodynamically very good. The presence of the cage in the ventricle 
appeared to cause no damage to the inner surface, and contact between the 
cage and the ventricle wall produced no disorders of rhythm.
In Starr’s first experiments, 80% of the dogs survived for at least 10 
days, one was described as in “ferociously good health” 7 months after the 
operation (5) and later Starr reported survival continuing at 13 months (6).
The survival of these dogs enabled careful examination of the effectiveness 
of the valve by cardiac catheterisation (to measure left atrial pressure), 
angiocardiography and cine angiocardiography even 12 months after 
implantation. In some dogs steel pins were inserted into the Silastic balls so 
that valve function and ball spin could be observed with fluoroscopy.
Thrombosis was a serious complication with all valves tested in the dog 
so that evaluation of the long-term efficacy of valves had been difficult. 
Nevertheless with the caged-ball valve it was “possible to obtain long-term 
dog survivors without anticoagulant treatment”(7). This meant it was possible 
to establish the adequate functioning of the valve.
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Encouraged by the experimental results, Starr performed mitral replacement 
in patients with a ball valve prosthesis from September 1960 (Fig. 11.2). This 
clinical work was published in October 1961 (7). By that time 12 patients had 
had mitral replacements. There were 2 post-operative deaths (not related 
to prosthesis) and 3 deaths from staphylococcal endocarditis (unfortunately 
there had been an epidemic of staphylococcal infection which eventually 
necessitated the closure of the operating suite). The remaining patients were 
well. The first 2 patients operated on were back at work. The Starr-Edwards 
caged-ball valve is still in use (8).
Fig. 11.2  Surgery to replace a mitral valve. Heart valve replacement surgery would not be 
possible without animal experimentation. The development of cardiopulmonary bypass 
techniques and cardioplegic solutions, necessary to carry out surgery on the heart, were 
explored in Chapter 10. © Science Photo Library, all rights reserved.
Refining Designs: Disc Valves
The relatively bulky construction of the caged-ball valve made it less suitable 
as a replacement for a defective aortic valve, particularly if the patient had 
narrow aortic roots. There was also the problem of the occlusion of the origins 
of the coronary vessels, which branch from the aorta just above the aortic 
valves.2 So-called “low profile” valves were developed, such as a caged-disc 
2  Actually, Hufnagel (17) had used a ball valve to combat aortic valve failure in 1951. Since 
this was before the development of cardio-pulmonary bypass techniques he implanted 
the valve in the descending aorta. Although not the ideal position, the prosthesis 
prevented 75% of the insufficiency and reduced the work load of the heart.
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valve, which took up less room and would thus fit into the position of the 
aortic valve. This was not really an improvement for mitral replacement 
however, since the ball valve, having a freely rotating occluder, suffered 
less wear (Fig. 11.3).
Fig. 11.3  Artificial heart valves were 
successfully developed in animals.
The relative success of the caged-ball valve 
provided a boost to research on prosthetic 
valves. Engineering principles were used 
to study aspects of design that would 
provide maximum flow and minimal 
clotting. Davila and his colleagues from 
Temple University implanted many 
variations of suspended occluder valves 
in over 100 calves (9). They found that 
blood coagulation round the valve could 
be minimised by using highly polished 
surfaces on the prosthesis, hydraulic 
streamlining to reduce areas of stagnation 
or “wake” and graphite-benzalkonium-
heparin coatings.
The design most favoured at present 
stems from the experiments of Wada, who 
implanted a tilting disc valve in the dog in 
1964 and in man in the following year. The 
disc opened by a hinge mechanism which 
occasionally failed, resulting in fixation 
of the disc in the open position. Shiley 
designed an experimental valve with a 
freely rotating disc in 1968. Björk used a 
slightly modified design and evaluated it 
clinically in 1969. The Björk-Shiley valve 
is arguably the manufactured prosthesis 
of choice today (Figs. 11.4 and 11.5). Its 
simple design consists of a free-floating 
disc occluder suspended in a Stellite 
cage covered with a Teflon ring. The disc 
opens to 600 and closes between two 
eccentrically situated legs (10). As with all 
other synthetic prostheses however, some 
122 Animals and Medicine
anticoagulant treatment is essential to prevent thrombosis. This is a distinct 
disadvantage of these devices, despite their proven efficacy over 30 years.
Fig. 11.4  The tilting disc aortic heart valve, with the tilting action shown in cross 
sectional profile. Picture courtesy of Medtronic, all rights reserved.
Fig. 11.5  Tilting disc aortic heart valve. © Science Photo Library, all rights reserved.
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Allograft Valves
Carrel had shown that vascular tissue could be transplanted and arterial grafts 
had been used to counter various vascular defects. Until 1952 however, only 
cylindrical sections of blood vessels had been so transplanted. Stimulated 
by the success of the ball valve, implanted in the descending aorta, in the 
treatment of aortic valve insufficiency, Lam transplanted the aortic valve 
from a donor into the aorta of a recipient dog (11). The transplanted valves 
would function but only if the recipients own aortic valve was rendered 
incompetent by cutting one of the cusps. Of significance was the fact that 
there were no thrombotic complications. This allograft transplant technique 
was used in humans (12) in 1960 and later Duran and Gunning actually 
managed to place the donor valve in the natural, subcoronary position. Not 
surprisingly, the valves functioned well haemodynamically. The rejection 
complications that were experienced with these non-vascular, relatively 
inert pieces of tissue in many cases appeared to be minor. Therefore there 
were many experimental studies in dog to establish the optimal methods of 
preparation and storage of the valves before transplantation (13). With the 
limited techniques examined, the use of fresh tissue appeared best, although 
freeze drying or storage in betapropriolactone conferred some advantages. 
Such studies began to subside when it became clear that there were severe 
logistic problems in the reliance upon the availability of sterile, allograft 
valves of the ideal size. By the mid-1960s it was realised that valves from 
other species would “solve all procurement and size problems if combined 
with a suitable sterilisation method” (13).
Transplantation of Animal Heart Valves: Xenografts
Freeze-dried pig aortic valves were placed into the aortae of dogs (14), some of 
which survived 8 months. Following this experiment there were many other 
studies where valves from pig, sheep, calf or goat were transplanted into 
other species, usually dog (15). Rejection phenomena were variable and were 
inhibited by azathioprine, although the use of long-term immunosuppressant 
therapy in patients was not considered a viable prospect. Significantly, there 
were no problems of clotting around the valve.
Research became focused on methods of treating the valves before 
transplantation to ensure durability and, by reducing antigenicity, prevent 
rejection. One of the most comprehensive studies was that of Carpentier 
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and his colleagues (16). These workers made various extracts of xenograft 
valves and tested their antigenicity by agglutination tests in appropriately 
inoculated rabbits, intradermal tests in guinea pigs and immunofluorescent 
studies of differently treated valves implanted subcutaneously in rat. It 
was found that extensive washing or electrodialysis could remove much 
antigenic material, the remainder (mainly glycoprotein) was denatured by 
metaperiodate oxidation. The remaining free reactive groups on the valve 
were bonded together by a tanning agent, glutaraldehyde (this also prevents 
the subsequent denaturing of the collagen in the implanted valve, which 
would result in loss of shape and flexibility).
By this treatment Carpentier and his colleagues produced a biologically 
inert, functional and durable valve. After such treatment it could not 
accurately be termed a xenograft. Carpentier described it as a “bioprosthesis” 
– something between a graft and a synthetic prosthesis. Clinical experience 
with the bioprosthesis (usually porcine) has been good, with a negligible 
rate of thromboembolism.
Corrigan’s quote: “cure of inadequacy of the aortic valve is probably 
beyond the reach of medicine” has been confuted. Today patients that 
develop serious valvular defects need no longer simply be advised to avoid 
“strenuous exertion or fatigue.” With a prosthetic or bioprosthetic valve they 
can anticipate a decade symptom-free, possibly without the disadvantage 
of anticoagulant therapy. It is difficult to imagine that this could have been 
achieved without the animal experiments that began in 1933 with Gibbon’s 
first attempt at cardiopulmonary bypass in cat.
Aanticoagulants for Prevention of Clotting 
Around Heart Valve Prosthesis
The foreign surfaces of artificial valves will inevitably initiate clotting. 
Anticoagulant therapy is thus essential for patients with valve prostheses. 
Although heparin (which is extracted from animal tissues) is a valuable 
anticoagulant that can be used temporarily after the immediate post-operative 
risk of haemorrhage, it is not orally active, and thus of no use for long-term 
anticoagulant therapy.
The standard anticoagulants used for prophylaxis with heart valves are 
all chemically similar to the prototype drug, Warfarin.
Warfarin was developed as a consequence of the study of a strange bleeding 
disorder that suddenly occurred in cattle on the northern prairies of the USA 
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in the early years of the last century. Surgical procedures such as dehorning 
could result in fatal haemorrhage. In severe cases animals developed large 
haematomas and would bleed from the nose.
An astute veterinarian noted that the condition invariably followed the 
ingestion of hay or silage of sweet clover which had become spoiled during 
storage. Sweet clover had been planted on the comparatively poor soil of 
North Dakota at the end of the nineteenth century since it could be used as 
a substitute for corn for use as silage.
The isolation of the active anticoagulant from the “biochemical rag-bag” 
of the spoiled clover/hay was no easy task (18). An assay method had 
to be developed to track the effects of the “haemorrhagic agent” during 
the various extraction procedures. A measurement of the activity of the 
extracts on the prothrombin time, performed on diluted plasma from 
a particular strain of rabbit was ultimately chosen as the most suitable 
assay. After four years the active substance was identified as dicoumarol 
(3,3’-methylenebis(4-hydroxycoumarin)).
Many derivatives were synthesised, including Warfarin. These are 
used today to treat deep vein thrombosis as well as to limit the danger of 
thromboembolism in patients with synthetic valve replacements.
An earlier version of this chapter was published as: Artificial heart valves: 
from caged ball to bioprosthesis. RDS News October 1995 6-11.
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12. Animals and Blood Transfusion
Doctors misled for over 200 years:
History shows that a dependence on animal research delayed the introduction 
of blood transfusion by over 200 years.
NAVS Leaflet, Ever had a blood transfusion?
The assertion that animal experiments delayed the development of blood 
transfusion derives from the superficial and inaccurate accounts found 
in animal rights literature (see for example Ref. 1, page 157; Ref. 2 page 
220). A brief review of primary sources reveals that animal experiments 
were crucial to the development of a) the concept of the benefit of blood 
transfusion, b) techniques for carrying out transfusion and c) the preservation 
of incoagulable blood and thus to the establishment of blood banks. 
The function of the heart and the details of the circulation of the blood 
through arteries and veins were, of course, demonstrated by William 
Harvey in 1628. Harvey used about 50 species to elucidate the nature of 
the circulation. He studied, by means of a magnifying glass, the motion 
of the heart in “a small shrimp” found in the Thames (probably a species 
of mysid (3)). He obtained clear proof that the heart pumped blood via a 
closed circulation through arteries to the veins by simple experiments, using 
ligatures, on the slowly beating hearts of cold-blooded animals. In warm-
blooded animals he could “neither rightly perceive at first when the systole 
and diastole took place, nor when and where dilatation and contraction 
occurred by reason of the rapidity of the motion, which in many animals 
is accomplished in the twinkling of an eye, coming and going like a flash 
of lightning” (4). Experiments on sheep, deer and dog demonstrated that 
the heart pumped in unit time a larger quantity of blood than is found in 
the whole body – thus clearly demonstrating a circulatory system.
http://dx.doi.org/10.11647/OBP.0055.12
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By the early 17th century therefore, the concept that blood was pumped 
via the arteries to the organs was well established. To some observers at least, 
the blood began to be perceived not only as “the vehicle of the soul with the 
secrets of individuality” (5), but as a transporting system. It was therefore 
no surprise that experimenters should endeavour to infuse medicaments 
into the circulating blood of a living animal. Christopher Wren and Robert 
Boyle, in 1656, inserted a quill attached to a bladder (in later experiments, 
a syringe) into a superficial vein of a dog and successfully injected first 
opium, then the emetic, antimony oxide (5).
Early Transfusion Experiments
Figs. 12.1a and 12.1b  Engraving showing transfusion in the neck and leg of a dog, from animal 
to man, and from man to man, by J. S. Elsholtz, 1667. Wellcome Library, London, CC BY. 
This experiment doubtless led to attempts to transfuse blood from one animal 
to another. The earliest, well-authenticated account of the transfusion of blood 
from one dog to a second is that of Richard Lower, who in February 1665 used 
quills (and later a silver tube) to transfer blood from the carotid artery of one 
dog to the jugular vein of a second (6) (Fig. 12.1a). A later demonstration of 
the technique is described in Pepys’s diary of November 14th 1666, where 
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the recipient dog was described as “very well, and likely to do well.” The 
diary also records subsequent discussion, which included musings as to the 
effect of transferring blood of a Quaker to an Archbishop. Boyle also queried 
whether the transfused dog would still recognise his master after receiving 
the strange blood (6). Thus although animal experiments had demonstrated 
the feasibility of transfusion, many still regarded the blood simply as the 
vehicle of the soul. The potential of the technique was clearly not appreciated.
The first person to transfer animal blood to a human was the French 
philosopher and mathematician Denis (spelt Denys in some accounts). 
With the help of the surgeon Emmerez Denis in 1666 allegedly transfered 
9 ounces of blood from the carotid artery of a lamb into a 15 year old youth, 
moribund following excessive venesections to alleviate an obscure fever (Fig. 
12.1b). Apparently, astonishing improvement resulted. Denis performed the 
operation on a further three subjects with no untoward effect, although the 
artery to vein anastomoses, with the chance of coagulation, made estimations 
of the amounts transfused dubious (Fig. 12.2). 
Fig. 12.2  Attempt at blood transfusion from lamb to man, depicted in an illustration 
dating from 1705. Wellcome Library, London, CC BY.
His last patient was a man “with an inveterate phrensy, occasioned by a 
disgrace he had received in some amours,” presumably a gentle euphemism 
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for neurosyphilis. Denis considered that calf’s blood “by its mildness and 
freshness might allay the heat and ebulition of his blood” (7). The patient 
apparently tolerated two transfusions with some benefit upon his mental state, 
although the second was followed by pain in the kidneys and the production 
of black urine. At the behest of the patient’s wife Denis attempted a third 
transfusion after which the patient died. Denis had enemies prominent in the 
Faculty of Medicine of Paris who were implacably opposed to transfusion 
of animal blood into man. He was charged with murder but eventually 
exonerated after counter charges that the patient had been poisoned by his 
wife. Nevertheless experiments on transfusion of blood into humans were 
prohibited by an edict of the French Parliament.
This official ban on transfusion in France is proposed by opponents of 
animal experiments as an argument that such techniques thus “delayed the 
practical availability of blood transfusions and led directly to the deaths of 
patients” (8). However, if transfusions between different species had been 
investigated before the transfusion of animal blood to man, the incompatibility 
of bloods of different animal species would have been established in the 17th 
century instead of 150 years later.
The efforts of 17th century opponents of transfusion to stigmatise the 
technique as evil and against nature probably worked for the best. Medicine 
and technology were not sufficiently advanced for doctors to use transfusion 
effectively. Knowledge of the function of the blood, of sepsis, of immunology 
and of clotting mechanisms were minimal or non-existent. Methods for 
transferring coagulable blood between individuals, without the benefit of 
materials available today, were fraught with problems and danger. It was 
therefore not surprising that during the 18th century references to transfusion 
were rare, and those described were irrational (in 1792 for example, Russell 
claimed to cure a child of rabies by injection of lamb’s blood (6)).
Scientific Reasons for Transfusion
The gradual accumulation of physiological and pathological knowledge 
changed the perspective with which transfusion was viewed. Rosa and Scarpa 
(1788) recommended transfusion as a treatment for anaemia, and in 1796, 
Erasmus Darwin (grandfather of Charles) advocated tranfusion of blood 
in cancer of the oesophagus and other conditions resulting in inadequate 
nutrition. Darwin suggested transfusion could be effected via goose quills 
connected by a piece of chicken gut (6). There is no evidence that he attempted 
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transfusion using this technique, but it is a salutary reminder of the primitive 
nature of the tools available for a complicated procedure.
Transfusion for Haemorrhage
Provost and Dumas in 1821 showed that animals haemorrhaged to the point 
of death could be revived by transfusion of blood, but not serum or water 
warmed to 38oC. Blood from animals of other species was not effective, since 
the animals appeared to survive but succumbed within a few days. Provost 
and Dumas did not attempt transfusion in humans, since they considered 
the basic knowledge of blood and its functions too rudimentary and, since 
the technique was too celebrated, it had already “been abused in an ignorant 
and barbarous century” (6).
Blood transfusion in humans was established as a sound scientific and 
clinical procedure by James Blundell (1790-1877), a lecturer in physiology 
and midwifery at the United Hospitals of St Thomas and Guy. Blundell was 
moved by the many deaths he had witnessed in patients with post partum 
haemorrhage. Even when bleeding had been suspended, frequently the 
patients had lost so much blood that one could do nothing but observe them 
sinking until death followed within 2-4 hours. In such cases, argued Blundell, 
“there is a fit opportunity for trying the operation of transfusion” (9).
In his extensive monograph (9) Blundell described his experiments in 
dogs that established that death from haemorrhage could be prevented by 
transfusion of blood from the same species, even if vital signs had been lost. 
Recovery occurred even if the volume of the blood transfused was a fraction 
of that lost (even just 20%). Transfusion of blood from another species was 
not effective, but venous blood was as effective as arterial blood, even if its 
transfusion was delayed or if it was passed through a syringe.
After his experiments in animals, Blundell took the giant step of attempting 
transfusion of human blood to patients with severe haemorrhage. He 
performed the operation 11 times, at first only as a last resort in patients 
who were clearly irrecoverable. As experience with the technique was 
gained it was used in appropriate, seriously ill patients quite successfully. 
A typical case was reported in The Lancet in 1828 (10). One and a half hours 
after delivery a woman collapsed with extreme prostration, “blanched and 
perfectly bloodless in appearance.” It transpired she had been bleeding 
freely into the uterus, unknown to the physicians. Stimulants (brandy and 
port wine) were freely given to no avail. Blundell transfused 8 ounces of 
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blood, and the patient “rallied and became in every respect much better.” 
The patient made a full recovery and later commented that she had “felt as 
if life were infused into her body.”
In view of the obvious difficulties associated with supplying blood by 
the direct connection of the donor’s artery to the recipient’s vein, Blundell 
developed apparatus that obviated the need to cannulate the vessel of the 
donor. Venous blood was allowed to collect into reservoirs from whence 
it was pumped by syringe or allowed to flow under gravity (Blundell’s 
“impellor” and “gravitator”; Fig. 12.3a; Fig. 12.3b).
Fig. 12.3a  Drawing of Blundell’s impellor, which allowed venous blood to be collected in 
reservoirs before being pumped or allowed to flow under gravity to the recipient. (From 
Ref. 9). Wellcome Library, London, CC BY.
Fig. 12.3b  Blundell’s apparatus in use. From J. Blundell (1828). ‘Observations on the 
transfusion of blood’, The Lancet, 2, 321. Wellcome Library, London, CC BY.
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Blood transfusion was thus established as a respectable and valuable 
procedure. It was not however commonly practised, but used as a last resort 
only. Some deaths still occurred even with human blood, but the real problem 
was simply the difficulty of carrying out such a formidable procedure. If 
reasonable volumes needed to be transfused, the clotting that was likely 
to occur meant that one had to transfuse by cannulation and connection of 
the artery of the donor to the vein of the recipient. This was certainly not a 
technique in which every physician was accomplished. It was not easy to 
persuade donors to have an artery cannulated and it was hard to regulate 
the amount transfused.
Landsteiner and the ABO Blood Group System
The necessity of transfusing blood of the same species, emphasised by 
Blundell, was reinforced by the observation by Crile (1869) that serum of 
different animals caused human red cells to clump. Landois (11) showed that 
animal serum caused actual lysis of human blood cells, thus explaining post 
transfusion haemoglobinaemia and the excretion of black urine in some early 
transfusions. These experiments definitively established that transfusion of 
animal blood to humans was absolutely contraindicated. It is thus surprising 
that even in the last quarter of the century some doctors, prompted by the 
lack of donors, were advocating transfusion of the blood of sheep.
The growth of immunology as a discipline provided clues to the reason 
for the incompatibility of human red cells with animal sera, since the lysis 
observed was considered analogous to the interaction of bacteria with 
antibody. Bordet found that the red cells of some species could generate 
antibodies in the plasma of another.
Prompted by earlier work, particularly that of Landois, Landsteiner was 
intrigued by the “biochemical species specificity” and considered “whether 
specific differentiation goes beyond the level of species, and also whether 
the individuals within a species show similar, though presumably slighter 
differences” (12). By mixing the serum and red cells of different human 
individuals Landsteiner established the ABO blood groups system. This 
obviously had great significance for the transfusion of compatible blood. 
Landsteiner’s work explained the failure of some early transfusions. The 
successes of Blundell and others were presumably due to the fortuitous use 
of compatible donors and recipients.
Some transfusion reactions occurred even with matched samples in the 
ABO system. In the 1920s Landsteiner and Levine detected other agglutinins 
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(MN and P) in all four blood groups by injecting rabbits with human blood 
and showing the presence of raised antibodies to the human antigens (13).
Methods of Transfusion
Even though the matching of blood reduced transfusion reactions, at the 
start of the century the problem of clotting still prevented blood transfusion 
becoming routine. Blood clots when it comes in contact with any surface save 
the inner lining of blood vessels. Thus clots formed perhaps in the transfusion 
cannulae could enter the circulation and cause pulmonary embolism. For 
this reason transfusion was rarely performed, particularly when infusions 
of isotonic salt solutions became popular.
Carrel in 1902 (14) developed a technique in animals for joining arteries 
to veins, thus providing a continuous endothelial surface that enabled blood 
to flow from one vessel to the other without clot formation. This technique 
was put to practical use in a celebrated case that occurred a few years later, 
when Carrel was working as Research Fellow at the Rockefeller Institute. An 
infant of 5 days, suffering from haemorrhagic disease of the newborn, was 
bleeding from the nose and gut and was near death. The father, who was 
Professor of Surgery at Columbia University, knew of Carrel’s experiments 
in anastomosing blood vessels of cats and dogs, and persuaded him to 
anastomose his own left radial artery to the child’s right popliteal vein. The 
baby’s colour changed from “white to pink and finally red all over.” The 
infant stopped bleeding and made a complete recovery (7). 
Carrel’s technique was not simple, but Crile developed an easier method 
using a carefully constructed ring through which a vessel could be pushed 
and then everted over. The other vessel could then be pushed over the 
ring so that the intimal surfaces of the two vessels were thus in contact. A 
ligature around the ring secured the anastomosis. George Crile published 
this work in 1907 in the Annals of Surgery, stating that the paper “is based 
on 225 experiments upon animals and 32 clinical cases” (15).
Anticoagulants
By the early 1900s the prevention of blood coagulation was intensively 
investigated. Some delay in clotting was achieved by using paraffin wax-
coated vessels to collect the shed blood prior to rapid transfusion via syringe. 
But what was obviously required was an innocuous substance that could be 
added to blood to prevent clotting. Some experimenters toyed with the use of 
the anticoagulant substance extracted from leeches, hirudin. Lewisohn (16) 
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tested hirudin in dogs, one of which died. Nonetheless he decided to risk 
the administration of a small amount of hirudin to a patient who required 
a transfusion following a laparotomy for carcinoma of the stomach. The 
patient became cyanotic, had precordial pain, imperceptible pulse and was 
in a precarious position for 36 hours. This effectively removed hirudin as a 
candidate anticoagulant, although some workers used it to rinse syringes 
and vessels used in transfusion in the hope that clotting might be slowed.
The breakthrough came with the discovery that citrate could prevent 
clotting when added immediately to freshly collected blood, and that properly 
citrated blood was relatively non-toxic.
The distinction of being the first to advocate the use of citrate in blood 
transfusion is difficult to assign. The contenders are Hustin, Agote, Weil and 
Lewisohn. Most accounts accept that the Belgian, Hustin (17) was the first 
to infuse citrated blood to a patient. However, Lewisohn probably deserves 
the most credit since his careful experiments established the minimum 
concentration necessary to prevent clotting, and the amount of citrate likely 
to produce a toxic effect. In his classic paper (16) Lewisohn did however 
acknowledge “the priority, not only for taking up this problem in a series of 
animal experiments, but applying it successfully in a case of human blood 
transfusion, belongs to Hustin, though his method, as we shall see later, 
limited its usefulness to small transfusions.”
Lewisohn added gradually increasing concentrations of citrate to 100 ml 
samples of dog’s blood. He found that whereas 0.1% citrate had no effect, 
0.2% and upward prevented clotting for days. Since 1,500 ml of blood might 
have to be transfused, Lewisohn obtained an estimate of the likely toxic dose. 
He withdrew 300 ml of blood from a dog, added increasing concentrations 
of citrate, and re-infused the blood. He found that a total of 1.5g of citrate 
in the blood was fatal for a dog of 11 lbs, suggesting that 15g would be toxic 
for a human of 110 lbs. Even an infusion of 1,500 ml of blood containing 
0.2% citrate would thus be unlikely to be toxic to humans. Next Lewisohn 
investigated whether the infusion of citrate might lengthen the clotting 
time of the recipient’s blood – certainly undesirable if the patient required 
a transfusion because of a haemorrhage. He found the coagulation time of 
blood taken from a dog was 5 minutes. He removed 300 ml of blood, added 
0.2% citrate and reinfused. Samples of blood taken at 3 minute intervals 
after reinfusion were found, much to Lewisohn’s surprise, to have a much 
shortened coagulation time (10 secs).
These careful experiments, and those of Weil, who showed that citrated blood 
could revive guinea pigs or dogs which had been practically exsanguinated 
(18), paved the way for the use of citrated blood for transfusions.
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As transfusion became common practice, aspects of the toxicity of citrate 
needed to be reassessed. During exchange transfusion in neonates, for example, 
it was felt that toxic levels of citrate might be reached if the transfusion was 
too rapid. Experiments in dogs (19) showed that infusion of citrate at a rate 
of 0.06 mmol/kg/min was lethal, but 0.04mmol was safe. Rates of transfusion 
of citrated blood were therefore kept below 0.03 mmol/kg/min citrate, or 
where large volumes needed to be transfused, heparinised, rather than 
citrated blood was used.
Similar animal experiments alerted physicians to the possible danger of 
transfusing large volumes of blood that had been stored for a long period. 
Such blood tends to have high plasma potassium levels, since this ion leaks 
out of red blood cells in time. Infusions in rabbits showed that whereas 
the citrate or potassium in transfused blood produced only mild toxicity, a 
combination of both killed 15 out of a group of 19 rabbits (20). Thus the toxic 
effects of citrate and potassium reinforced one another. Where large volumes 
need to be transfused therefore (as in exchange transfusion in the newborn) 
fresh or heparinised blood should be used. Also, where patients have already 
high plasma potassium, for example anuric patients or those with extensive 
muscle wounds, only the use of fresh citrated blood is indicated.
Storage of Blood for Transfusion
Rous and Turner in 1916 (21) noted that there had been no investigation of 
methods to preserve the life of red blood cells in vitro, yet their improved 
preservation might have practical importance, even for transfusion. If 
stored in the cold for too long the cells tend to lyse. After a series of simple 
experiments on rabbit blood, Rous and Turner found that the addition of 
dextrose as well as citrate protected against lysis (Rous believed that since 
the cells are relatively impervious to sugars they would act like a colloid and 
preserve the cells. Subsequent research showed however, that the dextrose 
has a favorable effect on red cell metabolism). Blood so treated could be 
stored for 15 days and was still capable of reviving severely haemorraged 
rabbits, which unlike control, untransfused animals, survived and showed 
no anaemia. Blood cells stored longer than two weeks were still able to 
restore the level of haemoglobin in the bled animals, but in these cases the 
improvement was temporary, the animals becoming progressively anaemic.
These observations on the stabilisation of red cells were put to use in 
World War I at a US base hospital by Oswald Robertson (22), who set up 
the first (albeit limited) blood bank. Robertson, during periods of relative 
quiet, collected blood from universal donors (selected from patients with 
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trivial wounds or those recovered from slight wounds) direct into dextrose/
citrate and placed it in an ice box. Transfusions of the stored (10-14 days) 
blood were given to 20 patients, mostly haemorrhage cases. The results of 
these transfusions were “quite as striking as those seen after transfusion 
with blood freshly drawn.”
The first recognised blood bank was set up in the 1930s at the Central 
Institute of Haematology and Blood Transfusion in Moscow. By 1937, 6,000 
effective transfusions of stored blood had been made (7). The outbreak of 
World War II resulted in the establishment of transfusion services for the 
collection and storage of blood on a substantial scale.
Today, the storage and transfusion of sterile, compatible blood or blood 
constituents is a routine and life-saving procedure, the development of 
which depended upon the vision, experimentation and ingenuity of many 
physicians and scientists (Fig. 12.4). To suggest that blood transfusion 
was delayed for 200 years through dependence on animal experiments is 
totally incorrect. The implication of this assertion is that in 1714 transfusing 
coagulating blood through avian quills in non-sterile conditions could have 
been a routine procedure.
Fig. 12.4  Today, the storage and transfusion of sterile compatible blood or blood constituents 
is a routine and life saving procedure. © Science Photo Library, all rights reserved.
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Such a denial of the contribution of animal experiments to human well-being 
stems from an unrealistic, facile conception of history.
Heparin
The potent anticoagulant heparin is not widely used to prevent the coagulation 
of blood to be transfused. It is, however, used for venous thrombosis and 
to prevent blood clotting during open heart surgery and kidney dialysis.
Heparin was discovered serendipitously in the liver of dog during a 
search for endogenous clotting substances (23). Heparin for clinical use 
must be obtained from pig intestine or bovine lung, and the crude extract is 
standardised by measurement of its anticoagulant action on sheep plasma 
(BP and USP).
The Rhesus Factor
Opponents of animal experiments have striven vigorously to establish that 
the rhesus (Rh) blood group system, despite its name, owes nothing to 
animal experiments. In fact it is difficult to establish who first discovered the 
Rh antigen. The history of this interesting scientific tale is well reviewed in 
Mollison (7). A reasonable interpretation is that Rh antigen was discovered 
in Landsteiner’s laboratory in the early 1930s, by injection of rhesus monkey 
red cells into rabbits and guinea pigs, and adding their plasmas (containing 
anti-Rh antibodies) to human red cells. Landsteiner, however did not publish 
the work until 1940 (24).
Meanwhile Levine (a former collaborator of Landsteiner) together with 
Stetson, discovered an antibody (later shown to be anti-Rh) in the plasma 
of a woman whose child had died in utero. Since this work was published in 
1939 (25), the credit for priority should go to Levine and Stetson. As far as 
the animal experimentation argument is concerned the question of priority 
is irrelevant. Levine and Stetson also described animal experiments in their 
paper, stating: “Agglutinins of this sort can rarely be investigated thoroughly 
because of their tendency to diminish in activity and eventually to disappear. 
Consequent attempts were made to produce a hetero-immune agglutinin 
of identical or similar specificity by repeated injections of sensitive blood 
into a series of rabbits. These experiments met with failure, since suitable 
absorption tests with such serums failed to reveal the presence of the desired 
agglutinin.” Landsteiner, using rhesus red cells as antigen, was able to raise 
antibodies, which enabled the distribution of Rh group system in humans 
to be investigated.
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THE DEVELOPMENT OF BLOOD TRANSFUSION
1628 Harvey The circulation of the blood (about 40 species)
1656 Wren Injection into vascular system (dog)
1665 Lower Transfusion of blood between dogs
1666 Denis Transfusion from lamb to man
1821 Provost and Dumas Blood transfusion revived haemorrhaged 
animals
1824 Blundell Must use blood of the same species for 
transfusion
1828 Blundell Blood transfusion saved women dying from 
post partum haemorrhage
1869 Crile Serum of animals causes human red cells to 
clump
1902 Landsteiner ABO blood group system
1902 Carrel Technique of anastamosis of blood vessels 
(cat and dog)
1915 Hustin and Lewisohn Citrate safely used as an anticoagulant (dog 
and rabbit)
1916 Rous and Turner With pre-treatment, blood stored for two 
weeks (rabbits)
1917 Robertson Institution of blood banks for wounded 
soldiers
1933 First large blood bank established in Moscow
An earlier version of this chapter was published as: Animals and blood 
transfusion. RDS News July 1994 7-12.
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III. DRUGS FOR ORGANIC DISEASES

13. Animal Experiments and the 
Production of Insulin
Before 1922, the diagnosis of what was then called juvenile onset diabetes 
(type I or insulin-dependent diabetes, IDD), meant a lingering death within 
months. In that year, however, a team of workers in the physiological 
laboratories at the University of Toronto isolated and purified the hormone, 
insulin, from the pancreas. The purified insulin was shown to control not 
only the symptoms induced by removal of the pancreas in dogs, but also 
those of diabetes mellitus in patients.
The production of insulin on a large scale from pig and cattle pancreas 
was achieved fairly rapidly, due no doubt to the striking benefit that injection 
of insulin could produce in the seriously ill, even comatose, diabetic patient.
The effects of the ready availability of insulin were dramatic. This 
is illustrated by objective actuarial data produced by Metropolitan Life 
Insurance. This leading American insurance company stated: “The results 
of this treatment have been brilliantly successful.” The data showed that the 
average age at death of diabetic patients in Toronto had increased by 22 
years between 1920 and 1931. It also showed that: “Deaths from diabetes among 
children under 20 years-of-age have almost ceased, and the death-rates under 50 
years-of-age have declined very sharply.” (1).
The success of the Toronto team; Banting, Best, Macleod and Collip is 
rightly acclaimed by biomedical researchers as a prime example of undoubted 
benefit for patients achieved by animal experimentation. Presumably for this 
reason, the story of the discovery of insulin has been subjected to vehement 
attacks from animal rights adherents.
http://dx.doi.org/10.11647/OBP.0055.13
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Early History of the Nature of Diabetes
Most physiologists accept that the observation of von Mering and Minkowski, 
that removal of the pancreas of dogs produced symptoms similar to those of 
patients with diabetes, was the crucial experiment linking the pancreas with 
the disease (2). Opponents of animal experiments claim that this observation 
was antedated1 by significant work by Cawley, who in 1788 noted lesions 
in the pancreas of a diabetic patient at post mortem (3). Such an observation 
of course does not prove the lesions cause the disease, only that there may 
be an association between the disease and the observed damage. Changes 
in the blood vessels, kidney, retina and nerves also occur, but as a result 
rather than a cause of the condition. Nevertheless, antivivisectionists claim 
that Cawley’s observation was a significant clue. They also imply that had 
this observation been followed up it could have provided a treatment for 
diabetes without recourse to animal experiments. Quite how this could 
have been achieved is not detailed by those who hold this view, and is not 
apparent to this writer.
Isolation and Purification of Insulin
By the end of the nineteenth century, the function of various glands was 
being investigated by their removal from animals and by examination of 
their extracts for physiological activity. Thus, adrenalin was extracted from 
the adrenal and thyroxin from the thyroid gland. It was therefore predictable 
that the then putative “antidiabetic” factor thought to be present in the islet 
cells of the pancreas should be designated “insulin” even before its successful 
isolation.2 It was obvious at this time that insulin in some way enabled blood 
sugar to be properly utilised by the body.
The morbidity and mortality associated with diabetes ensured that there 
were immediate attempts to extract a factor (insulin) from the pancreas that 
could be used to treat this disease. This proved less easy than for adrenaline. 
1  There is a claim that an exactly similar experiment to that of von Mering and Minkowski, 
demonstrating the appearance of diabetes in a depancreatised dog, was described in a 
book by Brunner in 1683, over 100 years before Cawley’s observation (4).
2  Schafer apparently suggested this term in 1915. In some antivivisection propaganda, 
Schafer is implied to have discovered insulin in 1915, “six years before Banting and 
Best’s experiments on dogs” (5). This is put forward as evidence against the contribution 
made by the Toronto workers, which is lauded by opponents of animal experimentation. 
(Adrenaline and thyroxine later acquired an ‘e’, presumably because they were 
eventually shown to be amines).
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Minkowski tried, as did the French physiologist Gley, but probably the most 
important of the early studies was that of Zülzer (6). Zülzer used alcohol, rather 
than water, to extract insulin and he certainly produced active preparations. 
Forschbach, working in Minkowski’s clinic in Breslau showed in 1909 that 
one of these extracts could reduce the blood sugar of depancreatized dogs 
by 90%. Unfortunately it also raised the temperature of the animal to 102.6°. 
Attempts to produce extracts of greater purity were made by chemists of the 
Schering Company, and these were given to two diabetic patients. The first 
produced no effect, the second caused a rise in temperature to 104° and the 
patient was unable to void urine for 12 hours. As a result of this toxicity the 
use of these extracts was abandoned in Europe at this time (7).
The Work in Toronto
Frederick Banting, a surgeon, and the medical student Charles Best began 
their attempts to prepare usable extracts of the pancreas in May 1921. Banting 
believed that it would be difficult to extract insulin, if it should be a protein, 
since during the process of extraction it would be bound to come in contact 
with protein-splitting enzymes which are also present in the pancreas. He 
therefore proposed ligating the pancreatic duct as a means of producing 
atrophy of the protease containing tissue. Extracts made from the pancreas 
so treated, Banting surmised, would have high insulin levels.
Banting’s premise was in fact false on two counts (7). For this reason his 
published work came in for some criticism which has provided a focus for 
irrational condemnation of the work of Banting and Best and the role of 
animal experiments in the discovery of insulin (vide infra).
First, it is extremely unlikely that the pancreatic tissue could contain an 
active protease, since the active enzyme is only produced if its precursor 
comes in contact with the intestine. So there was no necessity to produce 
atrophy of the gland. Secondly, ligation of the pancreatic duct can also 
destroy the islet tissue. It was not therefore, as Banting and others believed, 
a technique that caused selective destruction of the acinar tissue.
Banting presented his first results at the New Haven meeting of the 
American Physiological Society in December, 1921 (Fig. 13.1). Extracts from 
both normal and “ligated” pancreas were shown to reduce blood sugar 
and abolish glycosuria in depancreatized dogs. The extracts had not been 
injected into patients. When this was tried a few weeks later the results 
were disappointing. The patients developed fever, and abscesses occurred 
at the injection site.
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Fig. 13.1  The now famous picture of Frederick Banting, Charles Best and the dog Marjory, 
an early depancreatised dog treated with insulin, 1921. Wellcome Library, London, CC BY.
Non-Toxic Extracts
At this time Macleod, the head of the Physiology Department at Toronto, 
was persuaded to add a biochemist to the team to assist in the purification 
of the pancreatic extracts. This turned out to be a significant event. Within 
2-3 weeks the biochemist, James Collip, prepared the first sample of insulin 
pure enough to treat diabetic patients from beef pancreas obtained from the 
slaughter house (7).
Collip used established techniques based on the selective solubility of 
different proteins in ethyl alcohol. This purification method required the 
measurement of the amount of insulin present in the various fractions 
produced. Since neither the nature nor the structure of insulin was known, 
the only way of assessing the amount of insulin present was by measuring 
its activity, i.e. by its ability to lower blood sugar levels in animals. Collip 
assessed the potency of each precipitate and filtrate in the process of fractional 
precipitation of the crude extracts by subcutaneous injection into fasted 
rabbits. One “unit” of insulin activity was described as that amount that 
would reduce the percentage blood sugar of a 2kg rabbit to 0.045 within 
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four hours (8). The extracts prepared for clinical use were adjusted to contain 
one such unit in one millilitre. Thus animal experiments were absolutely 
crucial in the production of samples of insulin for the treatment of diabetes. 
An accurate method of standardisation of the extracts was essential. Even 
moderate overdosing with insulin can have serious consequences. Frank 
overdosing is lethal.
Clinical Success
The extracts prepared by Collip were used in dogs and patients with 
remarkable success (Fig. 13.2). 
Fig. 13.2  The effect of Collip’s highly-purified extract on the first patient to be successfully 
treated. Fourteen year old Leonard Thompson was given 10cc of the extract at 5pm on 23 January. 
The next day two injections of 10cc were administered. Sugar in the urine almost disappeared, 
ketonuria did disappear. Doses of 8cc of a new extract (presumably more potent) were given 
daily from 27 January onwards, markedly reducing sugar excretion in the urine. Data adapted 
from F. Banting, C. Best, J. Collip, et al. (1922), ‘The effect produced on diabetes by extracts of 
pancreas.’ Transactions of the Association of American Physicians, 1-11.
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When the results of the Toronto team were reported at a meeting of the 
Association of American Physicians in May 1922, the distinguished diabetologist 
Dr Frederick Allen said:
If, as seems to be the case, the Toronto workers have the internal secretion of 
the pancreas fairly free from the toxic material, they hold unquestionable priority 
for one of the greatest achievements of modern medicine (7).
Unless one has studied the case reports one can have no conception of the 
dramatic impact of the production of purified insulin. Diabetics placed on 
starvation diets, were reduced to emaciation and were barely able to hang on 
to a miserable life. With regular injections of insulin they could absorb and 
utilise a normal diet, gain weight, regain their vigour and flourish mentally 
and physically (Fig. 13.3).
Fig. 13.3  Photographed in 1922, this diabetic girl, aged 13, weighed just 45lb before 
treatment with insulin. A few months later she had made a dramatic recovery. 
Wellcome Library London, CC BY.
The Story of Elizabeth Hughes
A good example is that of Elizabeth Hughes. The daughter of an erstwhile 
Governor of New York State, she developed diabetes at the age of 11 years in 
1918. Under the guidance of probably the best-known American diabetologist, 
 Animal Experiments and the Production of Insulin 149
Dr Frederick Allen, she was placed on a restricted diet. Elizabeth became 
semi-invalid and was plagued by frequent infections. By 1922, although 5 
feet tall she weighed under 50 lbs, only kept alive by her remakable spirit 
and optimism. Elizabeth was taken to Banting’s clinic in Toronto in August 
1922. Banting’s notes after his first examination of Elizabeth were:
Weight 45 lbs. Height 5ft patient extremely emaciated, slight aedema of ankles, 
skin dry and scaly, hair brittle and thin, abdomen prominent, shoulders 
drooped, muscles extremely wasted, subcutaneous tissues almost completely 
absorbed. She was scarcely able to walk on account of weakness.
Banting placed Elizabeth on regular injections of insulin and, reasoning that 
she needed above all to put on weight, prescribed a liberal diet. For the first 
time for over three years Elizabeth ate bread, potato, macaroni cheese and 
also was allowed a daily pint of thick cream. She gained 10 lbs in 5 weeks, 
then gained a steady 21/2 lbs per week. Elizabeth grew taller and, no longer 
restricted by her lack of energy to armchair activities, enjoyed trips to concerts, 
the cinema and even visited Niagara Falls.
In November 1922 the leading diabetologists of North America came to 
Toronto for a conference to discuss the initial clinical findings with insulin 
and to recommend methods for the standardisation of insulin dosage. Banting 
took a group of physicians, including Frederick Allen, to visit patients in his 
clinic. Allen did not recognise Elizabeth, and was rendered speechless by the 
healthy appearance of his former patient. Elizabeth (who was a compulsive 
and eloquent correspondent) described Allen’s reaction in a letter to her 
mother: “Dr Allen said with his mouth wide open – Oh! – and that’s all he did”
On November 30th, Thanksgiving Day, Elizabeth Hughes returned to 
her home in Washington. A year after graduating from college Elizabeth 
married. She raised three children and also in other ways led an active life, 
being an inveterate world traveller. On April 25th, 1981, almost 60 years after 
receiving her first dose of insulin, Elizabeth died of a heart attack (21). The 
discovery of insulin undoubtedly was “one of the most dramatic achievements 
of modern medicine.”
Mixed Reactions
The familiarity that develops with passage of time obtunds the impact that 
a discovery such as the isolation of insulin had upon the medical profession 
and indeed upon the lay public. An effective way to get some sense of the 
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reaction is to read contemporary comment in the general medical journals. 
A review of the research findings Banting reported at the May, 1922 meeting 
of the Association of American Physicians states:
If these experimental observations prove clinically applicable to man clearly a 
magnificent contribution to the treatment of diabetes will have been made (9)
Other comments soon followed:
Results which, it is not too sanguine to hope, have opened a new chapter in 
the history of the treatment of diabetes.
As our readers have learnt from Professor Macleod, the effects observed in 
animals have justified the trial of insulin in man, and diabetic patients have 
eagerly flocked to take advantage of the new treatment (10).
Readers … cannot fail to draw the conclusion that a scientific advance of 
immense importance has already been accomplished (11).
As always, such approbation inevitably provoked some adverse criticism 
from the more conservative members of a markedly conservative profession. 
A particularly disparaging criticism appeared in the British Medical Journal 
on December 16th 1922. Dr Ff Roberts of the Department of Physiology, 
Cambridge University wrote:
So much prominence has been given to the “insulin” treatment of diabetes 
that it is perhaps not out of place to review the steps which have led up to 
the production of this new remedy.
Roberts went on to assert that the hypothesis that ligation of the pancreatic 
duct would result in the destruction of the acinar tissue was incorrect, that 
in any case there was no need to attempt such an experiment for there is no 
active protease in the pancreas, and that Banting and Best’s results clearly 
show that there was as much (or more) insulin activity in the “normal” as 
the “ligated” gland. Roberts concluded:
The production of insulin originated in a wrongly conceived, wrongly 
conducted and wrongly interpreted series of experiments.
He conceded:
apparent beneficial effects have been obtained in certain cases of human 
diabetes. Whether insulin will fulfil its promise time alone will show.
The next issue of the Journal (23 Dec, 1922) contained a letter from Henry Dale 
(later to become Sir Henry, Nobel Laureate) which was a devastating reproof 
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of the “censorious criticism” by Roberts. Dale was at the National Institute 
of Medical Research in London, and was concerned with the standardisation 
by biological assay of the batches of insulin that were being prepared at that 
time. Dale’s eloquent letter concludes:
Nobody can deny that a discovery of first-rate importance has been made, 
and, if it proves to have resulted from a stumble into the right road, where 
it crossed the course laid down by a faulty conception, surely the case is not 
unique in the history of science. The world could afford to exchange a whole 
library of criticism for one such productive blunder, and it is a poor thing to 
attempt belittlement of a great achievement by scornful exposure of errors 
in its inception.
The ungraciousness of the comments by Roberts were also elegantly put into 
perspective by a leader that appeared in the British Medical Journal later:
Dr Roberts’ points are of a technical kind, and the terms in which they were 
expressed, it must be admitted, were wanting in urbanity (12).
The Criticism from Antivivisectionists
Despite the immediate condemnation of the somewhat ungenerous comments 
by Roberts, the quotation: “a wrongly conceived, wrongly conducted and 
wrongly interpreted series of experiments” continues to appear regularly in 
antivivisection literature and leaflets (5, 13), put forward as evidence that the 
public has been misled as to the value of the animal experiments of the Toronto 
group. This is quite wrong. Each of the Toronto team made an important 
contribution to the production of clinically useful insulin preparations. It was 
certainly the biochemist Collip who was responsible for producing extracts 
relatively free from toxic material, but as mentioned, the use of animals to 
monitor the purification of insulin was an absolutely essential part of this 
process. It is to be regretted that even advocates for moderate organisations 
supporting the development of alternative methods in medical research 
perpetuate the myth “that chemical extraction techniques (not involving 
animal tests) allowed the production of pure and safe insulin” (14).
Over half a century’s experience has resulted in refinements in the use of 
insulin, particularly in the development of slow-release depot preparations 
to provide smooth therapy with the minimum number of injections. The 
miserable prospect for the IDD patient in the early 1920s is beyond the 
imagination of the lay public today, two generations divorced from direct 
anecdotal accounts. This public ignorance is utilised by antivivisectionists 
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in their attempts to belittle the contribution of insulin to the treatment of 
diabetes. They assert that it is an “absurd nonsense to claim diabetes has been 
cured” since the number of people dying of diabetes has increased over the 
last 50 years and the number of diabetics is doubling every ten years (15). 
The fatuity of such arguments is patently obvious. They were summarily 
dismissed over 10 years ago by Rowan, who commented:
These tactics are born of desperation. Since antivivisection protestors cannot 
deny that insulin therapy was derived from animal experimentation, the 
therapy itself is denigrated (16).
Insulin was never held to be a cure, it is merely a replacement therapy. 
Obviously, if diabetics treated with insulin can now survive for several 
decades rather than dying within a year or two of diagnosis, then the number 
of diabetic patients will increase. Even in insulin-treated diabetics the late 
complications of diabetes are often the ultimate cause of death. Thus deaths 
due to diabetes will appear to rise.
Another smoke screen raised by antivivisectionists is to introduce late 
onset diabetes (type 2 or non-insulin dependent diabetes, NIDD) into the 
equation. NIDD is of course more common than IDD and can often be treated 
by changing the diet. Thus antivivisectionists allege: “Today the great majority 
of diabetics who develop diabetes as adults control their disease through 
diet – they certainly do not need insulin injections.” (15)
Stated in the context of discussion about the value of animal experimentation 
in the production of pure extracts of insulin, which is life-saving in IDD, this 
statement is wholly misleading. It can only be assumed that its intention is 
deliberately to misinform the public.
The Future
Human insulin can now be prepared by recombinant techniques. 
Physicochemical methods obviate the need for tedious bioassays of insulin 
extracts, no doubt to the considerable relief of those responsible for quality 
control.
However, administration of insulin by injection can never mimic the 
refined, minute by minute control of insulin release from the β-cells of the 
pancreatic islets, which is governed by plasma glucose levels. Thus diabetics 
are frequently hyper- or hypoglycaemic, with obvious pathological sequelae.
Transplantation of islet cells, which could release insulin as required, is 
an obvious answer once the problems of supply of cells and tissue rejection 
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have been resolved. Porcine cells have been transplanted into nude mice and 
dogs. Rejection was prevented in the latter by antilymphocyte serum (raised 
in rabbit) and 15-deoxyspergualin. Such transplants have been attempted 
with some success in Swedish patients (17).
Another ingenious attempt to prevent rejection is the implantation of islet 
cells in capsules made of alginate. The capsule wall prevents access of host 
white cells to the islet tissue, but is sufficiently porous to allow passage of 
glucose and insulin. Exploratory experiments in diabetic dogs showed that a 
single treatment could replace injection of insulin for 6 months to 2 years (18).
Similar animal experiments will no doubt ultimately reveal the significance 
of the newly isolated compound “amylin.” This peptide, which appears to 
be co-secreted from β-cells with insulin, increases blood sugar and is present 
in excess in NIDD (19).
Finally, a strain of mouse that naturally develops IDD (the non-obese 
diabetic [NOD] mouse) should eventually reveal the nature of the antigen 
that activates the immune system to destroy the islet cells of IDD patients 
(20). Even if the particular combination of genes that determine the genetic 
susceptibility to diabetes is established, a model such as the NOD mouse 
would be essential to establish the ultimate mechanism that triggers the 
destruction of the insulin-producing cells. Research with such models will 
set the scene for the prevention, rather than control, of IDD.
ANIMALS AND THE TREATMENT OF INSULIN DEPENDENT DIABETES
1889 Von Mering & Minkowski
Pancreatectomy produces 
diabetes mellitus (dog)
1900-22 Zülzer, Gley. Banting & Best
Pancreatic extracts lower blood 
sugar (dog)
1922 Banting, Best, Collip, Macleod
Extracts made from cows and 
pigs
1922-25 Banting et al.
Biological standardisation of 
extracts (rabbit, mouse)
An earlier version of this chapter was published as: Animal experiments and 
the production of insulin. RDS News January 1996 9-14.
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14. Animals and Humans: 
Remarkably Similar
The assertion that animal experimentation is a “failed technology” (1) is the 
linchpin of the pseudoscientific attack on animal-based biomedical research 
that has been waged over the last two decades. However, it is an undeniable 
fact that our knowledge of the function of the organs of the human body 
stems almost solely from research in other animals.
For example, the investigation of the function of the heart by William 
Harvey (2) was one of the earliest adventures in experimental medicine. 
Harvey’s conclusion, that the movements of the heart caused the blood to 
circulate round the body, derived from observations in cold-blooded animals 
such as a living snake or toad as well as in the pig. Today, the rodent is the 
most widely used order for experimental work. It is evident that there is 
no difference in the way the conducting tissue in the heart of the rat or the 
human triggers the sequential contraction of the individual muscle fibres, so 
that the blood is caused to circulate first through the lungs then throughout 
the body.
The similarity extends to pathology, for should a coronary artery of the 
rat heart be ligated, thus preventing the flow of blood to a portion of the 
heart muscle, bursts of irregular heart beats occur – bigeminy, ventricular 
tachycardia – just as happens in patients suffering from acute myocardial 
ischaemia induced by coronary occlusion. Exactly as in patients, a proportion 
of rats so treated will die due to ventricular fibrillation unless resuscitation 
techniques are applied.
The mechanisms whereby the major organs are controlled and co-ordinated 
are likewise identical in man and laboratory species. The chemical messengers 
released from nerve cells in the brain and the peripheral nervous system 
to effect a response in adjacent cells are identical in all mammals. Thus, 
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for example, the increase in heart rate induced by circulating adrenaline 
or by noradrenaline released from sympathetic nerves in the heart can be 
blocked in both humans and rat by beta-adrenoceptor antagonists such as 
propranolol. Indeed even the selective blockade, by the more recent drugs, of 
the beta receptors on the heart as compared to those on the lung (preferred 
by asthmatics) is observed in the rat as well as man.
The more long-term regulation of organ activity of humans, that exerted by 
the endocrine system, is of course also analogous in laboratory animals. In 
fact in the absence of animal experimentation it is doubtful if knowledge 
of the functions of say, the pituitary and thyroid glands would be much 
different from the views current in the mid nineteenth century. At that time 
it was thought that they were concerned with the production of mucus to 
moisten the nasal and tracheal membranes respectively.
It is a fact that the hormones, insulin, obtained from the pancreases of 
pigs or cows, powdered thyroid gland of pig, thyrotropin obtained from 
cow pituitaries, calcitonin obtained from parathyroid glands of salmon, 
adrenocorticotrophic hormone from the pituitaries of “mammals used for 
food” and oxytocin and vasopressin from pig posterior pituitary glands have 
all been used in patients to correct hormone deficiencies or for diagnostic 
purposes. This surely speaks more powerfully for the similarity of the 
physiologies of these species rather than for patent differences.
One could of course fill a textbook with further evidence but these very 
general examples serve to illustrate the basic similarities in the physiology 
and biochemistry of all mammals and even non-mammalian species.
The Arguments
What are the arguments used by those attacking the validity of animal 
experiments? How do they attempt to justify their claims?
Diseases
First there is the claim that animals don’t suffer from the same pathological 
conditions as man and therefore cannot be used to study human diseases 
which, it is alleged, are entirely different. In fact there are many animal 
diseases which are the exact analogy of those in humans. The veterinary 
surgeon Cornelius (3) has published a list of some 350 diseases suffered by 
animals which have an exact human counterpart. The paper of Cornelius is 
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mentioned by the antivivisectionist Sharpe (4, p. 116) who quite erroneously 
claimed that Cornelius gives “a long list of animal models of human disease” 
(my emphasis), implying that these were induced, whereas in fact Cornelius 
was describing diseases that occurred spontaneously in animals. Cornelius 
went further to suggest that the study of such diseases was “a neglected 
medical resource” and called for coordinated interprofessional efforts between 
human and veterinary centres. This issue is also well-covered in a source 
readily available to the general public – the section on “Animal Disease” in 
Encyclopaedia Britannica. This contains a large list of diseases common to 
animals and humans and states: “it is likely that, for every known human 
disease, an identical or similar disease exists in at least one other species.”
Reaction to drugs
The second argument is the claim that animals respond differently to drugs. 
It is often stated that there are vast differences between lethal doses in 
animals and humans (4, p. 98). The problems in making such a claim are clear. 
Whilst it is relatively easy on the one hand to obtain a satisfactory estimate 
of the range of toxicity of a substance in an animal species it is not possible 
in humans. One must rely on data from suicides or accidental poisoning 
where one can never be absolutely confident of the amount ingested or 
the amount possibly lost by vomiting or stomach wash etc. Furthermore, 
individual variation in humans due to genetic constitution, age (many cases 
of poisoning occur in children), alcoholism, concurrent ingestion of alcohol 
or other drugs, existing disease etc., render any but the most vague estimate 
of toxic dose impossible.
Similarly spurious are the claims of a particular drug morbidity produced 
in an animal species but not in humans. One of the most preposterous is the 
allegation by Sharpe (4, p. 72) that aspirin is a proven teratogen in rats and 
other species yet, despite being widely used by pregnant women has failed 
to produce any malformation. The studies in which aspirin was shown to 
be teratogenic in rat used doses of 250 mg/kg/day, from three days prior to 
mating to the end of pregnancy (5), or 300 mg/kg/day from the 9th to the 
12th day of pregnancy (6). Transposed to the human (assuming a woman of 
55kg) it would mean a regimen of 46 aspirin tablets per day for the whole 
of pregnancy or 55 tablets every day from the 12th to the 17th week of 
pregnancy (Fig. 14.1).
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Fig. 14.1  Aspirin causes birth defects in rats, but not in people.
Not surprisingly, clinical data with this sort of regimen does not exist, 
however McNeil (7) cited 8 cases of fetal abnormalities in children from 
mothers who habitually took large doses of aspirin during pregnancy, and 
in a retrospective study by Richards (8) of 833 patients who ingested large 
amounts of aspirin during the first trimester, there was a significant rise in 
malformation.
One can similarly destroy the rather bizarre assertion that a hormone 
naturally produced by the body – insulin – “produces deformities in 
laboratory animals but not in people” (4, p. 72). In these studies (9) pregnant 
rabbits were given 20 units of insulin per day for between 2 and 13 days (a 
dose sufficient to cause hypoglycaemic convulsions for five hours each day) 
and many abnormal fetuses were born. Again, no comparable clinical data 
exists but one would hardly be surprised if pregnant women subjected to 
this treatment produced deformed children.
A final example is the perennial canard that morphine calms people but 
causes “maniacal excitement in cats” (4, p. 71). The source of this statement 
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is obscure but the veterinarians Davis and Donnelly (10) showed that doses 
of morphine equivalent to those used in humans (i.e. 0.1 mg/kg) “produced 
analgesia with no excitement in experimental cats,” and the current edition 
of a standard textbook of veterinary pharmacology (11) states: “Even in 
the cat, it is now accepted that very low doses (of morphine) can produce 
analgesia without excitement.” A high dose of morphine (1 mg/kg) will 
produce excitement in cats, as it will in humans (12).
The flaws in the arguments raised by those proposing that animal 
experiments are “bad science” are easily exposed by reading primary sources 
readily obtainable in any science library. The selection and promulgation of 
abstracts that transmit a persuasive misrepresentation of scientific method 
does nothing for the furtherance of scientific or ethical principles.
An earlier version of this chapter was published as: Animals and humans – 
remarkably similar. RDS News January 1993 8-10.
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15. Early Animal Experiments in 
Anaesthesia
In an attempt to make the history of scientific developments readable authors 
tend to highlight bizarre and amusing incidents, sometimes to the extent of 
inadvertently misleading the reader.
Thus most essays that purport to describe the background to the introduction 
of general anaesthesia to surgery inevitably refer to the laughing gas parties 
or ether frolics that were apparently commonplace in the 1840s (see (1) for 
example). The inhalation of nitrous oxide or ether produced instantaneous 
elation or inebriation. Social occasions where this activity was indulged 
were presumably more benign equivalents of today’s glue sniffing sessions 
or Ecstasy parties. The conventional story is that accidental injury sustained 
during such a party was not noticed until well after the effects of the inhaled 
substance had worn off, suggesting to the astute observer that the apparent 
analgesic action of the inhalants might be of use in surgery. A good story, 
but is it true? The answer is only partially.
Fifty years before an anaesthetic was used in patients Humphrey Davy 
had demonstrated that nitrous oxide produced a state of unconsciousness in 
animals that was reversible if the animal was returned to air. He described 
the administration of nitrous oxide to a “stout and healthy cat” (2):
after 5 minutes the pulse was hardly perceptible; he made no motions and 
appeared wholly senseless. After 5 minutes and a quarter he was taken out … in 8 
or 9 minutes he was able to walk … in half an hour he was completely recovered.
Davy similarly described the effect of breathing a mixture of 1 part oxygen 
and 3 parts nitrous oxide on a guinea pig:
... in 2 minutes reposed on his side, breathing very deeply ... he lived quietly 
for near 14 minutes. He was taken out and recovered.
http://dx.doi.org/10.11647/OBP.0055.15
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These experiments led Davy to conclude that animals could survive for 
long periods in an atmosphere of nitrous oxide mingled with air, and he 
subsequently inhaled the gas himself noting on one occasion that the gas 
relieved the pain caused by a wisdom tooth.
In his book Researches published in 1800 Davy concludes:
As nitrous oxide in its extensive operation appears capable of destroying 
physical pain, it may probably be used with advantage during surgical 
operations in which no great effusion of blood takes place.
Henry Hickman, a practitioner at Ludlow in Shropshire, took the experiments 
a stage further by actually performing surgery on animals during a state 
of “suspended animation” induced by inhalation of carbon dioxide or 
nitrous oxide (3). As a result of his experiments Hickman tried to direct the 
attention of the medical profession in Britain (and later in France) towards 
the possibility of preventing pain during surgical operations by the inhalation 
of these gases (Fig. 15.1). However, his pamphlet: “A letter on Suspended 
Animation containing experiments showing that it may safely be employed 
during operations on animals with the view of ascertaining its probable utility 
in surgical operations on the Human Subject,” appears to have been totally 
ignored by the Royal Society, before whom it was laid in 1823.
Fig. 15.1  Watercolour of Henry Hickman by Richard Cooper, painted in 1912. Hickman 
was a pioneer of anaesthesia, successfully performing surgery on animals anaesthetised 
with carbon dioxide as early as the 1820s. Wellcome Library, London, CC BY.
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It was not until over 20 years later that the dentist Horace Wells, under nitrous 
oxide anaesthesia, had a wisdom tooth removed by his partner Riggs. The 
nitrous oxide was administered (at the behest of Wells) by Quincy Colton, a 
onetime medical student who made his living by demonstrating the effects 
of laughing gas on members of the audience at his stage shows. By 1846 
major operations in both America and Britain were being performed under 
anaesthesia with ether, which Charles Jackson and Morton (an ex-partner 
of Wells) had found to produce a less erratic induction than the gas nitrous 
oxide, which only came into its own in 1868 when it was available compressed 
into cylinders. During the acrimonious dispute amongst the claimants that 
followed the announcement by the United States of a substantial prize for 
the inventor of anaesthetics, Jackson gave credit to Humphrey Davy when he 
wrote: “I have in former publications stated, as I do now, that my attention 
was first awakened to this subject while a student of medicine, by reading 
Davy’s researches.” (4)
It is clear that animal experiments paved the way towards the development 
of general anaesthetics and should have ensured their acceptance 50 years 
earlier but for societal reasons. The blossoming of humanitarianism and 
philanthropy that characterised the Victorian era fostered the desire to alleviate 
all suffering, even that of childbirth which was held to have authoritative 
support in the Book of Genesis.
It was the desire to find the perfect anaesthetic for the pain of childbirth 
that lead Simpson, the Professor of Midwifery at Edinburgh University, 
to search for an alternative to ether. Ether was not only an irritant but 
also inflammable, a risk when it was used in candlelight. Amongst other 
investigations he attempted to persuade Wemyss Reid to allow him to 
inhale ethylene dibromide, which had recently been prepared in the latter’s 
laboratory. Wemyss Reid quite rightly insisted that the liquid should first 
be tested on rabbits. Two were subjected to the vapour, quickly passed into 
anaesthesia and in due course recovered. The following day Simpson intended 
to test ethylene dibromide on himself and his assistant but sensibly did not 
proceed with the experiment upon discovering that the two rabbits had died 
overnight (5) (ethylene dibromide is used today as a soil fumigant to destroy 
nematodes; it causes pulmonary congestion and depression of the central 
nervous system if inhaled). This was probably one of the earliest examples of 
the necessity of preliminary animal testing before phase one clinical studies. 
Simpson eventually obtained a sample of chloroform (Fig. 15.2), a 
substance which had been tested on animals by Flourens and shown to 
produce unconsciousness (6). 
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Fig. 15.2  Drawing of Sir James Young Simpson and friends by unknown artist, representing 
Simpson’s discovery of the anaesthetic properties of chloroform in humans. Previously 
tested by Flourens on animals in the 1840s, chloroform was used almost immediately by 
Simpson to ease the pain of childbirth. Wellcome Library, London, CC BY.
Simpson used chloroform in midwifery and produced a paper describing its 
effects in November, 1847. As a result, chloroform rapidly came into use in 
general surgery and for a while was believed to be absolutely safe. However 
the first death under chloroform anaesthesia occurred two months later 
in January, 1848 (3) and there followed a high incidence of intraoperative 
and postoperative deaths due to the hepatotoxic and cardiotoxic actions of 
this anaesthetic. Animal rights propaganda, however, frequently avers that 
“chloroform is a useful anaesthetic for people, but poisonous to dogs.” (7) Its 
dangers to patients are obvious but where is the evidence that it is inordinately 
toxic to dogs? Wakely in 1848 (8) compared the effects of ether and chloroform 
on 100 animals of various species. Out of 32 animals anaesthetised with ether, 
11 died (34%). A total of 67 animals were given chloroform and 30 died (44%). 
Of the 17 dogs given chloroform only 4 died (24%). Hardly evidence for a 
selective toxic action.
It is clear that those who wish to promote the animal rights case on what are 
claimed as “scientific grounds,” can carefully select the evidence they choose 
to transmit and so put forward an apparently plausible argument. However, 
omission of evidence can result in a misinterpretation of history. Whatever 
one considers the morality of a particular crusade, facts should be sacrosanct.
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16. The Control of Malignant 
Hypertension
The reduction of the death and morbidity rates due to infective disease in 
the 1930s and 40s threw other pathological problems into sharper relief. 
Thus, in the developed world, cardiovascular disease and cancer became 
the major causes of death.
An important risk factor for many cardiovascular diseases is raised blood 
pressure, a symptom which the opponents of animal experiments imply 
could be avoided by changes in one’s lifestyle – stopping smoking, taking 
exercise and reducing fat intake, alcohol and stress (see for example Ref. 1, 
p. 44). Even if one disregards the mutable nature of the evidence connecting 
diet with cardiovascular disease, and the undeniable contribution of one’s 
genetic constitution to this condition, the implication that all cases of high 
blood pressure are so avoidable is certainly not in accord with clinical 
experience prior to the use of the first antihypertensive drugs.
Malignant Hypertension
High blood pressure accompanied by changes in the optic fundi (papilloedema) 
characterised a particular type of hypertension with a markedly rapid downhill 
course. Malignant hypertension, as it was known, could occur at virtually any 
age, and was generally fatal within one year of diagnosis. Contemporary clinical 
descriptions are to be found in the paper of Schottstaedt and Sokolow (2) who 
described the inexorable pathological progress of 104 patients aged from 13 
to 71 years, who attended their outpatient department during the 1940s. The 
average survival time after discovery of papilloedema was 8.4 months. Initial 
symptoms were blurred vision and headaches. According to physicians treating 
the patients, the headaches could be devastatingly painful (3).
The difficulties of dealing with severe hypertension are described graphically 
by Dollery (4) in his admirable review of the history of hypertension treatments. 
http://dx.doi.org/10.11647/OBP.0055.16
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As a junior clinical student in the early 1950s he had to deal with a female patient 
admitted to an ear, nose and throat ward with nose bleed. She was found to 
have a very high blood pressure and papilloedema. After the bleeding was 
stopped she was “discharged on the grounds that the condition was untreatable.” 
Dollery goes on to describe his subsequent experience (three years later) with 
the then current treatment of the most severe, refractory hypertension. This 
was the removal of both adrenal glands, and replacement therapy with the 
life-essential hormone cortisone. The aim, said Dollery,
was to find a precarious ledge between death from Addisonian crisis on the 
one hand and malignant hypertension on the other. It was a challenging 
experience for a preregistration house officer. If the blood pressure was brought 
under control there was dramatic clinical improvement. Pulmonary oedema 
vanished like magic, deterioration of renal function halted, and retinal cotton 
wool spots and papilloedema quickly regressed. 
The available treatment before the development of antihypertensive drugs was 
reviewed by Wilkins in 1946 (5). It consisted of bed rest and reassurance of the 
patient, weight loss through the adoption of a low fat diet, restriction of salt 
intake, no smoking and possibly the use of sedatives and hypnotics to alleviate 
stress. As is evident, this regimen is virtually identical with that advocated by 
antivivisectionists today as totally effective against hypertension (1), in their 
attempts to dismiss the need for drug treatment and thus animal experiments. 
Yet malignant hypertension was then, as described above, a dreadful disease, 
as a last resort only treatable by the removal of a life-essential endocrine gland 
and consequent life-long hormone replacement (see Table below).
MALIGNANT HYPERTENSION: CASE REPORTS.  
From Keith, Wagener & Kernohan (1928) Arch Int Med 41 141.
Case Sex Age History BP Duration of life from 
diagnosis (months)
18 F 24 Headache, visual 
disturbance
280/190 11
32 M 36 Headache, attacks of 
unconsciousness
235/135 5
38 F 15 Headache, 
albuminurea
200/140 11
40 F 19 Headache, dispnoea, 
blurred vision
270/150 1.5
46 M 28 Tachycardia, dispnoea 230/160 8
49 M 36 Constant headache 245/145 1.5
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Development of Antihypertensive Therapy
The first effective treatment of severe hypertension stemmed from the 
study of the autonomic nervous system, that is those peripheral nerves that 
control the minute-by-minute activity of individual organs. Activation of the 
sympathetic nerves of the autonomic system was shown, in animals, to cause 
constriction of blood vessels and hence a rise in blood pressure. Attention was 
thus directed at abolishing the activity of the sympathetic nervous system 
in hypertension, initially by its removal or “sympathectomy.” This was not 
an operation to be lightly undertaken and its efficacy in hypertension was 
never definitively established. 
Of great import was the demonstration, after many experiments on various 
mammals, that nerves affected the organs they innervate by the release of 
small amounts of a chemical as each impulse reached the nerve ending. This 
“chemical transmission” at nerve endings provided a potential site for the use 
of drugs to modify nerve activity. This could be achieved either by using a 
synthetic chemical to mimic the effect of the “transmitter,” or by the use of 
a chemical that could block either the release or the action of the transmitter.
Ganglionic Blocking Drugs
In all autonomic nerves there are neuron to neuron junctions (or synapses). 
The transmission across the synapse is achieved by the release of acetylcholine 
from the first neuron, which acts on a receptor on the second neuron to cause 
activation. The swelling in autonomic nerves which signifies where most of 
the synapses are present, is called a ganglion. Some quaternary ammonium 
compounds were shown to cause a blockade of the acetylcholine receptors 
at ganglia and hence a fall in blood pressure in animal experiments. This 
effect was however, too short-lived for clinical exploitation.
The major breakthrough in the control of severe hypertension emerged from 
a study of the actions of the polymethylene-bisquaternary ammonium salts 
in the anaesthetised cat by Paton and Zaimis in 1948 (6). These compounds 
consisted of two quaternised nitrogen atoms separated by a methylene chain 
of from 2 to 12 carbon atoms in length.
Chemical similarity with other drugs suggested that the 9-11 methylene 
compounds might be potent voluntary muscle relaxants, drugs of considerable 
importance for the control of convulsions and for use during surgery. The 10 
methylene compound (decamethonium) was indeed a potent neuromuscular 
blocking drug. This activity decreased with shortening of the chain and was 
absent in the 7 methylene compound.
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Fortunately, Paton and Zaimis continued with the investigation of the 
smaller molecules and found that they had other activity. The 5 and 6 methylene 
compounds markedly lowered the blood pressure of the anaesthetised cat, 
and on injection to the rabbit, caused the ears to flush bright red. The latter 
action impressed Paton, since he recalled Claude Bernard’s observation almost 
a hundred years earlier, that cutting the sympathetic nerve to the rabbit’s ear 
produced the same effect. Paton therefore suspected that these drugs were 
blocking sympathetic ganglia. Further experimentation established that this 
was indeed the action of the 5 and 6 methylene compounds, and Paton and 
Zaimis considered that the 6 methylene compound (hexamethonium) might 
be usable in hypertension as a “clean, specific ganglion-blocker.”
It is an interesting historical aside that Paton and Zaimis originally 
intended to restrict their first publication on the activity of these methonium 
compounds to their neuromuscular blocking actions. The reason for their 
decision to include a mention of the possible use of hexamethonium in high 
blood pressure, was that the head technician of the engineering workshop in 
their Hampstead laboratory had malignant hypertension, and was becoming 
incapacitated by splitting headaches and deteriorating sight. Paton described 
the technician as “a beautiful craftsman” and “a very nice man.” No doubt 
the publication of the blood pressure-lowering actions of hexamethonium 
hastened the clinical use of this drug for malignant hypertension, but unhappily 
it was too late for Paton’s technician, who died soon after.
Clinical studies with hexamethonium began almost immediately in 
Dunedin, New Zealand, and in two centres in London (4). The treatment 
of malignant hypertension with hexamethonium showed that reducing the 
blood pressure
•  relieved the severe headache;
•  enabled the retinal damage to regress and hence improved vision;
•  allowed the enlarged heart and oedema of the lung in hypertensive 
heart failure to return towards normal;
•  allowed the patient to return to work (7).
Development of Antihypertensive Drugs
The realisation that the raised blood pressure in hypertension was not a 
compensation for the narrowing of the lumen of blood vessels, and that 
simply lowering the blood pressure dramatically improved the prognosis 
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in hypertension, stimulated a tremendous research effort to produce other, 
improved hypotensive drugs. Although hexamethonium was of great 
significance since, as Paton said “it helped to get a foot in the door of really 
effective treatment of hypertension” (7), it had many undesirable side actions 
because of blockade of autonomic reflexes of the parasympathetic as well 
as the sympathetic system.
The development, after extensive animal experiments, of selective inhibitors 
of adrenergic neurones by pharmacologists at Burroughs Wellcome and the 
Ciba Company, provided a treatment without the unpleasant symptoms 
caused by block of parasympathetic ganglia (bethanidine and guanethidine). 
Further drug treatments for hypertension followed rapidly (4), with the 
development of reserpine (shown to cause hypotension in the cat (19)), 
hydralazine (hypotensive in dog and cat (20)), alpha methyldopa and the first 
thiazide diuretic, chlorothiazide (action established in dog, lack of toxicity 
in dog, rat and mouse (Figs. 16.1 and 16. 2).
Fig. 16.1  Deaths from hypertensive disease. Annual deaths per million population. Data 
from Paton et al. (1978), Highlights of British Science, Silver Jubilee Exhibition, Royal 
Society and Compendium of Health Statistics, 8th edition, 1992 (Office of Health Economics).
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Fig. 16.2  Treatment of malignant hypertension with ganglionic blocking drugs. 
Comparison between 140 treated and 105 untreated patients, percent surviving against 
time after diagnosis. Data from Paton et al. (1978).
Beta Blockers
The use of beta blocking drugs in hypertension stemmed from the observation 
by Prichard that administration of pronethalol (the first beta blocker in clinical 
use) to patients with angina resulted in a small but persistent fall in blood 
pressure (8). Pronethalol was withdrawn because it was shown to produce 
tumours in mice, but the use of the beta blocker propranolol in hypertension 
was described by Prichard the same year. Comparative trials of propranolol 
with proven antihypertensive drugs established the value of beta blocking 
drugs in hypertension.
The fact that such an important antihypertensive agent emerged from 
clinical observation is hailed by the National Anti-Vivisection Society as 
an example of “progress without animals” (9). The beta blocking drugs 
however, were developed and perfected for the treatment of angina and 
some forms of cardiac arrhythmia, after years of animal experimentation. 
Without that animal experimental work the drugs would not have been 
available for clinical use. The fact that whilst being used successfully for 
angina an additional indication was uncovered is certainly a tribute to the 
acumen and persistence of the clinician, but in no way a condemnation of 
animal experiments.
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After the hypotensive actions of propranolol were demonstrated in patients, 
the drug was also shown to reduce the blood pressure of spontaneously 
hypertensive rats (SHR) (10). These rats, as they mature, develop a high 
blood pressure, with consequent pathological changes in the kidneys, and 
cardiovascular and cerebrovascular complications similar to those that 
occur in patients (11). Had propranolol been tested before in SH rats, its 
antihypertensive activity would have been exposed. However, from all the 
clinical and experimental knowledge of the time, no-one could have predicted 
such an action. Even today, the mechanism of action of beta blockers in 
hypertension is not absolutely certain.
ACE Inhibitors
The discovery of the effectiveness of angiotensin converting enzyme (ACE) 
inhibitors in hypertension is a particularly interesting example of how 
animal experiments can contribute, sometimes in a circuitous way, to the 
development of new medicines.
Study of the effects of the venom of a Brazilian snake, Bothrops jararaca, 
led to the discovery of bradykinin, a peptide with potent pharmacological 
actions that could be formed in blood. The Brazilian pharmacologist Sergio 
Ferreira, also found in the venom a factor that markedly potentiated the actions 
of bradykinin. He called this bradykinin potentiating factor or BPF. In the 
1960s, Ferreira brought a sample of BPF to the Royal College of Surgeons in 
London, where he was to work with Professor John Vane as a postdoctoral 
fellow. Vane’s interest at this time was the biological importance of another 
peptide that could be formed in the blood, angiotensin II. This substance 
caused a marked rise in the blood pressure, and was formed from a relatively 
inactive precursor, angiotensin I, by a converting enzyme (ACE). It was thus 
inevitable that the action of BPF would eventually be tested on ACE, and 
it was found to be a potent inhibitor, thus preventing the production of the 
hypertensive angiotensin II in the body (12).
BPF was shown to reverse the rise in blood pressure produced in rats by 
occlusion of the renal artery, and lowered the blood pressure in other rat 
models of hypertension. Eventually the purified BPF was synthesised and was 
shown to lower the blood pressure in hypertensive patients. The preparation 
of a non-peptide, orally active enzyme inhibitor was thus shown to be a 
worthwhile therapeutic objective. The synthesis of a number of candidates, 
tested in rat models of hypertension, resulted in the marketing of captopril 
as a successful antihypertensive treatment in 1977 (12). Captopril was later 
also shown to be also useful in congestive heart failure.
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Conclusion
The drug treatment of hypertensive disease has been a remarkable success 
story. From the life-saving but clumsy ganglionic blocking drugs, with their 
miserable side effects and poor absorption, came the graduation to improved 
drugs with fewer, but still severe, side actions. Often, these side actions were 
dose-related and thus probably preventable (4). Today the drug treatment is 
relatively refined. For the vast majority of patients therapy for hypertension 
is effective and benign. With the prospect of the development of novel drugs, 
such as angiotensin receptor antagonists, even further refinement might 
be envisaged (13). The realisation of the crucial importance of the vascular 
endothelial cell in the control of the calibre of vessels through the continuous 
release of nitric oxide (NO) (14), and the demonstration that patients with 
untreated hypertension possess an abnormality of the NO-mediated dilatation 
of arterioles (15), will no doubt furnish additional treatments or even a cure 
for hypertension.
Although the most striking achievement has been the control of malignant 
hypertension, over the last 40 years a number of clinical trials have shown 
that treating less extreme cases of raised blood pressure can reduce the 
risk of stroke, coronary heart disease and renal disease (16). Since the drug 
treatment of the disease has improved so much, there is a risk that it might 
be instituted in patients with only slightly raised diastolic pressure. Provided 
their blood pressure is constantly monitored, such patients might be better 
helped by the more conservative measures of diet, reduced salt intake etc. 
that were the norm prior to the 1950s. A number of thoughtful papers have 
recently appeared which suggest such conservative treatments might be 
preferable (and cheaper) than drug therapy except in high risk groups, for 
example those with a family history of hypertension (17). Such papers are 
used by antivivisectionists to claim that patients are treated unnecessarily 
with drugs (18). Whereas one must be vigilant to ensure that drugs are 
not used without sound reason, it is a clinical decision at what systolic 
and diastolic pressure one institutes drug therapy, and nothing to do with 
animal experimentation. It is indisputable that animal experiments, through 
providing effective hypotensive drugs, have reduced mortality and morbidity 
from cardiovascular and cerebrovascular disease.
An earlier version of this chapter was published as: The control of malignant 
hypertension. RDS News October 1994 6-9.
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17. Penicillin And Laboratory 
Animals: The Animal Rights 
Myth
The dramatic impact of penicillin on the treatment of patients with severe 
infections has rightfully been paraded by biomedical researchers as a 
vindication of the value of laboratory animals in research. Opponents of 
animal experimentation are equally emphatic that animal experiments not 
only played no part in the development of penicillin but also that reliance 
on such techniques might well have caused penicillin to be discarded (1,2). 
The basis of the animal rights argument is that Fleming did not use animals 
but the “humble culture dish” (1) and that penicillin would never have 
been used in patients if physicians had known of its supposed inordinate 
and unique toxicity to guinea pigs (2). Both of these claims are incorrect 
and based on a superficial assessment of the literature. Fleming, after his 
chance observation that contamination with spores of a strain of Penicillium 
inhibited the growth of a culture of Staphylococcus aureus, tested the toxicity 
of the mould culture on animals. He reported (3):
the toxicity to animals of powerfully antibacterial mould broth filtrate appears 
to be very low. Twenty c.c. injected intravenously into a rabbit were not more 
toxic than the same quantity of broth. Half a c.c. injected intraperitoneally to 
a mouse weighing about 20gm. induced no toxic symptoms.
Rather than animal experiments making no contribution to the recognition of 
the remarkable potential of penicillin, it has been argued that the development 
of this drug was in fact initially retarded by the omission of a simple and 
well-established animal test. The mouse protection test, whereby mice are 
injected intraperitoneally with pathogenic bacteria, and potential antibacterial 
substances administered to assess their ability to prevent death, had been 
described in 1911. From 1927 onwards Domagk and his team at Elberfeld 
http://dx.doi.org/10.11647/OBP.0055.17
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used this in vivo technique routinely to assess the antibacterial efficacy of 
the azo dyes, this work culminating in the introduction of prontosil (which 
was inactive in vitro) and hence the sulphonamides (4). Had Fleming used 
this test during the studies that were the basis of his 1929 paper (3) he would 
have found, as did Florey and his colleagues at Oxford ten years later, that his 
crude broth contained sufficient active substance to protect mice artificially 
infected with susceptible organisms.
Penicillin and the Guinea Pig
The fact that penicillin, whilst being relatively innocuous for most species, 
appeared to be toxic to guinea pigs and hamsters, has served as a sheet anchor 
for the claims of antivivisectionists that species differences render animal 
experiments redundant and possibly dangerous. However, the apparent 
sensitivity of these species to penicillin, and indeed other antibiotics, is 
certainly not evidence of the futility of animal experimentation It is in fact 
a good example of the usefulness of the appropriate model in biomedical 
research.
The story began with the comprehensive and careful piece of work by 
Dorothy Hamre and her colleagues (5). These workers were interested in the 
effect of penicillin on gas gangrene. They therefore administered penicillin to 
guinea pigs that had been infected with Clostridium perfringens. The animals 
died 12-72 hours after receiving daily doses of penicillin for 3-4 days, yet 
showed no signs of gas gangrene.
Hamre therefore investigated the actual toxicity of penicillin to guinea 
pigs and found this species, unlike mice and rabbits, to be susceptible to 
repeated daily doses of the antibiotic. The samples of penicillin available 
at this time were very impure. It is clear from Hamre’s results with purer 
preparations that some of penicillin’s immediate and delayed effects were 
due to impurities. Nevertheless, daily doses 7-12 times those used in patients 
could result in lethargy, weight loss and often (but not invariably) death after 
3-7 days. However, a dose approximate to that used clinically administered 
even for twenty days did not kill the guinea pigs.
Hamre thus stated:
The fact that present preparations are toxic for guinea pigs when given 
subcutaneously does not mean that penicillin is toxic for man. When treated 
with the same dose of penicillin per kg. as that given to man, guinea pigs did 
not die and, in fact, failed to show any signs of toxicity. However, it is suggested 
that chronic toxicity for man be borne in mind [my emphasis].
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Hamre’s paper was carefully written and, as subsequent research showed, 
to some extent prophetic.
There were occasional attempts to explain the apparent toxic effects of 
penicillin over the following decade, but no progress was made until a group 
of Belgian workers suggested that a change in the composition of the bacteria 
in the gut was responsible. De Somer and his colleagues showed that the 
Gram-positive microorganisms that inhabit guinea pig intestine are completely 
removed by the penicillin and are replaced by insensitive bacteria. Injection into 
normal guinea pigs of a sterile filtrate of a culture of these bacteria produced a 
condition identical to penicillin poisoning (6). It was thus supposed these new 
bacteria colonising the gut produced toxins that are absorbed by the guinea 
pigs causing the illness and perhaps death of the animals. The theory that the 
guinea pigs thus die from an enterocolitis, rather than from a direct toxic effect 
of the penicillin was supported by the observation that penicillin is not toxic 
to germ-free guinea pigs (7). Such animals were unaffected by penicillin 240 
mg/kg/day but conventionally reared guinea pigs given this dose died within 
7 days of severe infection of the colon (Fig. 17.1).
Fig. 17.1  Effect of penicillin in normal and germ-free guinea pigs. Figures are number of 
animals per group. Data from S. B. Formal, G. D. Abrams, H. Schneider, and R. Laundy 
(1963), ‘Penicillin in germ-free guinea pigs.’ Nature, 198:712.
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The fact that penicillin itself is therefore not toxic is unlikely to impress 
the implacable opponent of animal experimentation, who requires only a 
simple quote for argument. However, this reaction, noted in the guinea pig 
in 1943, was in fact a prediction of what became, within ten years, a common 
iatrogenic condition in patients.
Antibiotic Associated Colitis
Pseudomembranous enterocolitis was first described in 1893 (8). It was 
commonly observed in post-operative patients. The characteristic of the 
condition is the appearance of a pseudomembrane over the gut mucosa. 
Microscopically the membrane can be seen to be composed of mucin, fibrin, 
white blood cells and sloughed mucosal epithelial cells. Occasionally the 
complete membrane is sloughed off and passed out as a “cast of the colon” (8).
Although most early cases of pseudomembranous colitis occurred post-
operatively, antibiotics also became implicated as causative factors soon after 
their introduction in the 1940s (9). The location of the lesion following antibiotic 
use was invariably the colon rather than the small intestine, thus this particular 
condition was named “antimicrobial-induced pseudomembranous colitis.”
The cause of the condition was the removal of sensitive bacteria from 
the gut by the antibiotic. This then results in profound alterations in the 
composition of the gut microflora due to recolonisation of the gut by other 
micro-organisms. This phenomenon was noted to follow administration of 
penicillin given by mouth or by injection. Generally the change in intestinal 
flora produced by penicillin (and other antibiotics) was of no significance, 
since the normal intestinal flora became re-established after therapy was 
stopped. In some patients however, after prolonged administration of the 
antibiotic, a superinfection occurred in the gut resulting in life-threatening 
pseudomembranous colitis (10).
Guinea Pigs and Humans: Remarkably Similar
The particular micro-organism recolonising the gut and causing 
pseudomembranous colitis eluded identification for many years. This, 
sometimes fatal, condition was originally attributed to mucosal ischaemia 
or a viral infection. Ultimately stools from affected patients were shown to 
contain a toxin that damaged cultured cells (11). Shortly after, this toxin was 
shown to be derived from Clostridium difficile (12, 13). It thus appeared that C. 
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difficile was the pathogen that caused pseudomembranous colitis. This was 
not easy for everyone to accept. C. difficile had been described in 1935 (14). It 
was difficult to isolate and slow to grow in culture (thus it was designated the 
“difficult clostridium”). As it was found in the stools of quite healthy infants 
C. difficile was considered to be innocuous and thus of little interest. When it 
became clear that infants are resistant to the effects of C. difficile toxin only 
until about 12 months of age (possibly due to the absence of toxin receptors 
on the immature cells of their gut (11) it became generally accepted that C. 
difficile was a pathogen and indeed the cause of pseudomembranous colitis.
Returning to the animal studies, veterinary research has strengthened 
the apparent similarity between guinea pigs and humans. Penicillin-induced 
inflammation of the large intestine of guinea pigs has been shown to be caused 
by clostridial toxins, and C. difficile has been isolated from the gut contents 
of these animals (16). Newborn guinea pigs, like germ-free animals, have 
been shown not to be susceptible to penicillin (17). Perhaps neonatal guinea 
pigs, like babies under 12 months of age, are insensitive to clostridial toxins.
It is clear that the now common, clinical problem of antibiotic-induced 
colitis (15) is analogous to the condition observed in guinea pigs by Hamre 
and her colleagues 50 years ago. An intensive investigation of the effects of 
penicillin on the intestinal flora of the guinea pig might have forewarned 
clinicians of the life-threatening superinfections that can occur with prolonged 
use of some antimicrobials. However it would be uncharitable to suggest 
the early experimental workers in the field were remiss. On the contrary, 
the admonition by Hamre that “chronic toxicity (of penicillin) for man be 
borne in mind” was an accurate and perceptive observation.
There is no basis for citing the effect of penicillin on guinea pigs as a 
prime example of species difference; in fact, it is an example of the exact 
opposite, namely of strikingly similar effects on the guinea pig and on people. 
The misrepresentation of the history of penicillin is but one example of the 
distortion of scientific fact perpetrated by opponents of animal research. 
It is the responsibility of scientists to correct these errors before they gain 
unwarranted credibility with the general public.
An earlier version of this chapter was published as: Burying the penicillin 
myth. RDS News July 1995 6-7.
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18. The History of Thalidomide
No drug has had a greater effect than thalidomide on the extent and 
intensity of the preclinical investigation of potential medicines required by 
the regulatory authorities. Indeed, the establishment of thalidomide as the 
cause of the apparent epidemic of children born with horrific deformities in 
the late 1950s was responsible for the institution of some regulatory bodies, 
such as the United Kingdom’s Committee on the Safety of Drugs, and for 
the strengthening of others, such as the Food and Drugs Administration 
(FDA) of the United States. Despite this, the history of the development of 
thalidomide, and of the subsequent studies of the teratogenic and other 
effects of the drug, has become confused, because of misrepresentation by 
those anxious to discredit the contribution of animal experimentation to 
medical advances.
Two categorical statements can be made about thalidomide. First, 
thalidomide was never administered to pregnant animals before it was 
used in humans. Secondly, only five months after the teratogenic effects of 
thalidomide had been established and the drug withdrawn, embryopathic 
actions of thalidomide were shown to occur in rat and rabbit (1). Over 
the following ten years fetal malformations caused by thalidomide were 
demonstrated in seven other species of small mammal and eight species of 
monkey (2).
Early Experimental Studies
The first paper describing the pharmacological actions of thalidomide was 
published in 1956 by Kunz, Keller and Mückter from the Research Laboratories 
of the German pharmaceutical firm Chemie Grünenthal (3). Thalidomide, 
designated then as K17, was alleged to reduce spontaneous movement in 
mice without the initial excitement phase observed with other sedative drugs 
http://dx.doi.org/10.11647/OBP.0055.18
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such as phenobarbitone and glutethimide. The onset of action of thalidomide 
was rapid and the sedative effect more profound and of longer duration of 
action than that of the comparator drugs. Coordination, as detected by ability 
of mice to cling to a slowly rotating rod, was not reduced even with doses in 
excess of those that produced sedation. Of greater significance, thalidomide 
was claimed to be virtually non-toxic, oral doses in excess of 5000mg/kg failing 
to cause death, whereas 600mg/kg and 300mg/kg doses of glutethimide and 
phenobarbitone respectively were sufficient to kill half of the mice in a test 
group. Chronic administration of 100-500mg/kg thalidomide to mice, rats, 
guinea pigs and rabbits for 30 days appeared to be well-tolerated. Thus it 
was proposed by the researchers at Chemie Grünenthal that thalidomide 
would be a useful sedative or hypnotic that did not carry the suicide risk of 
contemporary medicines.
Of significance, the authors emphasised that thalidomide was poorly 
water soluble but claimed, with no evidence, that the apparent innocuity 
is “not only due to the fact that the compound is sparingly soluble in water; 
it also indicates extremely low toxicity.” Crucially, no measurements of 
blood or tissue concentrations of thalidomide in treated animals were 
performed. Such data would have demonstrated that the lack of toxicity 
of thalidomide was indeed due to lack of absorption of the drug. The 
paper by Kunz, Keller and Mückter that appeared in Arzneimittel-Forschung 
was immediately followed by a clinical report by Jung (4) describing the 
sedative effects of thalidomide in 300 patients who were given 25-200 
mg thalidomide three times a day. There was no comparison with a placebo 
group and no indication of the duration of treatment was given. The blood 
picture of 20 of the patients was alleged to be unchanged over 4 weeks and 
liver function tests in 20 patients with enlarged livers showed no abnormality. 
However, no numerical data was provided to support these claims. With high 
doses side effects included sleepiness, giddiness and constipation. Some 
thirty years after the publication of these papers, the pediatrician Widukind 
Lenz, who played a significant part in the exposure of thalidomide as the 
cause of embryopathy, stated: “The papers published in 1956 by Kunz et al. 
on animal experiments and by Jung on clinical experiences with thalidomide 
have so little scientific value that in my opinion they should not have been 
accepted for print.” (5)
The actions of thalidomide were also investigated by G. B. Somers (6), chief 
pharmacologist at the Distillers Company, which was licensed by Grünenthal 
to distribute thalidomide in the British and Commonwealth markets. Somers, 
using thalidomide as a suspension in 1% carboxymethylcellulose, generally 
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confirmed the inhibition of spontaneous movement by the drug in mice and 
also remarked on its apparent lack of toxicity in animals. However, Somers 
added an important caveat when discussing the results of his toxicity studies: 
“It may well be that the absence of toxicity is due to a limited absorption, for 
the compound has a low solubility in body fluids, and when administered 
parenterally remains at the site of injection. In the absence of a suitable assay 
method absorption studies have not yet been made.”
Somers was later proved correct. Some months after his initial experiments 
he tested the actions of thalidomide prepared as a finely ground suspension 
in sugar solution. Such a preparation had just been marketed by Grünenthal 
as a sedative Contergan Saft that allegedly could be safely used by children. 
Somers was shocked to discover that microfined thalidomide mixed with 
sugar solution, unlike the suspensions originally used, was highly toxic to 
mice (7).
Even by the standards of the time, the preclinical and clinical investigation 
of thalidomide was superficial. This is illustrated by the animal studies 
performed upon meprobamate, a muscle relaxant and sedative agent first 
described by Berger in 1954 (8). Acute toxicity was measured in rats after oral 
administration and intraperitoneal injection, and in mice via these routes 
as well as after intravenous injection. Acute toxicity was also measured in 
monkeys. Subacute toxicity was examined in dogs given 1 g of meprobamate 
daily for between 60-75 days. The blood picture, urine analysis and kidney 
function tests were performed before administration of the drug and 30 
and 60 days after treatment; blood urea nitrogen and urea clearance were 
measured at 60 days. At autopsy, dogs showed no abnormalities of kidney, 
stomach, small intestine, liver, bladder or adrenal glands. Chronic toxicity 
studies were performed over 15 months on five groups of 20 male and female 
rats. Two groups were used as controls, the remaining groups received 2%, 
1% or 0.5% meprobamate in the diet. At the 12th week, male and female 
animals were mated and the resulting neonates examined for normality. 
There were no differences between control and test groups in the intensive 
examinations of the blood and urine, and the histological examination of 
all the major organs at autopsy. Unlike the relatively superficial preclinical 
examination of thalidomide reported two years later, Berger looked at 
the fate of meprobamate in the body, examining the urine for breakdown 
products. Approximately 10% of the drug was excreted unchanged in the 
urine, a much greater percentage excreted in a conjugated form, partly as 
an unknown metabolite conjugated with glucuronide.
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Clinical Usage
On the basis of the limited experimental studies, and further clinical trials 
(none double blind), thalidomide was launched in Germany in November, 
1957 as a novel “non-toxic” sedative under the trade name Contergan, although 
it had had limited use as a component, together with quinine, phenacetin, 
salicylate and vitamin C, of an anti-influenza preparation termed Grippex 
since November 1956 (9).
Contergan was marketed aggresively as a completely harmless sedative, 
and as a result its sales increased markedly throughout 1959. However, its 
alleged lack of toxicity soon came into question. In October 1959 a neurologist, 
Dr R Voss diagnosed polyneuritis in three patients who had taken Contergan 
for a year, and raised with Grünenthal his concern that the drug might have 
a toxic action on peripheral nerves. Despite the fact that, from April 1959, 
Grünenthal representatives had received information from pharmacists and 
physicians that Contergan caused numerous side effects including abnormally 
cold hands and feet, paraesthesia and giddiness, Grünenthal replied to Voss 
saying “no such side effects have come to our notice” (10).
Nonetheless Voss described his three cases at a neurological congress 
in Düsseldorf on April 30th 1960. The presentation by Voss prompted 
numerous other reports of apparent severe peripheral neuritis in long-term 
users of Contergan. Frenkel, a neurologist from Königstein, who like Voss 
had contacted Grünenthal earlier with concerns about the safety of Contergan, 
submitted a paper to Medizinische Welt describing 20 patients he believed to 
have thalidomide-induced peripheral neuritis. Grünenthal representatives 
attempted to persuade Frenkel to withdraw or delay publication but he 
refused. However, for reasons that are unclear, Frenkel’s paper did not 
appear in print until May 6th, 1961. This was well after the first literature 
report describing thalidomide-induced peripheral neuritis which was from 
Dr A. Leslie Florence of Aberdeenshire, United Kingdom. In a letter to the 
British Medical Journal of December 31st 1960, entitled “Is thalidomide to 
blame,” Florence described 4 patients presenting with marked paraesthesia 
affecting first the feet then the hands, coldness of the extremities, ataxia and 
nocturnal cramp. All patients had been taking thalidomide for between 
eighteen months to two years. Cessation of the drug resulted in alleviation 
but not removal of the symptoms (11). By the end of May 1961 there were at 
least 1,300 cases of peripheral neuritis associated with long-term thalidomide 
therapy, and Grünenthal were forced to take steps to have the drug supplied 
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only on prescription. This side action was soon to appear to be insignificant 
compared to the catastrophic result of ingestion of the drug by women 
during days 35-50 of their pregnancy, but the broad dissemination of the 
fact that thalidomide caused nerve damage was partially responsible for 
alerting Frances Kelsey, the FDA medical officer responsible for evaluating 
thalidomide before its use in the USA, to the fact that this supposed non-toxic 
medicine was potentially dangerous. The consequent delay in the approval 
of thalidomide until after its teratogenic effects were established in Europe 
thus averted a disaster for the United States (12).
Thalidomide and Fetal Abnormalities
The first indication of the emergence in Germany of an epidemic of particular 
fetal deformities was the description in 1959 by a Munich gynaecologist, 
Weidenbach, of a child with phocomelia of the arms and legs (13). Weidenbach 
knew this to be a highly unusual type of deformity since he could find no 
silmilar case in the German literature, nor had any case been described 
in the records of the Bavarian Institution for Crippled Children since its 
institution in 1913 (six years later, in 1965, four years after thalidomide had 
been withdrawn in Germany, Weidenbach finally established that the mother 
of the deformed child had been prescribed the thalidomide-containing 
preparation Grippex for a febrile condition between the 25th and 35th day 
post conception).
Other sporadic cases were reported but strong evidence that these fetal 
abnormalities had a common exogenous cause only emerged in September 
1960, when Kosenow and Pfeiffer, at a meeting of the German Paediatric 
Association, presented details of two cases of children born with severe skeletal 
malformations together with various other deformities such as duodenal 
stenosis and capillary hemangioma of the upper lip. Of great significance, 
both children had been born on consecutive days (February 28th and 29th) 
in the same small German town. Some years later it was finally established 
that both mothers had been prescribed thalidomide between the 44th and 
46th postmenstrual day (9).
By the beginning of 1961 it was clear that there was an epidemic of limb 
deformities in Germany, typically shortening or absence of the long bones 
of the arms or legs, producing flipper- or seal-like limbs, the condition 
designated “phocomelia.” Lenz was certain that one single common cause 
was responsible (14). He asked one affected parent specifically whether any 
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new drugs had been taken during pregnancy. He received a detailed list of 
the diet and diseases of the mother and a list of ten drugs. Contergan was 
not mentioned.
By August 1961, Lenz estimated that the incidence of gross defects of 
the long bones had increased 10-fold in Hamburg and probably 100-fold 
or more in some towns of Rhineland and Westphalia. In September, 1961 
Wiedeman published a paper in which he described seeing in his clinic in 
Krefeld only four cases of limb deformity between 1950-59, but 13 cases in 
the last 10 months (14). Careful investigation excluded infection, irradiation, 
anticonception chemicals and attempted abortion as possible causes, but 
Wiedeman was convinced that a newly introduced toxic factor was responsible.
Thalidomide (as Contergan) was originally considered as a candidate by the 
paediatrician Weicker, who in August 1961 had collected detailed data on 20 
cases, and found Contergan was mentioned in five. Unfortunately, he ignored 
the possible connection since he was mistakenly informed that thalidomide 
was widely used in the United States, where no cases of phocomelia had 
occurred (12). In November 1961 Lenz visited two further cases and established 
that both mothers had taken Contergan during pregnancy. Lenz told Weicker 
of his suspicions and the latter rechecked his now considerable collection 
of case histories and found 34 cases with positive evidence of thalidomide 
use by the mother. Encouraged by this and other confirmatory evidence 
from Professors Wiedeman (Kiel) and Kosenow (Krefeld), Lenz telephoned 
Grünenthal describing his concern. He was told he would be visited by 
representatives of the firm within a few days. Lenz considered the problem 
too serious for delay and, on November 16th, 1961 sent to Grünenthal a 
registered express letter detailing his reasons for assuming a connection 
between use of Contergan in early pregnancy and consequent birth defects, 
particularly limb deformities (14).
In Australia, where thalidomide was marketed as Distaval by the Distillers 
Company, the connection between the drug and fetal abnormalities was 
deduced rather more rapidly through the perception of the obstetrician 
McBride. On May 4, 1961 at the Women’s Hospital, Sydney, McBride delivered 
a baby with bowel atresia and phocomelia of both arms. An obstetrician of 
7 years standing, this was the first case of phocomelia McBride had seen 
at this hospital where there were 4,000 births each year. Twenty days later 
another child with similar limb malformations was delivered at the hospital. 
Two cases could be a coincidence, but when a third case with similar limb 
malformations was delivered on June 8th, 1961 McBride’s suspicions were 
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acutely aroused. Over the following days he examined the literature on 
drug-induced malformations and consequently examined the case notes 
dealing with the three pregnancies; the only drug administered to the 
mothers was Distaval.
On June 13th, 1961 McBride persuaded the Medical Superintendent at 
the Women’s Hospital to withdraw thalidomide from use. McBride also 
attempted to initiate some animal experiments, firstly using mice and guinea 
pigs kept at the hospital for diagnostic purposes. Lack of sufficient animals 
and McBride’s understandable lack of expertise prompted him to approach, 
on two occasions, the professor of pharmacology at the University of Sydney 
to suggest he examine the possible teratogenic potential of thalidomide 
in laboratory animals. Unfortunately, the professor was not convinced by 
McBride’s circumstantial evidence and did not consider the expense of an 
animal study justified (15).
McBride informed representatives of Distillers in Australia of his suspicions 
that thalidomide might be responsible for producing fetal abnormalities, and 
was assured by them that his anxieties would be transmitted to the London 
office. McBride nonetheless drafted a letter to the prestigious medical journal 
The Lancet stating that although congenital abnormalities can be expected in 
approximately 1.5% of babies, he had observed that the incidence of multiple 
severe abnormalities in babies delivered of women who were given the drug 
thalidomide during pregnancy to be almost 20%. McBride’s letter, which 
appeared on December 16, 1961 was the first published record of the possible 
teratogenic action of thalidomide (16).
Distillers received the report of McBride’s concern from their Australian 
representatives on November 21, 1961. This, together with the co-incidental 
information from Lenz in Germany resulted in the withdrawal of thalidomide 
from the German and British markets. The incidence of thalidomide-induced 
deformity in Germany, together with a record of other significant observations 
is depicted in Figure 1.
With 50 years hindsight, some may view with incredulity the delay in 
the association of thalidomide with the ever increasing number of cases of 
severe congenital defects. Yet even in April 1962, Josef Warkany, then probably 
the most distinguished expert on teratogenic agents, expressed doubts 
that thalidomide was the cause of the epidemic of limb defects, since some 
mothers who had taken thalidomide during pregnancy produced normal 
offspring, and some mothers who gave birth to children with phocomelia 
claimed not to have taken the drug (17). These doubts disappeared when it 
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was established that mothers who took thalidomide after the sensitive period 
of 50 days into pregnancy could have normal children; and mothers who did 
not believe they had taken the drug could have taken it unknowingly, since it 
was present in some preparations without being specifically named (18). As 
Warkany stated: “The real proof came when disappearance of the epidemic 
followed withdrawal of the drug from the market.” (18) (See Figure 18.1)
Fig. 18.1  Columns represent the monthly incidence in Germany of births of children deformed 
because of ingestion of thalidomide by the mother. Data was collected by the meticulous 
retrospective epidemiological studies of Widukind Lenz (5). The first case occurred in 
December, 1956. The child’s father worked for Chemie Grünenthal and had received samples 
of thalidomide tablets for his wife. The association of the abnormalities with administration of 
thalidomide was not suspected until May 1961 in Australia, and November 1961 in Germany. 
The rapid fall in incidence of deformity after withdrawal of thalidomide confirmed that 
thalidomide was responsible. In April 1962, 5 months after the withdrawal of the drug, Somers 
was the first to demonstrate the embryopathic action of thalidomide in animals.
Experimental Studies
Upon hearing of the concerns of Lenz and McBride, the chief pharmacologist 
of Distillers in Britain, Dr George Somers, launched studies of the effect of 
thalidomide on the fetus. Thus November 1961, after the withdrawal of the 
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drug, was the first time thalidomide was administered to pregnant animals, 
apart from the unsophisticated attempts by McBride four months previously.
Somers published his results barely five months later, on 28 April 1962 
also in a letter to The Lancet (1). In this letter he stated that thalidomide given 
to pregnant rabbits resulted in the birth of neonates in which: “The front 
legs were foreshortened owing to a reduction in long-bone formation of the 
radius and ulna; while the rear legs showed a varus deformity involving 
the tibiofibula.”
Therefore, within six months of the suggested association between 
thalidomide and human fetal deformity, it had been possible to produce 
in a common laboratory animal a teratogenic effect identical to one of the 
many produced by thalidomide in humans. Surely this was evidence for a 
striking similarity between mammalian species rather than for a manifest 
difference. Somers used a dose (150 mg/kg) that was higher than that used 
in humans. Somers simply wanted to know if thalidomide was teratogenic in 
rabbit and thus did not carry out a dose-response study, which would have 
been wasteful of animal life. However, he subsequently obtained the same 
effects with a 30 mg/kg dose as did Seller with 50 mg/kg (19). Somers also 
later measured plasma concentrations of thalidomide after oral administration 
of suspensions in carboxymethylcellulose and found that with doses of 150 
mg/kg the peak plasma concentration in rabbits was only three-times as 
high as those in humans on normal doses (19).
Within a further six months, again in The Lancet, a report appeared 
describing the teratogenic effects of thalidomide in the Sprague Dawley rat 
(20) and this was confirmed by other reports (21). However, a more common 
response of the rat fetus to the challenge of thalidomide was intrauterine 
death followed by resorption. In the two years following the withdrawal of 
thalidomide approximately 20 papers were published that reported decreased 
litter sizes, together with numerous uterine resorption sites, in rats given 
the drug during pregnancy. Christie (22), who also reported a significant 
increase in resorptions in thalidomide-treated pregnant rats, suggested that 
fetal abnormalities produced in the rat embryos might well be of sufficient 
severity to kill the embryo and thus account for the increase in resorption.
Other papers subsequently appeared showing negative effects of 
thalidomide on the fetuses of laboratory animals. Obviously, when such 
conflicting results occur one assumes that the negative results are wrong, 
for there may be many reasons for a false negative, but a positive result is 
unlikely to be due to chance provided adequate controls are carried out. There 
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were probably a number of factors responsible for the false negative results. 
Teratology was an orphan discipline in the 1960s, with few practitioners. 
Inexperienced experimentalists were possibly not aware that laboratory 
animals, which generally give birth at night, cannibalise their pups if they 
are born deformed, thus the litters should be delivered by Cesarean section at 
term to be sure of detecting deformed neonates. Also, detecting deformities 
(particularly of the skeleton) in fetuses of small laboratory animals such 
as rats and mice is not easy; the technique of staining with alizarin dye is 
necessary. King and Kendrick (20) for example, found that they could double 
the detection of skeletal defects in rat by alizarin staining of the skeleton.
The most significant reason for the false negative results was exposed 
by the definitive biochemical studies of thalidomide by the group led by 
Professor R.T. Williams at St Mary’s Hospital in London. Williams and his 
colleagues established that the distinct optical isomers of thalidomide were 
far more toxic than the mixture of the isomers (the racemate) (23). Subsequent 
studies of the relative effects of the separate enantiomers in the rat suggested 
that the teratogenic action was due to the S(-)-enantiomer. Since there is a 
rapid interconversion of the two isomers in vivo the role of stereochemical 
factors in thalidomide teratogenesis is probably significant but unresolved 
(24). Of greater significance, Williams et al. also showed that thalidomide 
was inherently unstable, rapidly breaking down to 12 inactive metabolites if 
in aqueous solution above pH 6 (25). It is probable that many workers were 
using solutions containing only the inactive metabolites of thalidomide and 
therefore obtained no fetal abnormalities. This is particularly likely, since 
in the British patent specification (1957) Grünenthal, commenting on the 
lack of solubility of thalidomide, stated quite erroneously, that thalidomide 
“is soluble in strong lyes, the solution obtained being yellowish in colour” 
(26). Such a treatment would result in the instantaneous breakdown of the 
substance. Chemical breakdown was certainly the reason for the apparent 
lack of teratogenic activity in rabbit reported by Fox et al. (27). Schumacher 
(28) repeated these experiments and showed that the procedures used by Fox 
to solubilise thalidomide resulted in considerable chemical breakdown, an 
observation subsequently accepted by Fox (29). Schumacher also emphasised 
the facilitating effect of carboxymethylcellulose (a suspending agent frequently 
used to make supersaturated solutions of thalidomide for experimental use) 
on hydrolysis. Carboxymethylcellulose contains from 7 to 8.5% sodium and 
therefore would tend to buffer the solution, maintaining the alkaline milieu 
that would foster the hydrolysis of thalidomide (28).
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Unfortunately, many early papers on the experimental production of 
abnormalities in laboratory animals neglected to record how solutions or 
suspensions of thalidomide were prepared and for how long they were 
stored, but it is likely that negative results may well be explained by lack 
of absorption of the drug or the inadvertent administration of hydrolysis 
products rather than thalidomide itself. By 1967, Meredith Runner had stated 
that the embryos of all mammals so far studied are affected by thalidomide 
(30) and in 1989, Schardein and Keller listed 17 mammalian species in 
which thalidomide produced fetal abnormalities (2). It also produces limb 
deformities in the newt (31).
Thalidomide and the Regulation of Drug Use
The catastrophic effects of thalidomide on the developing fetus shook the 
confidence of the general public in the pharmaceutical industry. The dramatic 
improvement in the treament of infective diseases such as puerperal sepsis, 
pneumonia and streptococcal septicemia by the sulphonamides and penicillin, 
and the control of tuberculosis by streptomycin, isoniazid and aminosalicylic 
acid were all forgotten amid the realisation that there was no procedure 
in place that could prevent the marketing of a medicine that manifested a 
horrific toxic effect. As stated by the British Minister of Health, the Right 
Honourable Kenneth Robinson in May 1963: “The House and the public 
suddenly woke up to the fact that any drug manufacturer could market any 
product however inadequately tested, however dangerous, without having 
to satisfy any independent body as to its efficacy and safety and the public 
was almost uniquely unprotected in this respect.” (32)
To remedy this situation a joint subcommittee of the English and Scottish 
Standing Medical Advisory Committees was set up to advise the Government 
on suitable measures to ensure that potential medicines were subjected to 
intensive preclinical investigation to establish their pharmacological and 
possible toxic actions, and to confirm their efficacy and safety in the clinic. 
A further remit of the Subcommittee was to advise on procedures to ensure 
early detection of untoward effects that may emerge after the marketing 
of the product and its widespread use in patients. After discussions with 
the Association of the British Pharmaceutical Industry (ABPI) and other 
professional bodies the Subcommittee recommended that the responsibility for 
the preclinical investigation of new drugs should remain with the individual 
manufacturer and that there should be an expert body created that would 
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review the evidence and offer advice on the toxicity of new drugs. Thus, in 
June, 1963 the Committee on the Safety of Drugs was established under the 
chairmanship of Professor Derrick Dunlop (later to become Sir Derrick). It 
became the responsibility of this committee to assess the data presented 
in support of each preparation and to consider whether it may be released 
for marketing. The assessment of the experimental studies on the toxicity 
of the drug was the responsibility of a subcommittee on toxicity (32). As a 
minimum requirement this subcommittee would expect the drug to have 
been tested according to the recommendations in the report prepared for the 
ABPI by the Expert Committee on Drug Toxicity (33). This report describes 
in detail the recommendations for the general investigation of the acute, 
subacute and chronic toxicity of a compound, its possible carcinogenicity 
and its liability to interact in a toxic fashion with concurrent medication. Not 
surprisingly, since the stimulus for the institution of regulations governing 
the marketing of drugs was the toxic action of thalidomide on the fetus, the 
report recommended particular tests to examine possible effects of the drug 
on fetal development.
The recommendations were that two species should be used to study 
toxic effects upon the fetus, the mouse or rat, and the rabbit. Test groups 
should be large enough to ensure 5 pregnant animals in the control rodent 
group and 3 in the rabbit. Three doses of the test drug should be used: the 
maximum dose tolerated by the mother, a second dose large enough to 
produce clinically relevant effects, and an intermediate dose. Dosing should 
begin on day one of pregnancy and continue until the day before term. On 
the day before term the animals should be killed, the uteri should be removed 
and examined for number of resorption sites, and the number and weight of 
live, dead or abnormal fetuses should be determined. From this preliminary 
test a range of doses should be selected to establish the threshold dose for 
fetal loss or any aspect of fetal toxicity. In this main test, the number and 
weight of progeny should be monitored up to weaning, when the progeny 
are killed and examined externally and internally. The normality of the 
skeleton should be observed after staining with alizarin red.
There is no doubt that if these premarketing procedures, instituted in the 
early 1960s, had been applied to thalidomide its toxicity to the developing 
embryo would have been detected. Unlike the situation in the United Kingdom, 
the United States did have some legislation to regulate the marketing of novel 
medications. New drug applications had to be submitted to the Food and 
Drug Administration (FDA) to be cleared for marketing, which at that time 
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was on the basis of safety claims alone. The FDA had 60 days to decide if 
the safety data supplied was adequate. A failure to communicate by day 60 
would mean automatic approval of the drug. An American pharmaceutical 
company signed an agreement with Grünenthal to market thalidomide in 
the United States and submitted an application for approval to the FDA 
on September 12 1960. According to Frances Kelsey, the medical officer 
assigned to the review of the thalidomide application, “Deficiencies in 
all areas were found during the initial review and in several subsequent 
resubmissions” (12). Kelsey was particularly concerned about the report of 
peripheral neuritis as a side effect, of which the FDA were only informed 
in February 1961, despite the fact that in Britain thalidomide had carried a 
warning of the risk of peripheral neuritis since September 1960. The severity 
of peripheral neuritis as a side effect led to questions of its use during 
pregnancy, since the application had described its use for the treatment of 
insomnia in pregnancy; yet there were no data as to whether it was safe to 
use in this condition (12). The legitimate concerns raised by Kelsey delayed 
the approval of thalidomide until its withdrawal from the market in Europe 
and Australia in November, 1961.
Even though the requirements of the FDA and Kelsey’s perception 
prevented the marketing of thalidomide in the United States, a few cases of 
thalidomide deformity did occur there since the company seeking approval 
to sell the drug distributed free samples of thalidomide tablets to over a 
thousand doctors who administered them to an estimated 20,000 patients. 
The realisation that potentially noxious medicines could be administered to 
patients prior to the approval by the FDA resulted in the Kefauver-Harris 
Amendment, which required that the FDA should monitor all stages of drug 
development before its use in humans (12).
Misrepresentation
An objective examination of published papers and contemporary accounts 
confirms that the preclinical tests upon thalidomide were cursory in the 
extreme, and there is no doubt that it was never administered to pregnant 
animals prior to its use in patients. Further, within a short time of thalidomide’s 
withdrawal from the market due to its suspected association with fetal 
abnormalities, it was shown to produce fetal toxicity in laboratory animals. 
Clearly, the disaster occurred because of insufficient testing in laboratory 
animals.
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Antivivisection organisations are however loath to accept that the 
thalidomide disaster offers no propaganda for their cause, asserting in 
leaflets and newspaper advertisements that “The thalidomide disaster is just 
one example of how vivisection damages us.” (34) In the United Kingdom 
the Advertising Standards Authority (ASA) ensures that all advertisements 
should be “legal, decent, honest and truthful, and when capable of objective 
assessment, data should be supported by evidence.” Upon assessing the above 
statement the ASA ruled that: ”The common claim, that thalidomide was 
tested in various species and did not show the teratogenic effects that it had 
in humans, was considered unjustified.” The agency therefore requested that 
reference to thalidomide in this context in future advertising be omitted (35).
Unfortunately, there are no strictures on the perpetration of 
misrepresentations in general literature. One of the more bizarre descriptions 
of the history of thalidomide is that of Greek and Greek, who state that some 
toxicity tests were carried out on pregnant rodents prior to thalidomide’s 
release (36). This is not so. In fact one of the lines of defense used by the 
suppliers of the drug was that safety tests were not normally carried out 
on pregnant animals at the time thalidomide was developed. However, 
the preclinical investigation of meprobamate (described above) shows this 
claim to be false. Greek and Greek also state that it was known for five years 
that thalidomide was teratogenic in humans but “since animal testing had 
not indicated a problem with thalidomide, its use persisted. Hence animal 
testing delayed the recall of this highly teratogenic drug.” The reviews by 
Lenz, Warkany and Kelsey, the leading protagonists in this field, published 
as the proceedings of a symposium to commemorate the 25th anniversary 
of the American Society of Teratology (5, 12, 17), show that the account by 
Greek and Greek is wildly inaccurate. However such propaganda has been 
eagerly grasped by antivivisectionists and widely quoted in letters to the 
press and in internet discussions. The public must be constantly reminded 
of the facts before they are swamped by the erroneous, emotive rhetoric of 
the opponents of animal experiments.
An earlier version of this chapter was published as: Botting, J. The history of 
thalidomide. Drug News and Perspectives 2002, 15(9): 604-11. Copyright 2002-
2014 Prous Science, S.A.U. or its licensors. All rights reserved, http://dx.doi.
org/10.1358/dnp.2002.15.9.840066
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19. Misleading Research or 
Misleading Statistics: Animal 
Experiments and Cancer 
Research
Scientists supported by the Cancer Research Campaign have prepared a 
vaccine which it is hoped will protect against infection with Epstein-Barr virus 
(EBV). Apart from causing glandular fever EBV is believed to be one causative 
factor for certain cancers. There is firm evidence for the involvement of this 
virus in Burkitt’s lymphoma and in cancer of the throat and nasopharynx, 
and evidence for the suggested link between EBV and Hodgkin’s disease is 
becoming more conclusive.
Progress has recently been made in the search for a vaccine against the 
Epstein-Barr virus. A new vaccine has undergone Phase I clinical trials in 
China, where there is a high incidence of nasopharyngeal carcinoma caused 
by the Epstein-Barr virus (21). Progress to Phase III trials of this vaccine has 
been recommended by a recent meeting of cancer experts (22).
Should the vaccine prove successful, its widespread use will ultimately 
prevent approximately 80,000 deaths per year world-wide.
To the scientist involved in research into the prevention and cure of 
neoplastic disease this news will be viewed as another significant step in the 
steady progress made over the last 50 years in reducing mortality from cancer.
Those devoted to attacking the scientific credibility of researchers who 
use animals, however, look to cancer research to provide evidence to support 
their campaign to achieve the abolition of animal experiments.
In a recent article (1) it is claimed that despite the continued use of animals 
there is still an “inexorable rise in cancer mortality.” The claim is allegedly 
http://dx.doi.org/10.11647/OBP.0055.19
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supported by selected examples of mortality figures for various cancers for 
1981-85 compared to 1971-75, with the percentage change listed.
Such carefully chosen statistics provide limited information to the serious 
investigator. If the change in incidence is also included one can see that the 
increase in mortality is small in comparison with the increase in incidence 
(Fig. 19.1). The apparent increase in incidence is undoubtedly due to a 
general increase in longevity and also because the percentage of actual cancer 
patients surviving longer than 5 years has increased steadily in England and 
Wales since 1960. The more recent statistics (1988) for the USA indicate that 
this trend is being maintained.
Fig. 19.1  Trends in cancer survival in the USA (male and female white), 1960-1963 and 
1983-1988. Lu: lung; S: stomach; My: myeloma; Le: leukaemias; NHL: non-Hodgkin’s 
lymphoma; K: kidney; R: rectum; Co: colon; La: larynx; HD: Hodgkin’s disease; Pr: 
prostate; Bl: bladder; Br: breast; ME: melanoma; U: uterus; Te: testis.
If mortalities from cancer for different age groups are examined, changes 
over the last 30 years show an encouraging trend. In the age group 0-19 
years mortality from cancer has dropped to under half that in 1953, in 
those 20-44 to 65% and in those 44-64 to 80%. Only in those aged over 65 
has the mortality risen, this because of the increased longevity mentioned 
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above. Earlier diagnosis may be a factor in the increased survival time, but 
undoubtedly improved treatment is significant (Fig. 19.2).
Fig. 19.2  Trends in cancer mortality in England and Wales (males), 1950-1990.
In fact, the prognosis for some cancers has improved markedly. 95% of 
patients with disseminated cancer of the testis are now cured,1 40-50% of 
patients with acute non-lymphocytic or chronic myelogenous leukaemia are 
also curable (2). Fortunately, the most striking progress has occurred in the 
treatment of childhood cancers, where 5 year survival rates have shown a 
striking increase over the past 30 years, with high cure rates for the childhood 
leukaemias and even for solid tumours (Fig. 19.3). It is perhaps significant 
that these statistics were not chosen for inclusion in the report referred to (1).
1  “It is certainly fortunate that the platinum drugs were discovered when they were, or it 
(cancer of the testis) would by now be a major cause of death in young men.” Sir Richard 
Doll (1990) Are we winning the war against cancer? Eur J Cancer 76 500-508.
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Fig. 19.3  Trends in survival of children under 15 in the USA, 1960-1963 and 1983-
1988. AML: Acute myeloid leukaemia; Bra: brain; NB: neuroblastoma; Bo: bone; NHL: 
non-Hodgkin’s lymphoma; ALL: acute lymphocytic leukaemia; WT: Wilm’s tumour;  
HD: Hodgkin’s disease.
Chemotherapy
Unquestionably, the great improvements in cure rate for childhood cancer 
and increased life expectancy for cancer patients in general is due to the 
development of chemotherapy with antineoplastic agents.
Before 1940 there were no anticancer drugs. The first (1941) edition of 
a standard textbook on the pharmacological basis of therapeutics does not 
even mention cancer in the index. The eighth edition (1990) devotes 61 pages 
to the discussion of some 40-50 antineoplastic drugs (3).
The starting point of this dramatic change in cancer treatment was the 
investigation of the biological and chemical actions of the nitrogen mustards 
by Gilman and Philips (4). Although not published until 1946, this work 
was actually initiated prior to World War II due to the possible use of these 
vesicants in chemical warfare. For reasons of security publication was delayed.
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The striking toxic action of nitrogen mustards on lymphoid tissue 
prompted experiments upon the effects of these chemicals on transplanted 
lymphosarcoma in mice (5). The suppression of tumour growth observed in 
this study was responsible for the first clinical investigation of a medicine 
to combat cancer (6).
Numerous other anticancer drugs have now been produced. Aminopterin, 
shown to be effective in treating various experimental neoplasms (7), 
actinomycin D, effective against five experimental tumours (8) and vincristine, 
isolated from the periwinkle (Vinca rosa). This drug was initially shown to 
produce bone marrow depression in animals and hence was used in an 
experimental leukaemia model where it was shown to be curative (9).
As knowledge of the mode of action of anticancer drugs unfolded so 
did the production of analogues with increased potential, either because of 
greater activity or diminished toxicity. This necessitated the investigation of 
the effectiveness of potential methods to screen compounds for activity. This 
was undertaken as a co-operative venture involving many national centres. 
Numerous in vitro systems were examined for the investigation of potential 
anti-tumour activity, including various mammalian cells in culture, bacteria, 
fungi and viruses (10). However the results indicated that no in vitro method 
could replace a whole animal tumour model (some drugs, cyclophosphamide 
for example, were only active in vivo after conversion in the liver to an active 
form). Furthermore, the use of no single animal tumour model could with 
certainty discover all the potentially useful drugs. Thus three mouse tumour 
models were selected for an initial screen; leukaemia L1210 (for its good 
predictive value for clinical activity), sarcoma 180 and adenocarcinoma 755 
(these for their cytological similarity to human cancers) (10).
As more compounds were produced, tested and forwarded for clinical 
assessment, feedback from oncologists as to clinical efficacy enabled the 
experimental test systems to be reassessed and thus various other animal 
tumour sytems were found useful, such as the P388 mouse leukaemia, 
mouse B16 melanotic melanoma and the mouse Lewis lung carcinoma. 
The informative review by Johnson and Goldin (10) contains a table of 34 
chemicals established as active against one or more human cancers. Most 
were effective in prolonging the life of mice with L1210 and P338 leukaemia, 
the majority were also active against B16 melanoma. Few clinically effective 
drugs failed to show an activity against at least one of the established animal 
tumour models.
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It is of interest that one critic of the contribution of animal research towards 
the treatment of cancer (1) surprisingly cites the above paper as evidence 
of the futility of animal models, since “estrogen (sic) is effective against some 
cancers in women but, like prednisone fails to work in animal experiments.” To use 
these two drugs as evidence to diminish the value of experimental tumour 
systems, and to ignore the concordance of response of these experimental 
tumours and human cancers to the other drugs listed indicates remarkable 
prejudice, together with a superficial knowledge of cancer chemotherapy. 
Certainly, both prednisone and sex hormones were listed as inactive against 
the four experimental tumours examined. Prednisone and other corticosteroids 
seldom exert benefit in adult leukaemias and only produce cures in childhood 
leukaemias if given in combination with other antineoplastic agents. Oestrogen 
is only used for cancer of the breast (no experimental mammary cancer model 
was used) and then only in carefully selected patients. In fact oestrogen 
antagonists such as tamoxifen are more often used. (Oestrogens have of 
course been established as cancer causing when administered under some 
conditions, an action predicted by studies in the mouse by Lacassagne (11) 
and subsequently confirmed in other animal species).
Treatment Regimens
Animal models were not only of use for the generation of novel anticancer 
drugs, but were also crucial for the establishment of the principles that 
underpin modern cancer chemotherapy.
Using only the L1210 mouse leukaemia model, Skipper and co-workers (12) 
demonstrated that; 1) since a single malignant cell can divide and eventually 
form enough cells to kill the host, it is essential to destroy every such cell. 
2) The immune system plays little or no part in the therapy of malignant 
disease, and 3) the destruction of cancer cells by cytotoxic drugs follows 
first order kinetics, i.e. a given dose of drug will kill a fixed proportion of 
sensitive cells regardless of the total size of the malignancy.
The consequence of these experimental studies has been to ensure total 
removal of malignant cells originally, by continuance of therapy after 
apparent remission, and later by the use of several drugs concurrently or 
in a logical sequence.
These studies emphasised the importance of the influence of tumour 
cell numbers at the start of therapy as an indicator of a favourable outcome 
(methotrexate, for example, was only curative in mice when treatment 
was started shortly after inoculation of a small number of cells). This 
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observation did much to encourage research into methods of early diagnosis 
of malignant disease, since treatment at an asymptomatic stage increases 
the probability of a cure.
The Alternatives?
The alternative to animal experiments, assert the abolitionists, is epidemiology. 
To support this proposal a paper by the eminent epidemiologist Burkitt 
has been cited (13), in which it is argued that a “shift in emphasis towards 
prevention” is required. Few would dream of disagreeing that epidemiology, 
and ultimately prevention, is of paramount importance in the field of cancer 
research and indeed of most diseases. The discussion paper by Temple and 
Burkitt does not however support the abandonment of animal experiments. 
It is a plea for “simple” as against “complex” research and specifically states:
it (simple research) should use several types of investigation in parallel: 
(1) population comparisons, (2) prospective and case-control studies, (3) 
controlled clinical trials, (4) analogous studies on animals, and (5) envisaging 
a plausible mechanism.
It is surprising that Sharpe, in support of his condemnation of the past and 
future contribution of animal experimentation to research into cancer (1), 
should quote so extensively from a paper that specifically recommends 
animal experiments.
Reducing the Toxicity of Anticancer Therapy
All cancer chemotherapy is accompanied by unpleasant effects, since the 
drugs used are all cytotoxic, the selectivity against the cancer cells being 
governed by the accelerated rate of division of these cells. Research using 
animals has however, provided adjunctive therapy that has greatly eased 
the suffering of the patient.
One of the most discomforting symptoms accompanying anticancer 
chemotherapy or radiotherapy is nausea and vomiting. This can be combated 
with dramatic effectiveness with the newly developed 5-HT3 receptor 
antagonists. Two of these drugs, ondansetron and granisetron, are now 
widely used in cancer clinics to suppress completely the nausea and vomiting 
that accompanies treatment. The potential of these drugs was established by 
the demonstration that they could potently inhibit retching and vomiting 
induced in ferrets by cisplatin (14).
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Since new blood cells are constantly being formed from rapidly dividing 
stem cells in the bone marrow, this organ is inevitably affected by anticancer 
therapy. Supportive therapy can help to alleviate this problem, for example 
prevention of anaemia can be achieved by the administration of factors, such 
as erythropoietin, that promote the formation of red blood cells. This has only 
been made possible by the elucidation of the circulating factors responsible 
for the maturation of red blood cells, starting with the significant experiments 
on rabbits by Carnot and Deflandre (15).
The Future
Though it is clearly justified to emphasise the progress that has been made 
in the treatment of cancer, it must be admitted that slow growing tumours, 
such as those in the lung and colon, are generally difficult to treat and are 
amongst the biggest killers, often because of the generation of metastases. 
The elucidation of the processes by which metastases develop can only be 
achieved by the study of tumour development and spread in laboratory 
animals.
A promising approach to the possibility of suppression of metastases has 
emerged from the observation by Folkman (16) that the antibiotic fumagillin 
inhibits the growth of the cells that line the inner surface of blood vessels, 
the endothelial cells. It is the endothelial cells that initiate the growth of 
new blood vessels, and tumours cannot grow above a few millimetres in 
size unless they can form blood vessels. A relatively non-toxic derivative of 
fumagillin has been shown to reduce substantially the number of metastases 
in mice, presumably by the inhibition of the growth of blood vessels.
Similarly one can anticipate that monoclonal antibodies (originally 
generated from tumour antigens) may contribute to diagnosis, imaging 
of tumours and to therapy, perhaps by being made to deliver a toxin or 
destructive radioisotope selectively to the tumour.
In some respects cancer therapy today is analogous to bacterial chemotherapy 
in the early 1930s. Decades of research looking for compounds that would 
kill the bacterial cell and leave intact the surrounding, rather similar, host 
tissue had produced somewhat hazardous treatments for a few conditions. 
But death and morbidity rates for common infections were high. Over a span 
of a mere seven years or so the sulphonamides and then the antibiotics had 
rendered infectious disease a relatively minor medical problem.
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Gene therapy, the biological response modifiers and maybe a vaccine 
against tumour antigens (17) (in conjunction with suitable adjuvant therapy) 
may provide the turning point that will make the successful treatment of 
neoplasms routine medicine.
In recent years, the development of vaccines to prevent or treat some 
cancers has progressed significantly. The FDA has approved two vaccines 
to prevent cancer. One is a vaccine against the hepatitis B virus which can 
cause liver cancer (18) and the other is a vaccine against the papillomavirus, 
which is responsible for the majority of cervical cancer cases (19). Also, in 2010, 
the FDA approved the first cancer treatment vaccine for use in a particular 
group of men with metastatic prostate cancer. This vaccine, sipuleucel-T, is 
designed to stimulate an immune response to prostatic acid phosphatase, 
an antigen found on most prostate cancer cells (20).
Vaccines for the treatment of many forms of cancer, such as cancers of 
the bladder, kidney and lung, are the subject of current extensive studies.
An earlier version of this chapter was published as: Misleading research or 
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